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 1 INTRODUCTION AND FUNDAMENTAL PRINCIPLES 
1.1 DEFINITIONS, CONCEPTS, AND TERMINOLOGY 
1.1.1 HOSPITAL PHARMACY 
According to the definition of the European Association of Hospital Pharmacists 
(EAHP), hospital pharmacy is “the health care service, which comprises the art,  
practice, and profession of choosing, preparing, storing, compounding, and dispensing 
medicines and medical devices, advising healthcare professionals and patients on their 
safe, effective and efficient use. Hospital pharmacy is a specialised field of pharmacy 
which forms an integrated part of patient health care in a health facility“ (EAHP 2010).  
 
The centre and overarching goal of hospital pharmacists regarding all medicine-related 
activities in the hospital is to apply the “seven rights”, which are as follows: the right 
patient, the right medicine, the right dose, the right route, the right time, and the right 
information and documentation. The focus lies on optimisation of patient outcomes 
through the judicious, safe, efficacious, appropriate, and cost-effective use of medi-
cines (EAHP 2010).  
 
Hospital pharmacy originated primarily in response to the needs of hospitals regarding 
drugs and other pharmacy goods and the structure of their different clinics.  
The duties of the hospital pharmacist encompass each step of the medicine use  
process (Figure 1).  
 
 
Figure 1: The medicine use process (FIP 2008) 
 
Within this process, several duties and responsibilities are addressed by the hospital 
pharmacist. These duties can be roughly divided into three main areas (ÖAK 2000): 
 
 Tasks regarding the supply of drugs and other pharmacy goods (e.g., chemicals 
and reagents) or medicinal products (e.g., dressings, sutures, and diagnostics). 
This area also includes storage and dispensation of drugs.  
 9
  Drug production and individual patient-specific compounding activities. Here, 
the hospital pharmacist often addresses unmet needs regarding the production 
of drugs that are not provided by the pharmaceutical industry and of individual-
ised extemporaneous preparations (e.g., patient-specific ointments and  
capsules for children).  
 Other pharmaceutical services, which comprise interdisciplinary activities  
(e.g., collaboration in working groups, including pain team, wound management 
team, and others), the provision of drug information to other healthcare provid-
ers and patients, and the provision of ward-based services (i.e., clinical phar-
macy services).  
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 1.1.2 CLINICAL PHARMACY 
Several definitions of clinical pharmacy are published in the medical and pharmaceuti-
cal literature, and these definitions describe the concept of clinical pharmacy services 
as well as their objectives, scope, and contents (Table 1).  
 
American Association of Colleges of 
Pharmacy 
1968 
“Clinical Pharmacy is that area within the pharmacy curriculum 
which deals with patient care with emphasis on drug therapy. 
Clinical pharmacy seeks to develop a patient-oriented attitude. 
Acquisition of new knowledge is secondary to attainment of skills 
in interprofessional and patient communication.” (MEYER et al.  
2003) 
European Society of Clinical Phar-
macy (ESCP) 
1983 
“A Clinical Pharmacist is a health care provider promoting the 
effective, safe, and rational use of drugs by the individual and by 
the society.” (MEYER et al. 2003) 
Bundesvereinigung Deutscher Apo-
thekerverbände (ABDA), Deutsche 
Pharmazeutische Gesellschaft 
(DPhG) 
1997 
„Clinical pharmacy is the discipline of pharmacy, which aims at 
optimising the use of drugs in and by the patient on the basis of 
pharmaceutical and natural scientific knowledge.” (literally trans-
lated from MEYER et al. 2003) 
American College of Clinical Phar-
macy (ACCP) 
2004 
“A health science discipline that embodies the application and 
development, by pharmacists, of scientific principles of pharma-
cology, toxicology, therapeutics, clinical pharmacokinetics, 
pharmacoeconomics, pharmacogenomics, and other life sci-
ences for the care of patients.” (ACCP 2008) 
United Kingdom Clinical Pharmacy 
Association (UKCPA) 
- 
“Clinical pharmacy encompasses the knowledge, skills and atti-
tudes required by pharmacists to contribute to patient care.” 
(FRANKLIN and VAN MIL 2005) 
 
Table 1: Definitions of clinical pharmacy 
 
The term ‘clinical pharmacy’ (Klinische Pharmazie, in German) is not used consistently. 
In the German language, the term ‘Patientenorientierte Pharmazie’ (literally translated 
‘patient-oriented pharmacy’) is often used synonymously.  
The adjective ‘clinical’ suggests a narrow scope of clinical pharmacy services that are 
limited to hospitalised patients. However, clinical pharmacy can also be provided in 
areas outside of the hospital, e.g., nursing homes, the home of the patient, or in any 
other institution or area where drugs are prescribed and applied (SCROCCARO et al. 
2000). Clinical pharmacy services are one aspect of hospital pharmacy, but they are in 
no way limited to the hospital area.  
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The primary objective of clinical pharmacy services is the optimisation of pharmaco-
therapy. By working with other healthcare professionals, e.g., physicians, nursing staff, 
dieticians, and others, in an interdisciplinary and interprofessional context, the clinical 
pharmacist is co-responsible for the rational and effective use of drugs, the application 
of evidence-based medicine criteria, and economical considerations. The clinical 
pharmacist provides information regarding all relevant pharmacotherapy issues and the 
selection and use of drugs.  
The occurrence of adverse drug reactions (ADRs) and drug-drug interactions (DDIs), 
just to name two of common drug-related problems (DRPs) in hospitalised patients with 
polypharmacy (see 1.1.5), is thought to be decreased by clinical pharmacy services 
(BOND and RAEHL 2006, KRÄHENBÜHL-MELCHER et al. 2007,  
VIKTIL and BLIX 2008). Furthermore, the clinical pharmacist addresses adherence 
issues by providing patient information and counselling.   
Taking into account the shortage of financial resources in healthcare systems, the clini-
cal pharmacist plays an important role by providing information on economical drug use 
and contributes to balancing the increasing cost of drugs and medical services by ap-
plying cost reduction strategies (SCHUMOCK et al. 2003).   
 
The optimisation of pharmacotherapy by clinical pharmacists can be addressed in vari-
ous settings, e.g., during ward round participation, medical chart reviews, interdiscipli-
nary discussions, and any other form of ward-based clinical pharmacy, and at three 
different levels, i.e., before, during, and after the prescription (Table 2). 
 
Before the prescription During the prescription After the prescription 
Clinical trials; 
development, observation, and 
management of formularies; 
drug information 
Counselling activity on drug 
selection; pharmacokinetics and 
therapeutic drug monitoring 
Counselling activity; patient-
specific compounding; drug use 
evaluation; outcome research; 
pharmacoeconomic studies; 
pharmacovigilance 
   
Table 2: Main levels of clinical pharmacy activities (SCROCCARO et al. 2000) 
 
As a member of the patient care team, the clinical pharmacist is involved in several 
different time points during the patient journey. All clinical pharmacy activities are per-
formed as shared responsibilities, and they do not diminish the responsibilities of other 
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 healthcare professionals (CLARK 2001). The contact points and possibilities for inter-
action and contribution by the clinical pharmacist are depicted in Figure 2. 
 
 
 
Figure 2: The patient care journey (CLARK 2001) 
 
The complexity within the patient care journey is due to several interfaces that require 
transitions between primary care (extramural) and secondary care (in-hospital) as well 
as the involvement of several healthcare professionals. Several studies report benefi-
cial effects of clinical pharmacy services on humanistic (e.g., quality of life), clinical 
(e.g., disease control), and economic (e.g., reduced healthcare costs) outcomes 
(SCROCCARO et al. 2000, KABOLI et al. 2006, VIKTIL and BLIX 2008).  
 
1.1.3 PHARMACEUTICAL CARE 
The definition of pharmaceutical care originally dates to the 1980s (BRODIE et al. 
1980) and was extended and concretised in 1989 (HEPLER and STRAND 1989) (Ta-
ble 3). In the German language, pharmaceutical care can be literally translated as 
’Pharmazeutische Betreuung’. 
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 1980 
“Pharmaceutical care includes the determination of the drug needs for a given individual and 
the provision not only of the drug required but also the necessary services (before, during or 
after treatment) to assure optimally safe and effective therapy. It includes a feedback mecha-
nism as a means of facilitating continuity of care by those who provide it.” (BRODIE et al. 
1980) 
1989 
“The responsible provision of drug therapy for the purpose of achieving definite outcomes that 
improve patient’s quality of life.” (HEPLER and STRAND 1989) 
1998 
“A practice in which the practitioner takes responsibility for a patient’s drug-related needs and 
is held accountable for this commitment. In the course of this practice, responsible drug ther-
apy is provided for the purpose of achieving positive patient outcomes.” (CIPOLLE et al. 1998) 
2005 
“…the person-focused care relating to medication, which is provided by a pharmacist and the 
pharmacy team with the aim of improving the outcomes of therapy.” (FRANKLIN and 
VAN MIL 2005) 
 
Table 3: Definitions of pharmaceutical care 
 
The early definitions of this concept are consistent in that ‘the pharmacist’ is not part of 
the definition. Although developed by pharmacists, the provision of pharmaceutical 
care to patients was not thought to be and is still not reserved to pharmacists, and oth-
er professionals can deliver pharmaceutical care as well. However, as pharmacists in 
many countries are well-educated professionals with a solid knowledge of drugs, in-
cluding their functions and associated problems, they generally have all of the neces-
sary capabilities to deliver pharmaceutical care and address all steps of the pharma-
ceutical care process (Figure 3). However, in addition to pharmacological knowledge, 
social and communication skills and a certain patient-oriented attitude is also neces-
sary (VAN MIL et al. 2004). 
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Figure 3: Hepler’s pharmaceutical care process (VAN MIL et al. 2004) 
 
Pharmaceutical care describes the process of close interprofessional cooperation and 
co-working (of a pharmacist) with a patient and other professionals in designing,  
implementing, and monitoring a therapeutic plan with the goal of producing specific 
therapeutic outcomes for the patient that are beyond the boundaries of in-hospital pa-
tient care, ambulatory patient care, and extramural patient care (HEPLER and  
STRAND 1989). For the first time, the accountability of the pharmacist for patient  
specific outcomes was defined and included in the definition of pharmaceutical care. 
 
The patient, with his or her medical and pharmacotherapy-related needs, is in the  
centre of the pharmaceutical care process. Pharmaceutical care has been described as 
a philosophy on which clinical pharmacy should be based, relating to the morality of the 
relationship between the pharmacist and patient and encompassing both clinical  
pharmacy and social pharmacy. All interventions are performed with focus on positive 
patient outcomes and an ultimate improvement of the individual’s quality of life.  
 
1.1.4 CLINICAL PHARMACY AND PHARMACEUTICAL CARE 
Clinical pharmacy and pharmaceutical care are closely related, intertwined, comple-
mentary concepts (FRANKLIN and VAN MIL 2005). Clinical pharmacy is an essential 
component in the delivery of pharmaceutical care (Figure 4), and the two disciplines 
possess similar goals.  
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Figure 4: The concept of pharmaceutical care in relation to clinical pharmacy (HERSBERGER 2005) 
 
The discipline of clinical pharmacy contributes to the greater concept of pharmaceutical 
care by achieving pharmacotherapy-related goals and increasing health-related quality 
of life (HEPLER 2004). The ACCP states that “clinical pharmacy embraces the phi-
losophy of pharmaceutical care and blends a caring orientation with specialized thera-
peutic knowledge, experience and judgment for the purpose of ensuring optimal patient 
outcomes” (ACCP 2008). 
This new aspect rendered the pharmacist responsible for the outcomes of drug therapy 
by refocusing the clinical pharmacy practice from process to outcome (CALVERT 
1998). It is evident that both disciplines (either taken individually or as one comprehen-
sive integrative system) are truly interdisciplinary and that cooperation with all involved 
groups of healthcare professionals and the patients is, therefore, necessary.  
 
For the purpose of the underlying scientific thesis, the term clinical pharmacy will be 
used consistently throughout as defined by the ESCP (ESCP 2010). 
 
1.1.5 DRUG-RELATED PROBLEMS  
Pharmacotherapy not only may have beneficial effects for the patient but also may be 
associated with problems or even cause harm. Conventional definitions and illustrating 
examples are given in Table 4.  
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 Drug-related problem (DRP) 
“A circumstance that involves a patient’s drug 
treatment that actually, or potentially, interferes 
with the achievement of an optimal outcome” 
(JOHNSON and BOOTMAN 1995). 
i.e., drug over- or under-
dosage; drugs used that 
are not indicated; indica-
tions, but no drug 
Medication error (ME) 
“Any error in the process of prescribing, dis-
pensing or administering a drug, whether there 
are adverse consequences or not” (LEAPE 
1995) 
i.e., unreadable writing 
leads to drug over-dosage; 
infusion to be administered 
centrally is accidentally 
administered peripherally 
Adverse drug reaction (ADR) 
“Any response to a drug which is noxious and 
unintended and which occurs at doses nor-
mally used in humans for prophylaxis, diagno-
sis or therapy of disease, or for the modifica-
tion of physiological function, given that this 
noxious response is not due to a medication 
error” (ANONYMOUS 1995) 
 
Adverse drug event (ADE) 
“An injury related to the use of a drug, although 
the causality of this relationship may not be 
proven” (LEAPE 1995) 
 
 
Table 4: Definitions and examples of problems associated with pharmacotherapy 
 
Because of the different types of DRPs, definitions overlap and are linked to each oth-
er. The relationship between various types of DRPs is depicted in Figure 5.  
 
Figure 5: Relationship between types of DRPs (VAN DEN BEMT et al. 2000) 
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 DRPs are common in the hospital setting. In a prospective study among 830 medical 
patients, 81% of the patients had at least one DRP, and an average of 2.1 clinically 
relevant DRPs per patient was observed (BLIX et al. 2004). Risk factors for DRPs  
include age, number of drugs, number of co-morbidities, and female gender  
(KRÄHENBÜHL-MELCHER et al. 2007). 
 
The occurrence of DRPs is closely linked to increased patient morbidity, and if not  
adequately addressed and resolved by any healthcare professional, it can lead to drug-
related mortality. Furthermore, DRPs can lead to a decreased health-related quality of 
life and an increased length of hospital stay and increased costs (PIRMOHAMED et al. 
1998). Therefore, any measures addressing the prevention of DRPs deserve great 
attention. 
 
A study in the United States estimated the costs of drug-related morbidity and mortality 
in a 700-bed teaching hospital (expressed as costs attributable to all ADEs and  
preventable ADEs) to be approximately $5.6 million and $2.8 million, respectively  
(BATES et al. 1997). The overall costs of drug-related morbidity and mortality in the US 
exceeded $177.4 billion in 2000 (ERNST and GRIZZLE 2001). However, data from 
other countries or healthcare settings are scarce. The Austrian Chamber of  
Pharmacists estimated that the costs related to misused medical products and the as-
sociated morbidity and mortality would account for €3.77 billion in Austria (ÖAK 2010).  
 
ME rates published in the literature range from 1.7% to 59%, but generally assumed 
rates report 15% for floor stock distribution systems and 2-5% for unit-dose distribution. 
In Austrian hospitals, the floor/ward stock system is the predominant distribution  
system. Prescribing errors, which are not included in the aforementioned numbers, are 
reported to be between 0.3-2.6% (VAN DEN BEMT et al. 2000). Almost 1% of MEs 
result in an ADE (BATES et al. 1995). 
 
The incidence of ADRs, additional commonly encountered problems in hospitalised 
patients, ranges between 1.9 and 37.3%. This wide range can be explained by differ-
ences in detection and reporting methods of ADRs (VAN DEN BEMT et al. 2000).  
A meta-analysis reports a fatality rate of 0.32% (LAZAROU et al. 1998). 
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 ADEs occur with a frequency of 0.7 to 6.5%, depending on the strictness of their  
definition. Between 28 and 56% of ADEs are reported to be preventable  
(VAN DEN BEMT et al. 2000). Incidence rates from American hospitals report a range 
from 2 to 7 ADEs per 100 admissions (AHRQ 2001). 
 
The exact magnitude of DRPs is, however, unclear. Prevention strategies that have 
been shown to be beneficial involve mainly technical interventions at the level of  
distribution and prescription, e.g., unit-dose systems, computerised physicians order 
entry systems (CPOEs), automated dispensing systems, and the use of bar coding. 
Further measures address gaps in education and knowledge and tackle early detection 
of ADEs (VAN DEN BEMT et al. 2000).  
 
Clinical pharmacists on the ward also significantly contribute to a reduction in MEs 
(KRÄHENBÜHL-MELCHER et al. 2007) and ADEs (AHRQ, 2001).  
 
1.1.6 EVOLUTION OF CLINICAL PHARMACY SERVICES 
Clinical pharmacy services first evolved in the 1960s and 1970s in the United States 
and around ten years later in the UK. The emergence of clinical pharmacy services as 
an element of hospital pharmacy reflected similar changes worldwide, especially in 
North America, Australia, and New Zealand (HUDSON et al. 2007).  
For the first time, an analysis of risks and errors associated with drugs and pharmaco-
therapy was performed, and areas with an urgent need for improvement and optimisa-
tion were highlighted. During this time, the process of prescribing, dispensing, and  
applying drugs was commonly performed without any coordination of or communication 
between the healthcare professionals involved (MEYER et al. 2003). The awareness of 
this far-from-ideal situation and the realisation that pharmacists could intervene and 
contribute by applying their knowledge and experience in this specialised field initiated 
a shift from the traditional roles of the pharmacists at that time («focus on the drug  
itself») to a more patient-oriented approach («focus on the patient»). Through this  
concept, pharmacists could evolve into patient-focused healthcare providers  
(UKCPA 2010) and expand their traditional roles.  
The presence of the pharmacist on the ward and his or her active participation in pa-
tient care as a member of the healthcare team was revolutionary (CALVERT 1998).  
A shift from a reactive role towards a more proactive role was initiated.  
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 The development of the discipline of clinical pharmacy in the US and the awareness of 
drug-associated morbidity and mortality and its costs were the basic stimuli for the im-
plementation of such services in other countries. However, differences between  
national healthcare systems and implicit roles and responsibilities of healthcare  
professionals as well as the lack of human and technical resources significantly influ-
enced this progress and set limitations to the development of the discipline. Another 
main influencing factor was the lack of clinical orientation during pharmacy education, 
which is still a major and continuing barrier to professional advancement in several 
European countries (HUDSON et al. 2007).  
 
1.1.7 CLINICAL PHARMACY SERVICES IN AUSTRIA 
In Austria, the emphasis of pharmacy services within the hospital still rests on  
non-clinical services offered by hospital pharmacists (see 1.1.1). However, the practice 
of clinical pharmacy services and a more regular clinical role of hospital pharmacists 
began with the implementation of the compounding of patient-specific ready-to-use 
cytotoxics and total parenteral nutrition. 
 
Clinical pharmacy was first defined in the Regulation on the Operation of Pharmacies 
2005, an ordinance to the Austrian Medicines Act, as adjunctive terminology for  
patient-oriented services (ABO 2005). For the first time, a legal definition of the function 
of pharmaceutical services was given. Among others, these services consist of the 
provision of patient-oriented services (i.e., clinical pharmacy), assistance in optimising 
pharmacotherapy, and the provision of information and counselling of physicians, other 
healthcare professionals, and patients regarding all aspects of drugs and pharmaco-
therapy. Furthermore, this new ordinance authorised the pharmacist to be granted  
access to patient medical records in order to fulfil the legal requirements of his profes-
sion. However, an official and legal job title of “clinical pharmacist” does not exist in 
Austria as of 2011, and an explicit framework of competencies, duties, and responsibili-
ties in relation to other professions for clinical pharmacists is lacking. 
 
The provision of regular and continuous clinical pharmacy services is influenced, 
among other factors, by the availability of adequately trained (hospital) pharmacy staff.  
In Austria, there are a total of 266 hospitals with a capacity of 64.267 beds. Only 17.3% 
(n=46) of all hospitals operate their own hospital pharmacy, with a total of 280 hospital 
pharmacists employed (ÖAK 2010), resulting in a ratio of 0.44 hospital pharmacists per 
100 beds. Data from the EAHP Survey in 2005 indicate a lower ratio of 0.31 hospital 
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 pharmacists per 100 beds, taking into account that not all of the 280 hospital pharma-
cists are working full time (SURUGE and VULTO 2006).  
In other words, there is one hospital pharmacist responsible for the care of 300  
patients. Compared with data from other European countries (data available from 23 
countries), e.g., 1.91, 1.75, and 1.69 hospital pharmacists per 100 beds in Estonia, 
Norway, and Portugal, respectively, Austria ranks antepenultimate regarding hospital 
pharmacist staffing. 
 
Systematic data on clinical pharmacy services and their extent and characteristics in 
Austria are lacking. An unofficial survey of the Austrian Association of Hospital  
Pharmacists (AAHP) among all Austrian hospitals pharmacy shows that taking together 
the complete time of hospital pharmacists on the ward, there are 8 full-time clinical 
pharmacists within a group of 148 full-time hospital pharmacists. The average Austrian 
hospital pharmacist spends 55 hours per year as a clinical pharmacist on the ward 
(HETZ 2008). 
 
Further data from 2010 report that 68% of Austrian hospitals have implemented regular 
clinical pharmacy services. Regular clinical pharmacy services were defined as  
participation in ward rounds, provision of drug information, and examination of medica-
tion profiles. Regarding the extent of clinical pharmacy service implementation, the 
average Austrian hospital has two clinically active hospital pharmacists in charge of 
one to two wards, with a median frequency of ward attendance of once per week 
(FRIEDL 2010). 
 
Hence, data are scarce, and the overall number of clinical active pharmacists varies 
with the definition of services implemented and the frequency that they are offered. 
When interpreting the aforementioned data and when making comparisons with other 
countries, these limitations must be considered. Data on the number of patients  
receiving clinical pharmacy services and those receiving patient education from clinical 
pharmacists during their inpatient stay are lacking.   
 
Apart from lacking an adequate number of hospital pharmacy staff, educational pro-
grammes in clinical pharmacy are lacking compared with the US or the UK, where 
there are postgraduate education programmes, e.g., PGYs and MSc-programmes in 
clinical pharmacy. Advanced training for clinical pharmacists is essential for the promo-
tion of the profession (HUDSON et al. 2007).   
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 Only the minority of Austrian hospital pharmacists attending wards and providing  
clinical pharmacy services have received specified clinical pharmacy education and if 
so, then mainly abroad (FRIEDL 2010). Practicing clinical pharmacists in Austria are 
often autodidactic and have to develop necessary skills and specific knowledge on their 
own. However, plans for implementation of a postgraduate clinical pharmacy education 
do exist (LEMMENS-GRUBER 2011).  
 
Some training and continuing education are currently available in Austria implemented, 
but a career structure that facilitates the development and specialisation within the  
clinical pharmacy area is absent. Some skills necessary for the practice of clinical  
pharmacy are currently being taught in the “Krankenhausapothekerweiterbildung”  
(literally translated ‘continuing education for hospital pharmacists’), which was imple-
mented by the Austrian Chamber of Pharmacists. At the university level, no systematic 
specialisation exists. However, with the implementation of the new pharmacy  
curriculum in 2007, the old curriculum was amended by the introduction of a mandatory 
seminar in patient-oriented pharmacy, which focuses on pharmacokinetics and further 
clinical pharmacy activities, and a combined lecture and practical course on chemical 
diagnostics and clinical pharmacy. However, clinical pharmacy research and the 
measurement of efficacy of clinical pharmacy services are still lacking. 
 
Clinical pharmacy services are growing in Austria, although they are still in their early 
phases. On the basis of international comparisons, the development of these services 
in the German-speaking countries of Germany and Austria started ten to fifteen years 
later than in the US (MEYER et al. 2003). Main obstacles to the routine implementation 
of clinical pharmacy services are the low number of hospital pharmacists (lack of  
human resources), a lack of a systematic clinical pharmacist education programme, 
which would ideally begin at the university level (lack of educational measures), and  
a lack of research within this area to prove the need for and benefit of clinical pharmacy 
services at a national level in Austria, which has already been published for other 
healthcare settings and countries.   
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 1.2 RENAL CLINICAL PHARMACY SERVICES 
1.2.1 DEVELOPMENT AND CONCEPT OF RENAL CLINICAL PHARMACY SER-
VICES 
Renal clinical pharmacy services (or nephrology pharmacy) began in the US in the 
1970s, after the overall benefits of general clinical pharmacy had been demonstrated 
(JOY and MATZKE 2007). In the mid-1980s in the UK, clinical pharmacists dedicated 
to renal pharmacy founded the UK Renal Pharmacy Group (UKRPG 2011).  
In 1996, the Renal Pharmacists Network was founded in Canada  
(RENAL PHARMACISTS NETWORK 2011).  
 
At that time, there was an ever-increasing knowledge of drug behaviour and pharmaco-
therapy in patients with renal impairment. The need for dose individualisation for  
primary renally excreted drugs was determined. Nephrology education programmes 
were developed to educate pharmacists on renal diseases, drug prescribing in renal 
impairment, and further specifics. Special needs of different nephrology patient groups,  
e.g., haemodialysis or peritoneal dialysis patients, were described, and the  
pharmacists’ role in their care was defined and investigated. Special interest groups, as 
mentioned at the beginning of this section, were formed to address these needs  
(JOY and MATZKE 2007). 
 
The first services implemented were steadily amended by optimising pharmacotherapy 
with the goal of improving associated outcomes and the highly prevalent co-morbidities 
of renal patients, e.g., hypertension, anaemia, and hyperparathyroidism.  
The role of the clinical pharmacist expanded. With the beginning of the 21st century, 
several renal clinical services were provided by renal clinical pharmacists, including 
outpatient CKD or dialysis patient management, supervision of the specific pharmaco-
therapy-related needs of renal patients, contributions to the understanding of drugs and 
their removal during different types of renal replacement therapy, and outcome re-
search in the nephrology patient population (JOY and MATZKE 2007). Development of 
specialised renal services occurred as a result of the growing number of CKD patients 
and, consequently, different renal replacement therapies (e.g., any form of dialysis or 
kidney transplantation) (see 1.2.3). Significant contributions to the literature regarding 
the efficacious and safe utilisation of drugs in transplant and dialysis patients have 
been made (MANLEY and CAROLL 2002, MANLEY et al. 2003). 
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 Suboptimal management of risk and progression factors of renal impairment and CKD 
complications, such as anaemia, malnutrition, renal osteodystrophy, and metabolic 
disorders, have been commonly reported (JOY et al. 2005). One strategy that  
addressed this gap in care was the introduction of clinical pharmacists as pharmaco-
therapy experts in multidisciplinary care teams.  A possible framework for the multidis-
ciplinary care of CKD patients is depicted in Figure 6.  
 
 
 
Figure 6: The multidisciplinary approach to CKD care (JOY et al. 2005) 
 
Several opportunities for the clinical pharmacist to contribute to complex patient care 
and to assume responsibility for drug therapy monitoring and management are  
described in the literature (ZILLICH et al. 2005).  
 
Within multidisciplinary patient care teams, the clinical pharmacist addresses multiple 
tasks and fulfils many roles (JOY et al. 2005): 
 
 Blood pressure management 
 Glycemic management 
 Screening for microalbuminuria/proteinuria and initiation of pharmacologic  
therapy with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin 
receptor blockers (ARBs) 
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  Anaemia management 
 Screening and management of metabolic bone disease 
 Hyperlipidemia management 
 Drug dosage adjustments and avoidance of nephrotoxic agents 
 Medication education 
 
A survey among Canadian nephrologists reported that only 65% had access to a  
clinical pharmacist in a multidisciplinary care team environment, whereas access to 
nurses, social workers, and dieticians was available for over 90% of all nephrologists  
(MENDELSSOHN et al. 2006). Data from the US show that pharmacists are not  
routinely involved in the monitoring of common CKD complications, i.e., anaemia and 
bone metabolism problems (BENNETT et al. 2006). In Austria, there is no routine  
involvement of clinical pharmacists in renal clinical pharmacy services.  
 
Standards for the provision of renal clinical pharmacy services have been developed, 
e.g., those by the UK Renal Pharmacy Group (UKRPG), with the goal of not only  
guiding clinicians and defining audit measures and outcome parameters but also  
standardising the education of clinical pharmacists.  
These standards involve the following: regular prescription reviews for defined patient 
groups, e.g., in-hospital patients, kidney transplant recipients, and dialysis outpatients; 
medication counselling due to complicated prescriptions with multiple drugs in order to 
maximise their effects; patient discharge planning; the provision of renal medicine  
information; and protocol and guideline development (UKRPG 2004).  
To avoid overlapping responsibilities among healthcare providers, a framework of 
competencies and responsibilities must be developed, defined, and mutually agreed 
upon by the multidisciplinary team to reduce overlap, increase efficiency, and optimise 
patient care. 
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 1.2.2 RENAL FUNCTION AND ITS IMPAIRMENT 
1.2.2.1 The kidney and its function 
The kidney is mainly responsible for three functions (BRIGGS et al. 2005): 
 Maintenance of body fluid composition by regulating fluid volume, osmolarity, 
electrolyte (e.g., sodium, potassium, chloride, calcium, magnesium, and  
phosphate) content and concentration, and acidity by correcting perturbations 
caused by food intake, metabolism, environmental factors, and exercise, 
 Excretion of metabolic end products and foreign substances (e.g., drugs,  
toxins), and  
 Production and secretion of enzymes and hormones (e.g., renin, erythropoietin, 
1,25-dihydroxyvitamin D2). 
 
1.2.2.2 Evaluation of kidney function 
Knowledge of kidney function is essential for disease staging and influences all aspects 
of drug and non-drug therapy. The most important parameter to be clinically evaluated 
is the glomerular filtration rate (GFR). Estimates of GFR, which are based on a 24-hour 
creatinine clearance (CrCL), require timed urine collections, a time consuming and  
error-prone process. The measurement of inulin clearance is the gold standard of GFR 
evaluation. Inulin is an ideal filtration marker that is simply filtered in the glomeruli and 
neither reabsorbed nor secreted. More sophisticated methods, especially in clinical 
research, involve the measurement of clearance of radiolabeled markers, such as  
iothalamate (a radiographic contrast agent), diethylenetriamine pentaacetate (DTPA), 
and ethylenediamine tetraacetate (EDTA) (HSU 2005). However, in clinical practice, 
these methods are not feasible. Serum creatinine, which is endogenously produced by 
the muscle and excreted by the kidney, is a commonly used parameter to judge kidney 
function. However, serum creatinine alone is not an ideal marker of GFR because it is 
both filtered in the glomeruli and secreted by the proximal tubule in the kidney.  
 
In clinical practice, the evaluation of kidney function is generally performed by  
estimating the CrCL and GFR, using the Cockcroft-Gault and Modification of Diet in 
Renal Disease (MDRD) equations, respectively. Generally, these equations are based 
on serum creatinine values, but are corrected for numerous variables such as age, sex, 
race, and body size (Table 5). Creatinine clearance approximates GFR, but tends to 
overestimate kidney function by around 20% in healthy individuals and even more in 
CKD patients.  
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Cockcroft-Gault Equation 
female) if (0.85x 
(mg/dL)S x 72
(kg) bodyweight x age)(140Cl
 Cr
Cr
  
Modification of Diet in Renal Disease (MDRD) Equation (simplified) 
black] if 1.21[x  female] if 0.742[x  age x (mg/dL)S  x 186  )73m(mL/min/1. GFR 0.2031.154 Cr2   
 
Table 5: Equations for the prediction of creatinine clearance or GFR in adults with kidney disease  
(SCr serum creatinine) 
 
The accuracy of such equations is limited if serum creatinine levels fluctuate. The 
MDRD equation yields more accurate results of kidney function in patients with known 
renal disease. Compared with the Cockcroft-Gault equation, the MDRD equation is  
superior in patients with a GFR lower than 60 mL/min/1.73m2.   
Especially in extreme deviations of normal body size (e.g., malnutrition, overweight, 
extremes of age and size), the presence of muscular disease or paralysis, a vegetarian 
diet, undulating kidney function, and pregnancy, the performance of a 24-hour urine 
collection and the measurement of creatinine clearance may, nevertheless, be valuable 
and provide a more accurate estimate of kidney function.   
 
1.2.2.3 Types of kidney failure 
Acute renal failure describes a medical condition that is accompanied by a sudden and 
generally reversible decrease in GFR that occurs over hours to days and the need for 
renal replacement therapy (FAUBEL et al. 2009).  
 
Chronic kidney disease (CKD) is a progressive condition that is marked by  
deterioration of kidney function over time. It is defined as either kidney damage or  
GFR < 60 ml/min/1.73m2 for over three months (NKF 2002).  
The most common staging criteria used for CKD are those given by the US National 
Kidney Foundation KDOQI, which are based on GFR (Table 6). Staging of kidney  
function is necessary for the application of guidelines, measurement of clinical  
performance, and other evaluations of CKD patients, but does not necessarily reflect 
the extent of residual kidney function, the presence of comorbidities or complications, 
or other disease issues (NKF 2002). 
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 Stage GFR (mL/min/1.73m2) Description 
1 ≥90 Normal or increased GFR, with other evidence of kidney damage* 
2 60-89 Slight decrease in GFR, with other evidence of kidney damage* 
3 30-59 
Moderate decrease in GFR, with or without other evidence of kidney 
damage* 
4 15-29 
Severe decrease in GFR, with or without other evidence of kidney 
damage* 
5 <15 Established renal failure 
* Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in 
blood or urine tests or imaging studies. 
 
Table 6: Classification of chronic kidney disease 
 
Impaired renal function (defined as decreased GFR) is associated with several  
complications that are secondary to the progression of kidney disease, including  
hypertension, anaemia, secondary hyperparathyroidism, and malnutrition. The severity 
of symptoms generally worsens with a decline in renal function.  
 
Kidney failure (or end-stage renal disease, ESRD) is defined as either a level of  
GFR < 15 mL/min/1.73m2 that is most commonly accompanied by signs and symptoms 
of uraemia or the need for initiation of kidney replacement therapy, which can either be 
any mode of dialysis (e.g., haemodialysis or peritoneal dialysis) or kidney  
transplantation. ESRD is associated with a high morbidity and mortality (NKF 2002).  
 
1.2.2.4 Risk factors  
Risk factors associated with CKD include susceptibility factors, initiation factors, and 
progression factors (NKF 2002, JOY et al. 2008; Figure 7).  
 
Susceptibility factors to CKD consist of advanced age, low income or education,  
racial/ethnic minority status, reduced kidney mass, low birth weight, and a family  
history of CKD. These factors have not been proven to cause kidney damage them-
selves, but they may be useful for identifying patients at a high risk for CKD (JOY et al. 
2008). 
 
Initiation factors directly initiate kidney damage and can be treated with pharmacologic 
therapy. Impaired kidney function is also a major risk factor for patients with  
cardiovascular disease. Examples of initiation factors are diabetes mellitus,  
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 hypertension, autoimmune diseases, polycystic kidney disease, systemic infections, 
urinary tract infections, urinary stones, and drug toxicity. Diabetes, hypertension, and 
glomerular diseases are the most common causes of CKD (JOY et al. 2008).  
 
Progression risk factors are those associated with the worsening of kidney function. 
Underlying initiation factors (e.g., diabetes, hypertension, and glomerulonephritis) may 
persist and predict the progression of CKD. The presence of albuminuria is a predictor 
of not only CKD but also cardiovascular morbidity and mortality. Obesity and smoking 
are also progression factors (JOY et al. 2008).  
 
 
 
Figure 7: Development and progression of CKD (NKF 2002) 
 
1.2.2.5 Clinical presentation of CKD and management of comorbidities 
Symptoms are generally absent in CKD stages 1 and 2 and may be minimal during 
stages 3 and 4. General symptoms associated with stages 1 to 4 include oedema, cold 
intolerance, shortness of breath, palpitations, cramping and muscle pain, depression, 
anxiety, fatigue, and sexual dysfunction.  
Signs include evidence of left ventricular hypertrophy, weight loss, arrhythmias,  
secondary hyperparathyroidism, anaemia of CKD, iron deficiency, bleeding, and  
several electrolyte disorders (JOY et al. 2008).  
 
The goal of therapy at early stages is to delay disease progression and minimise the 
development or severity of associated complications, including cardiovascular disease. 
Generally, the patient benefits from modest dietary protein restriction  
(non-pharmacological therapy) and a multimodality pharmacological treatment  
approach, which targets the optimal control of underlying conditions, such as diabetes 
mellitus and hypertension. ACEIs and/or ARBs to control proteinuria are key elements 
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 in this pharmacological management. Other interventions may include the addition of 
lipid-lowering agents, smoking cessation, and anaemia management. 
 
Symptoms of CKD stages 4 and 5 are generally related to uraemia and include fatigue, 
weakness, shortness of breath, nausea, bleeding, and loss of appetite. Itching,  
peripheral neuropathies, and weight gain may also be common. Oedema and changes 
in urine output in terms of volume and consistency could be prominent signs of late 
stage CKD. The most common complications of an aggravation of renal function to 
CKD stages 4 and 5 involve fluid and electrolyte abnormalities, metabolic acidosis, 
anaemia of CKD, secondary hyperparathyroidism, and cardiovascular disease  
(e.g., hypertension, hyperlipidaemia) in dialysis patients (HUDSON 2008).  
 
The general approach to patient care should include frequent medication reviews to 
reduce the risk of DRPs and exposure to nephrotoxic agents. Adherence to drug  
dosing guidelines and avoidance of the chronic use of non-steroidal anti-inflammatory 
drugs (NSAIDs), radiocontrast agents, and nephrotoxic antibiotics are key. As drug 
regimens of CKD and ESRD patients are often very complex because of a high number 
of drugs and a high frequency of application, patient education on the characteristics 
and the correct use of all prescribed drugs is essential (NKF 2002).   
 
Appropriate management of the secondary complications of CKD usually involves a 
multidisciplinary approach. Recommendations on the management of several  
complications are published in guidelines, which are systematically collected by the 
Kidney Disease: Improving global outcomes (KDIGO) initiative (KDIGO, 2011). The 
following paragraphs include short summaries of therapy goals and descriptions of the 
main drugs involved in this management. For detailed and more comprehensive  
information on the management of individual complications and pharmacology, the 
consecutive guidelines and summary of product characteristics (SPCs) of these drugs 
should be consulted. 
 
Cardiovascular disease in CKD: The management of hypertension (blood pressure 
goal in early stage CKD is < 130/80 mm Hg) and hyperlipidaemia  
(LDL cholesterol < 100 mg/dL) is key in CKD patients as major risk factors for  
cardiovascular disease. In addition to non-pharmacologic therapy strategies  
(e.g., sodium and fluid intake restriction, lifestyle modifications including regular  
exercise and weight loss), blood pressure reduction can often only be achieved through 
multiple combinations of antihypertensive agents. Thiazides generally lose their  
 30
 efficacy with lower GFR rates. ACEIs or ARBs are preferred agents in patients with 
progressive CKD and proteinuria. However, all classes of antihypertensive drugs (also 
calcium channel blockers, beta blockers, alpha-blockers and central acting antihyper-
tensives) can be used, with regard to concomitant disease states and CKD stage 
(HUDSON 2008). 
 
Anaemia of CKD: To achieve desired outcomes of anaemia management  
(e.g., decreasing dyspnoea, orthopnoea, and fatigue, and prevention of left ventricular 
hypertrophy (LVH) and cardiovascular mortality), iron, folate, vitamin B12, and erythro-
poiesis stimulating agent (ESA) levels must be sufficient. The target haemoglobin val-
ue, the preferred monitoring parameter, is generally set between 11-12 g/dL. Higher 
levels are associated with increased cardiovascular morbidity. Generally, in addition to 
iron and vitamin B substitution if necessary, erythropoiesis-stimulating agents (e.g., 
erythropoietin alpha or beta, darbepoietin) are used to improve haemoglobin levels 
(HUDSON 2008).  
 
Treatment of secondary hyperparathyroidism and renal osteodystrophy: Important  
diagnostic criteria for the diagnosis and management of bone disease are levels of 
calcium, phosphorus, the calcium-phosphorus-product (Ca x P), and intact parathyroid 
hormone (iPTH). The use of phosphate-binding agents in high quantities  
(e.g., calcium-containing binders, aluminium salts, lanthanum, and sevelamer) is often 
necessary to target hyperphosphataemia. Concomitant vitamin D therapy (in its active 
form, calcitriol) or with vitamin D analogues (e.g., paricalcitol, alfacalcidol) suppresses 
PTH secretion by stimulating serum calcium absorption. Cinacalcet, a calcimimetic 
agent, is used for the treatment of secondary hyperparathyroidism in ESRD patients 
(HUDSON 2008).  
 
1.2.3 ETIOLOGY AND EPIDEMIOLOGY OF RENAL IMPAIRMENT  
The leading causes of CKD and, ultimately, of ESRD worldwide shifted from  
glomerulonephritis to diabetes mellitus and hypertension. These disease states are 
currently the two major causes worldwide, especially in countries of the developed 
world.  
 
Chronic kidney disease represents a major public health problem. In the US, around 
5% of the adult population is affected by CKD, when defined by a serum creatinine 
concentration greater than 1.2 to 1.4 mg/dL. Data from the National health and nutrition 
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 examination survey (NHANES) study show that nearly 11% (19.2 million) of the US 
adult population had reduced kidney function, as evidenced by serum creatinine  
concentrations equal to or higher than 1.5 mg/dL (JONES et al. 1998). Screening  
surveys from Australia and Japan report that 6-11% of the population have some de-
gree of CKD (EL NAHAS and BELLO 2005). 
 
Few studies have been performed on the epidemiology of CKD in European countries. 
For Austria, prevalence numbers of CKD are not available. A study conducted by  
HALLAN et al. 2006 reports a prevalence rate of CKD stages 1-5 of 10.2% in Norway, 
which is comparable to that in the US. Further data for European countries are avail-
able from the EUGLOREH project (EUGLOREH 2007). The prevalence of CKD stages 
3-5 in males ranges from 3.6% in Norway to 7.2% in Germany. Prevalence rates were  
comparable across European countries. In general, females were more often affected 
than men (Figure 8). The EUGLOREH project reports increasing prevalence rates of 
CKD stages 3-5 with advanced age. 
 
 
Figure 8: Prevalence rates of CKD stages 3-5 by gender in selected EUGLOREH countries  
(EUGLOREH 2007)  
 
 
The incidence and prevalence numbers of ESRD patients are available because of 
widespread dialysis registries (e.g., the US Renal Data System, the  
ERA-EDTA-Registry) that provide good quality data.  
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 In the year 2008, the incidence rate of ESRD in the US, the UK, and Austria was 362, 
108, and 147 per million people, respectively. Incidence rates of ESRD in the US are 
1.5 to 3 times higher than those in Europe. This difference can be partly be explained 
by a higher incidence rate of diabetic ESRD in the US (EUGLOREH 2007). 
 
In the year 2009 in Austria, 1198 patients with ESRD were initially started on dialysis 
(1088 on haemodialysis and 110 on peritoneal dialysis). These numbers result in an 
incidence rate of 143 per million people. Altogether, there have been 4198 patients on 
dialysis (3819 on haemodialysis and 379 on peritoneal dialysis), which represents a 
prevalence of 501.3 per million people. The prevalence of patients living with a  
functioning kidney transplant was 476 per million people (3978 patients). By the end of 
2009, a total of 8176 patients were on some form of renal replacement therapy 
(KRAMAR and OBERBAUER 2009). 
 
The number of patients with ESRD probably does not truly reflect the number of  
patients with CKD, which may even be higher than those numbers extrapolated from 
the ESRD numbers. Reasons for this disparity may stem from differences in disease 
definitions and CKD staging and limitations in the use of single creatinine  
measurements to estimate kidney function, which is not a valid method. Furthermore, 
because of a high mortality rate of patients with impaired renal function, which provides 
a fourfold higher risk of death before reaching the ESRD stage, the ESRD patient 
population does not necessarily represent the overall CKD population  
(WALLNER 2006).  
 
The increasing trend in incidence numbers is expected to continue at an annual rate of 
5-8%. Underlying reasons for this continuing increase may involve the ageing of the 
population, increasing life expectancy and longevity, and an increasing number of  
diabetic people as the major underlying reason for development of CKD  
(EL NAHAS and BELLO 2005). 
  
1.2.4 SUSCEPTIBILITY FOR DRUG-RELATED PROBLEMS IN PATIENTS WITH 
RENAL IMPAIRMENT 
The incidence of evident and potential ADEs is reported to be 10 and 55.3 per  
100 admissions, respectively, in patients with a serum creatinine concentration greater 
than 1.5 mg/dL (HUG 2009). In this study, most of the adverse events were  
preventable, but almost none were intercepted. Incorrect dosing in renal insufficiency 
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 leads to most of the preventable adverse events. Accurate assessment of renal  
function and adaptation of dosing is key to avoid unwanted drug effects and ensure 
optimal patient outcomes. Only through collaboration of different healthcare providers, 
can the task of ensuring correct dosing, especially with large numbers of drugs, be 
achieved. 
 
Patients with impaired renal function are a particularly relevant target population in 
which the assurance of safety and appropriateness regarding medication use is critical 
for several reasons: 
 the severity of coexistent medical conditions, 
 the prevalence of comorbidities that frequently require complex drug therapy 
regimens, and 
 the substantial clinical impact that dialysis procedures have on the pharmaco-
dynamics and pharmacokinetics of the medications taken by ESRD patients. 
 
 
 
Figure 9: High-risk factors that under circumstances of poor disease recognition, can lead to adverse pa-
tient safety events (FINK and CHERTOW 2009)  
 
Patients with impaired renal function are at high risk for developing DRPs, such as 
drugs without indication, indication without drugs, improper dosages, and incorrect 
drugs among others. In one study, haemodialysis patients were shown to experience 
four DRPs at their initial visit on average, decreasing to 0.6 DRPs over a follow-up time 
of six months (MANLEY et al. 2005).  
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 Drug dosing in renal impairment is particularly complicated by the removal of drugs 
through haemodialysis and peritoneal dialysis.  
Fluctuating renal function, other altered pharmacokinetic factors due to CKD,  
chronically impaired renal function, and poor medication compliance or adherence are 
predisposing factors to adverse drug events. Drug absorption, distribution, rate of  
protein binding, biotransformation, and most importantly, renal excretion may be  
altered (HASSAN et al. 2009, KUCZYNSKA 2009): 
 
Effects on absorption: Absorption (and, therefore, bioavailability) may be reduced  
because of nausea, vomiting, or uraemia-associated diarrhoea. The bioavailability of 
drugs that require an acidic environment for absorption may be decreased because of 
increased gut pH. 
 
Effects on distribution: Because of changes in states of hydration (e.g., oedema,  
ascites, general volume overload) and a decreased concentration of serum albumin, 
the distribution of drugs can be altered.  
 
Effects on metabolism: The rate of drug metabolism, e.g., reduction and hydrolysis, is 
decreased. Serum concentrations of parent drugs and consequent toxicities may  
increase if the drug is metabolised to inactive metabolites.  
 
Effects on elimination: The reduction in glomerular filtration and tubular secretion leads 
to higher plasma drug levels, and the reduction in reabsorption results in higher drug 
concentrations in the urine. Drugs may accumulate because of impaired elimination 
capacity. 
 
In addition to these pharmacokinetic changes due to renal impairment, the clinical  
response of drugs (i.e., the pharmacodynamics) may also be altered, which is caused 
by concomitant uraemia in most cases. Increased sensitivity to drugs that target the 
central nervous system, risk of hyperkalaemia with potassium-sparing drugs, and risk 
of gastrointestinal bleeding or oedema with NSAIDS have been described  
(KUCZYNSKA 2009). 
 
There is a great rate of incompliance with dosing guidelines in patients with CKD  
according to the study of LONG et al. 2004, which reports a non-compliance rate of  
19-67%. Dose adjustments were necessary in 24% of all patients discharged from the 
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studied hospital, but were only performed in 59% of these cases (VAN DIJK et al. 
2006). These findings show an imminent need for improvement.  
In addition to neglected needs for dose adjustments and the resulting drug  
accumulation, drug-induced renal dysfunction also occurs because of drug  
nephrotoxicity. The kidney is highly susceptible to nephrotoxic agents, and the kidneys 
are exposed to circulating drugs to a great extent because of ~25% of cardiac output. 
Furthermore, nephrotoxic drugs may also alter renal haemodynamics and blood flow, 
e.g., cyclosporine (VERBEECK and MUSUAMBA 2008).  
 
The involvement of pharmacists at the point of drug prescription is beneficial, as this is 
the time for decision making regarding dosing. Algorithms and recommendations on 
how to ensure the effectiveness of the prescription process include (HASSAN et al. 
2009): 
 
 Detailed initial assessment: Comprehensive assessment of previous drug  
exposure, allergies, current medication, clinical status (e.g., fluid volume), etc. 
 Evaluation of degree of renal impairment: The most commonly used equations 
for this evaluation are the Cockroft-Gault and the MDRD equation (see 1.2.2.2). 
 Review of medication list: All current drugs should have specific indications. 
The review is comprised of an evaluation of potential drug interactions and 
ADRs and correct posology according to renal function. 
 Selection of drugs with no or minimal nephrotoxicity: If there is an imminent 
need for a nephrotoxic drug, the least nephrotoxic drug should be chosen and 
monitoring of the appropriate therapeutic drug and narrow renal function should 
be implemented.  
 Selection of loading doses and a maintenance regimen: Generally, loading 
doses are the same as in normal renal function. The maintenance doses should 
be decided according to well-established dosing guidelines that are derived ei-
ther from the SPC or other compendia (e.g., Drug prescribing in renal failure, 
BNF, The Renal Drug Handbook) (ARONOFF et al. 2007, BNF 2009,  
ASHLEY and CURRIE 2009) 
 Monitoring of outcomes and frequent reassessment: Frequent reassessment of 
renal function and dose appropriateness may be necessary. Certain drugs may 
also be titrated on the basis of the pharmacodynamic response.  
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 2 AIM OF THE THESIS 
To describe renal clinical pharmacy services and the activities of clinical pharmacists 
involved in the care of CKD, ESRD, and SOT patients and synthesise published  
evidence. 
 
To describe the roles of clinical pharmacists and areas for possible contributions and 
interventions, and to evaluate areas with room for improvement in patient care. 
 
To describe and evaluate the characteristics and extent of renal clinical pharmacy  
services in a large tertiary care hospital. 
 
To describe the extent and characteristics of DRPs and clinical pharmacist  
interventions and their significance in a large tertiary care hospital. 
 
To describe additional clinical pharmacist activities and possibilities of interdisciplinary 
functions.  
 
To discuss barriers to and limitations of clinical pharmacy services in general and at the 
level of the Austrian health system and the Austrian health organisation. 
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3 SCIENTIFIC WORK
In the introduction, important clinical pharmacy activities are presented and classified 
into three main levels according to prescription time (SCROCCARO et al. 2000;  
Table 2). The studies included in this thesis and presented in the following section de-
scribe several clinical pharmacy activities that can be categorised within these  
levels, in order to address the aims of the thesis.  
 
The following literature reviews (STEMER and LEMMENS-GRUBER 2010,  
STEMER and LEMMENS-GRUBER 2011; see 3.1 and 3.2) on clinical pharmacy  
services in CKD, ESRD, and SOT patients depict the current status of this field and 
form a knowledge framework.  
The retrospective study on risk factor management (STEMER et al. 2009; see 3.3)  
investigates the need for specific therapy improvements in patients treated on a highly 
specialised internal nephrology ward in which renal clinical pharmacy services were 
implemented. This ward constituted the study setting for all further clinical pharmacy 
studies.  
The clinical pharmacist’s impact on the study ward was evaluated in several studies 
with evolving methodology. Whereas the first study (STEMER and  
LEMMENS-GRUBER 2010; see 3.4) yielded data on the contributions of the clinical 
pharmacist who applied a reactive approach to issues and questions raised by mem-
bers of the ward round team, the following studies (STEMER and LEMMENS-GRUBER 
2011, STEMER et al. 2011; see 3.6 and 3.7) deliver results of the proactive  
interventions relating to DRPs provided by the clinical pharmacist.  
The tasks of counselling and providing drug information are both major issues in  
clinical pharmacy services. The analysis of prescribing patterns on the study ward and 
the evolution of a synopsis of drug properties that are highly relevant in patients with 
impaired renal function represented strategies to address the informational needs of 
the healthcare professionals on the study ward (STEMER and LEMMENS-GRUBER 
2010; see 3.5). 
The clinical pharmacist, who possesses unique, specialised skills and expertise, also 
contributes to physician-led interdisciplinary study projects and clinical trials  
(KAUTZKY-WILLER et al. 2010, HAIDINGER et al. 2010; see 3.8 and 3.9).
39
  40
  
3.1 CLINICAL PHARMACY ACTIVITIES IN CHRONIC KIDNEY AND  
END-STAGE RENAL DISEASE PATIENTS: A SYSTEMATIC LITERATURE 
REVIEW 
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Abstract  
Background: Chronic kidney disease (CKD) and end-stage renal disease (ESRD) 
represent worldwide health problems with an epidemic extent. Therefore, attention 
must be given to the optimisation of patient care, as gaps in the care of CKD and 
ESRD patients are well documented. As part of a multidisciplinary patient care 
strategy, clinical pharmacy services have led to improvements in patient care. The 
purpose of this study was to summarise the available evidence regarding the role and 
impact of clinical pharmacy services for these patient populations. 
Methods: A literature search was conducted using the Medline, Embase and 
International Pharmaceutical Abstracts databases to identify relevant studies on the 
impact of clinical pharmacists on CKD and ESRD patients, regarding disease-oriented 
and patient-oriented outcomes, and clinical pharmacist interventions on drug-related 
problems. 
Results: Among a total of 21 studies, only four (19%) were controlled trials. The 
majority of studies were descriptive (67%) and before-after studies (14%). Interventions 
comprised general clinical pharmacy services with a focus on detecting, resolving and 
preventing drug-related problems, clinical pharmacy services with a focus on disease 
management, or clinical pharmacy services with a focus on patient education in order 
to increase medication knowledge. Anaemia was the most common comorbidity 
managed by clinical pharmacists, and their involvement led to significant improvement 
in investigated disease-oriented outcomes, for example, haemoglobin levels. Only four 
of the studies (including three controlled trials) presented data on patient-oriented 
outcomes, for example, quality of life and length of hospitalisation. Studies investigating 
the number and type of clinical pharmacist interventions and physician acceptance 
rates reported a mean acceptance rate of 79%. The most common reported drug-
related problems were incorrect dosing, the need for additional pharmacotherapy, and 
medical record discrepancies.  
Conclusions: Few high-quality trials addressing the benefit and impact of clinical 
pharmacy services in CKD and ESRD patients have been published. However, all 
available studies reported some positive impact resulting from clinical pharmacist 
involvement, including various investigated outcome measures that could be improved. 
Additional randomised controlled trials investigating patient-oriented outcomes are 
needed to further determine the role of clinical pharmacists and the benefits of clinical 
pharmacy services to CKD and ESRD patients.  
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Background 
Chronic kidney disease (CKD) represents a major public health problem in developed 
and developing countries. It is estimated that approximately 5% of the adult U.S. 
population is affected by CKD, which is defined as serum creatinine concentrations 
greater than 1.2 to 1.5 mg/dL [1]. The European Kidney Health Alliance (EKHA) reports 
that approximately 10% of European citizens are affected by some degree of CKD [2].  
CKD and end-stage renal disease (ESRD) are associated with an increased risk of 
mortality, increased rate of hospitalisation, and decreased life expectancy [3]. 
Progression from early to late stages of CKD generally results in the onset of new 
symptoms and concomitant complications. Frequent complications and comorbidities of 
CKD include fluid and electrolyte abnormalities, anaemia, secondary 
hyperparathyroidism and renal osteodystrophy, hypertension and hyperlipidaemia, 
metabolic acidosis, and several other comorbidities involving malnutrition, pruritus and 
uremic bleeding. CKD patients are at increased risk of cardiovascular disease (CVD), 
which includes coronary heart disease (CHD), cerebrovascular disease, peripheral 
vascular disease, and heart failure. The management of underlying and evident 
comorbidities (either as causes or consequences of CKD) and the prevention or delay 
of its progression to ESRD are complex.  
In ESRD patients, the initiation of renal replacement therapies (RRTs), such as long-
term dialysis (including haemodialysis (HD) or peritoneal dialysis (PD)) or 
transplantation, is usually indicated to relieve uremic symptoms and detoxify, whereas 
kidney transplantation (cadaveric or living donor transplantation) is the therapy of 
choice for ESRD [4].  
Multidisciplinary health care teams of physicians, nurses, dieticians, and clinical 
pharmacists share the goal of preventing disease progression and managing comorbid 
conditions in CKD and ESRD patients. As specialists in pharmacotherapy, clinical 
pharmacists are routinely involved in patient care and interact with other health care 
professionals, addressing multiple, often unmet needs for pharmacotherapy 
optimisation. Ideally, this happens through a preventive, rather than a reactive, 
approach. Evidence from the literature supports the involvement of clinical pharmacists 
in several disease areas and underlines the positive patient outcomes and 
improvement of care that result [5, 6]. The medical management of predialysis and 
dialysis patients involves complex and highly variable pharmacotherapy, including 
frequent monitoring and evaluation to ensure optimal pharmacotherapy, adherence to 
medication, and control of comorbidities and other risk factors. A high number of 
prescribed medications, poor medication adherence, and frequent dosage changes 
may contribute to drug-related morbidity and related problems [7]. Several studies 
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report poor quality and gaps in the care of CKD patients with respect to the treatment 
of comorbidities, referrals to specialists, and the preparation for RRTs [8, 9]. Clinical 
pharmacists are directly engaged in the care of CKD and ESRD patients in different 
settings. Various possibilities and opportunities for clinical pharmacists to contribute to 
this field are described and exemplarily supported by evidence in an American College 
of Clinical Pharmacy (ACCP) opinion paper [10].  
This literature review aims to systematically summarise the published evidence on the 
role of clinical pharmacists in the care of CKD and ESRD patients across different 
settings, to synthesise and highlight findings on the impact of clinical pharmacists, their 
various key activities, and their main areas of involvement, and to describe the different 
characteristics of clinical pharmacy services for the CKD and ESRD patient population.  
 
Methods 
A literature search was conducted using the Medline (1970 – Week 46, 2010), Embase 
(1996 – Week 45, 2010) and International Pharmaceutical Abstracts (IPA) (1970 – Oct 
2010) databases to identify relevant articles. In Medline, the following combinations of 
Medline Medical Subject Headings (Mesh) terms were used as our search strategy: 
(“pharmacy service, hospital” OR “pharmacists” OR “pharmaceutical services”) AND 
(“renal insufficiency” OR “kidney” OR “renal replacement therapy”). In Embase and 
IPA, the search strategy combined the terms (“clinical pharmacy” OR “pharmaceutical 
care” OR “pharmacist” OR “hospital pharmacy”) AND (“renal insufficiency” OR “kidney” 
OR “renal replacement therapy”). The references sections of the returned publications 
and review articles were further screened for additional hits. Data were extracted and 
reviewed by the first study author (GS) and independently reviewed by the second 
author (RLG). Discrepancies were solved by discussion among the study authors.  
All studies addressing the impact of clinical pharmacy services (either at the patient or 
the physician level) on the care of CKD and ESRD patients for both HD and PD were 
included. Therefore all studies reporting on disease-oriented and patient-oriented 
outcomes, and clinical pharmacist interventions on drug-related problems (DRPs) 
together with the physician acceptance rate, were assessed. Studies addressing the 
impact of clinical pharmacy services in kidney transplantation were excluded. A 
detailed review of these kinds of services was recently published [11]. Detailed 
inclusion and exclusion criteria are described in Table 1. The weakest study design 
included was observational and solely descriptive, as a high number of randomised 
controlled trials could not be anticipated. Results published in abstract form (e.g., 
congress abstracts) were included only if they provided numerically assessable data, 
such as outcome data, the number of resolved DRPs, or physician acceptance rates.  
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Predefined data parameters (namely, the study design, duration and setting, the 
number of included patients, the types of interventions, the relevant outcomes, the 
results, and available statistical values) were extracted from the literature, summarised 
in an Excel spreadsheet, and reviewed.  
 
Results 
The initial Medline, Embase and IPA searches yielded 339, 199, and 323 citations, 
respectively. The detailed search results are described in Figure 1.  
A total of 861 citations were initially screened for inclusion criteria, and after removing 
duplicates, a total of 21 citations remained for full review and analysis. The 
predominant reason for exclusion was a lack of interventional and/or assessable data. 
Several initial citations had to be excluded because they provided data only on the 
impact of screening on appropriate renal dosing, with or without computerised support, 
or they provided only economic data. 
General study characteristics 
Detailed descriptions on the included studies of CKD and ESRD patients are shown in 
Tables 2 and 3, respectively. Three study types were identified, including 14 descriptive 
studies (DSs) (66.7%), four (randomised) controlled (R)CTs (19%), and 3 before-after 
studies (BASs) (14.3%). A total of seven (33.3%) of the published studies were only 
available as abstracts. The earliest included study was published in 1993. The study 
sites were predominantly located in the United States (n=16, 76.2%). The majority of 
the studies investigated the impact of the clinical pharmacist on the HD patient 
population only (n=15, 71.4%). Six studies (28.6%) addressed care issues in CKD 
patients. Only two studies (9.5%) [12,13] included PD patients. Most of the studies 
were performed in an ambulatory HD or CKD patient care setting (n=17, 81%), 
whereas only four studies contained data on in-hospital clinical pharmacist activities. 
Using data from 18 reported studies, the median (range) number of study participants 
was 60 (10-408), and the median (range) study duration was six (1-32) months.  
Scope of clinical pharmacy activities 
The interventions performed in the included studies could be roughly grouped into the 
following categories: (1) general clinical pharmacy services (n = 12, 57.1%) [12-15, 19-
22, 29-32], (2) clinical pharmacy services focusing on disease management (n = 7, 
33.3%) [17, 18, 23-27] and (3) clinical pharmacy services with a focus on educational 
activities (n = 2, 9.5%) [16, 28]. A listing of reported clinical pharmacist activities is 
provided in Table 4.  
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Outcomes 
In 47.6% (n=10) of the included studies [13, 16-19, 23-27], disease-oriented outcomes 
were reported, whereas patient-oriented outcome data were only available in four 
studies (19%) [16, 28, 31, 32]. A synthesis of the disease- and patient-oriented 
outcome data is shown in Table 5. Four controlled trials (three of which were 
randomised) revealed that clinical pharmacy interventions had a positive impact on 
patient-oriented outcomes in the intervention group as compared to the available 
standard of care. 
The third type of outcome parameter in the included studies was the total number of 
clinical pharmacist interventions performed or recommendations given together with 
the physician acceptance rate. These were considered primary (n=7) or additional 
secondary (n=3) outcome parameters in 10 out of 21 (47.6%) studies.  
In the subanalysis of DSs, a weighted mean acceptance rate (±SD) based on study 
size of 78.7% (±19.5) was calculated. DRPs were mainly classified according to the 
system presented by Strand et al. [33]. However, in several included studies, 
information on classification methodology was scarce, or a system developed by the 
author was used. The DRPs most frequently described in the included studies were 
untreated indications, super- or supratherapeutic dosages and consequent dose 
adjustments, and medication record discrepancies. Assessments of the clinical 
significance of clinical pharmacist interventions were performed and reported in five of 
10 included studies. For this purpose, the significance criteria published by Hatoum et 
al. [34] was used in two studies [12, 22]. Unspecified categorisation systems were used 
in the other studies. Bias minimisation methods used during clinical significance 
assessments generally included a review by independent clinical pharmacists or the 
achievement of consensus among the ratings of clinicians, nephrologists and 
pharmacists. 
Information on the drug classes among which the clinical pharmacists detected the 
majority of DRPs was reported in four of 10 studies [12, 22, 31, 32]. The most 
commonly affected drugs were those used for treatment against renal bone disease 
and renal osteodystrophy together with anaemia and cardiovascular drugs. 
The most common comorbidity in CKD or ESRD patients managed by clinical 
pharmacists was anaemia. Clinical pharmacists were primarily responsible for ordering 
and checking laboratory values and managing independent dosing and dose 
modifications of erythropoiesis-stimulating agents (ESAs) and iron within specific 
prescribing guidelines. Furthermore, comprehensive disease management 
programmes also included patient education and adherence-enhancing activities. All of 
the studies reported that a significantly higher proportion of patients managed by a 
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clinical pharmacist maintained relevant target ranges (e.g., haemoglobin and 
haematocrit) as compared to patients receiving standard care. Aside from two studies 
addressing lipid management and cardiovascular risk reduction in HD patients through 
multiple disease interventions, no studies on diseases common to CKD or ESRD 
patients (e.g, hypertension or secondary hyperparathyroidism) with applicable inclusion 
criteria could be identified.  
 
Discussion  
Evidence of gaps in the care of patients with renal impairment is published in the 
literature [8, 9]. For the patient’s sake, these gaps must be addressed using all 
available methods. Enhancing the involvement of clinical pharmacists may be one 
potential strategy. Our systematic review synthesises evidence on the impact of clinical 
pharmacist involvement in DRPs in general, with respect to different comorbidities 
(e.g., anaemia and lipid management), and regarding educational issues in CKD and 
ESRD patients.  
By addressing the issues illustrated in Table 4 in their general and more specified 
clinical work, clinical pharmacists fulfil the requirements stated in the NKF–K/DOQUI 
Guidelines “Chronic Kidney Disease: Evaluation, Classification and Stratification” [35], 
which explicitly highlight the need for regular medication reviews, including dosage 
adjustment, adverse drug event (ADE) detection, drug interaction detection, and 
therapeutic drug monitoring (TDM). Given the nature of their major responsibilities and 
tasks, clinical pharmacists interact with patients, physicians, and other health 
professionals and share the goal of optimising pharmacotherapy and patient care. This 
multidisciplinary and multilevel approach is underlined by all included studies. Clinical 
pharmacists, as pharmacotherapy experts, are engaged in the care of the CKD and 
ESRD patient population at different stages and with different responsibilities, as 
further described in the position statement of the Ambulatory Care and Nephrology 
Practice and Research networks of the American College of Clinical Pharmacy [10].  
The CKD and ESRD population can be characterised by its vulnerability and 
susceptibility to drug-therapy-related morbidity due to many factors. Commonly 
reported DRPs in CKD or ESRD patients (e.g., dosing problems and medical record 
discrepancies) are not surprising given the complexity of dosing during either type of 
renal replacement therapy due to common changes in drug pharmacodynamics and 
pharmacokinetics [36]. This fact is further aggravated by the high number of 
concomitant drugs used and comorbidities, as studies report an average number of 10 
to 12 drugs per day and five comorbidities for HD patients [7]. Intensified care and 
additional monitoring are warranted for patients taking more than five drugs, patients 
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with more than 12 total medication doses, patients with drug regimens prone to 
frequent changes and three or more concurrent disease states, and patients with a 
history of non-compliance, and the presence of drugs requiring TDM [37]. CKD and HD 
patients generally fulfil all of these criteria and therefore warrant increased monitoring. 
Problems with medical record discrepancies and the accuracy of medication profiles, 
which are among the most commonly reported DRPs, are further highlighted in a 
prospective observational study of 63 HD patients, which reports record discrepancies 
in 60% of all patients . Several clinical pharmacy studies provide insights into the risk 
factors for DRPs. One study [15] highlights an inverse correlation between residual 
kidney function (based on creatinine clearance) and the number of DRPs. Another 
study reports a positive correlation between the number of DRPs, on the one hand, and 
age and length of time on dialysis, on the other [30]. All of these aspects present 
opportunities for clinical pharmacist to engage in CKD and ESRD patient care.  
Generally, more than three-quarters of clinical pharmacist interventions and 
suggestions were accepted by physicians. This physician acceptance rate is well within 
the range of other reported acceptance rates based on a review of clinical pharmacist 
impact on DRPs and clinical outcomes [6]. Due to the use of different classification 
systems and the resulting heterogeneity of DRPs, a profound statistical analysis was 
not performed.  
No studies could be identified that explicitly addressed the issue of adherence in CKD 
or ESRD patients; nonetheless, it presents a major barrier to optimal patient care. 
Especially among patients taking a high number of prescription drugs, complex 
medication schemes and long treatment periods cause adherence to wane [38]. 
Guaranteeing a high level of medication knowledge may be one strategy to increase 
adherence and to prevent DRPs resulting from incorrect drug use or overall failure to 
take medications. Clinical pharmacist intervention to improve patient medication 
knowledge was the study objective in two of the included studies, which could be 
achieved.  
There seems to be a balance in the proportion of studies investigating patient- versus 
disease-oriented outcomes. Patient-oriented outcomes are those that directly matter to 
patients, that is, those regarding longer life and improved quality of life. From an 
evidence-based point of view, studies investigating patient-oriented outcomes 
contribute more to the overall evidence and therefore have to be weighted more 
heavily. However, further studies with hard endpoints, as highlighted in Table 5, as well 
as longer study periods are definitely warranted, as they provide further evidence on 
the role of pharmacists in the care of CKD and ESRD patients and other patient 
groups. 
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Several studies on clinical pharmacist involvement were identified by our search 
strategy, but only four of them were controlled trials (two by the same authors) with 
high-quality methodological design and therefore a higher evidence impact. We 
decided to also include abstracts in our review, because we are convinced that these 
small studies of the impact of clinical pharmacy on patient care contribute to the overall 
evidence on this topic. We could not identify any studies that specifically addressed PD 
patients. However, in the two studies that included PD patients, the authors did not 
comment on any special issues (e.g., regarding the type of DRPs or adherence). Given 
the complexity and specifics of drug dosing during PD, the high need for education and 
patient training, and the high risk of infections (e.g., peritonitis), data specific to this 
patient population would be interesting and warranted. We hypothesise that clinical 
pharmacists are routinely integrated into different aspects of PD patient care, but due 
to irregular clinical attachment (as compared to HD patients, who generally attend clinic 
three times per week), such studies are more difficult to perform.  
Furthermore, regarding CKD patient studies, it was not possible to subdivide different 
clinical pharmacist activities and further relevant findings (e.g., common DRPs and 
performed interventions) according to CKD stage.  
Our review is subject to publication bias. We could not identify any studies showing that 
clinical pharmacy interventions had a negative impact on patient care. Furthermore, 
studies that used DRPs and physician acceptance rates as outcome parameters 
lacked information about rejected interventions and the reasons for rejection. The 
reporting of clinical significance assessments for performed interventions increases the 
scientific value of clinical pharmacy research, primarily by reducing bias. Data on the 
impact of clinical pharmacists on hospitalised inpatients is also scarce. In addition, the 
majority of the studies were published in the United States. Interestingly, only one 
study [16] from Europe could be identified; three of the remaining four studies were 
from Asia [14, 25, 28], and one was from New Zealand [30]. However, we hypothesise 
that clinical pharmacists are widely engaged in the care of CKD and ESRD patients. 
There are, for example, special interest groups dedicated to their care, such as the 
United Kingdom Renal Pharmacist Group [39]. Further high-quality studies on the 
impact of clinical pharmacists on key issues such as adherence and disease 
progression are thus warranted. 
 
Conclusions 
All identified studies on the involvement of clinical pharmacists in the care of CKD and 
ESRD patients showed some benefit. However, high-quality evidence on the impact of 
clinical pharmacy services is limited to a few studies. Clinical pharmacists address 
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areas requiring improvement as well as unmet DRPs responsively and preventatively. 
By doing so, clinical pharmacists positively contribute to the care of patients with 
impaired renal function and reduce the gaps in current patient care.  
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Tables  
Table 1 Inclusion and exclusion criteria for literature search 
 Included Excluded 
Study types 
Randomized controlled trials (RCTs), descriptive 
studies (DS), before-after studies (BAS) with 
interventional data 
Case reports, case studies, surveys, cost-
effectiveness studies, narrative reviews 
Interventions 
Any type of clinical pharmacist intervention 
embedded in comprehensive clinical pharmacy 
activities if data were assessable numerically and 
outcomes were reported  
Solely screening for inappropriate renal dosing, 
evaluations of computerised decision support 
systems 
Language Publications in English and German Any other language 
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 Table 4 Comprehensive listing of clinical pharmacy activities 
 
 Taking a thorough medication history 
 Matching computerised medication profiles with verbally obtained medication history 
 Medication review at different time points, such as at admission, during inhospital treatment, during each 
dialysis session, and at discharge (including OTC drugs, herbal supplements, drugs prescribed by non-
nephrologists, and CAM drugs) 
 Therapeutic recommendations 
 Prevention and resolution of DRPs 
 Therapeutic monitoring (treatment, laboratory values, and specific drugs) 
 Counselling and provision of drug information for patients and other health care professionals 
 Patient and health care provider education 
 Compliance assessment 
 Compiling of guidelines for proper drug use and implementation of treatment algorithms 
 Independent prescribing within the scope of specific guidelines (e.g., anaemia managements or lipid 
management) 
 Medication order review and checking adherence to prescribing guidelines 
 Medication use evaluation 
 Further audit measures 
 
 
Table 5 Disease versus patient-oriented outcomes 
Disease-oriented outcomes Patient-oriented outcomes 
Total cholesterol, LDL, HDL Rate of hospitalization 
HbA1c Length of stay 
Haematocrit, Tsat, ferritin, haemoglobin Health-related quality of life 
SBP, DBP Medication-related knowledge 
Phosphorus, calcium-phosphorus 
product Renal quality of life 
Drug dosages (e.g., EPO dosage or 
ferrous dosage) Patient satisfaction survey 
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Abstract Aim of the review Organ transplantation rep-
resents the therapy of choice for most types of end-stage
organ failure, and post-transplant patient care warrants
great attention. The aim of this study was to summarise the
available evidence regarding the role and impact of clinical
pharmacy services in the care of solid organ transplant
patients. Methods A search of the literature was conducted
using the MEDLINE, EMBASE and IPA databases to
identify studies relevant to our investigation of the impact
of clinical pharmacists’ interventions. Results Only five out
of nineteen of the included studies were randomised con-
trolled trials; eleven studies were descriptive, and three
were before-after studies. Interventions performed in these
studies consisted of routine clinical pharmacy services with
a focus on identifying, resolving and preventing drug-
related problems; clinical pharmacy services with a focus
on therapeutic drug monitoring; and those with a focus on
compliance enhancement and educational interventions.
The number and type of interventions and the physicians’
acceptance rates were assessed in the majority of the
included studies. Acceptance rates were generally above
95%, and most studies reported that clinical pharmacy
services had a positive impact on the care of solid organ
transplant patients. Positive perceptions of patients and
health care professionals are also reported. In two of the
studies, patients’ compliance rates and drug knowledge
were assessed following counselling by a pharmacist.
Dosing-related interventions were the most common
interventions proposed. Immunosuppressants, cardiovas-
cular drugs and antimicrobials were the drug classes most
affected by the clinical pharmacists’ interventions. Con-
clusions High quality evidence that supports the benefit of
clinical pharmacy services in the care of solid organ
transplant patients is rare. Nevertheless, all of the included
studies showed that clinical pharmacy services had a
positive impact. Furthermore, all included studies showed
that patients and physicians appreciated clinical pharma-
cists. The various outcome measures used in these studies
were improved by interactions with clinical pharmacists.
More randomised controlled trials are needed to contribute
to the paucity of the existing evidence.
Keywords Clinical pharmacy services 
Immunosuppressant medications  Literature review 
Solid organ transplantation
Impact of findings on practice
• Evidence exists regarding the positive impact clinical
pharmacy services have on several aspects of the care
of solid organ transplant patients.
• This literature review may serve as a basis for further
implementation of clinical pharmacy services in the
care of solid organ transplant patients.
Introduction
The era of successful clinical organ transplantation began
in the middle of the twentieth century when the first
G. Stemer (&)
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transplantations of the heart, kidney and lung were per-
formed [1]. This coincided with a better understanding of
immunological processes, the development and introduc-
tion of highly effective immunosuppressive agents, such as
azathioprine, corticosteroids and cyclosporine A, and an
improvement in organ preservation and surgical tech-
niques, all of which paved the way for solid organ trans-
plantation (SOT) to become the treatment of choice for
most types of organ failure. The most frequent SOTs per-
formed are those of the visceral organs (kidney, liver and
pancreas) followed by those of the thoracic organs (heart
and lung). The most common indications for SOTs are end-
stage renal disease of different aetiologies (kidney); car-
diomyopathy, myocarditis or heart valve defects (heart);
pulmonary hypertension, pulmonary emphysema or cystic
fibrosis (lung); end stage of liver cirrhosis of different
aetiologies (liver); and diabetes mellitus I (pancreas) [2].
The number of kidney and liver transplantats is increasing,
whereas the number of heart, lung and pancreas trans-
plantats is relatively constant or even declining (in the case
of pancreas transplants) (Fig. 1).
Immunosuppressant pharmacotherapy is a critically
important aspect of post-transplant patient care. Patients
must take immunosuppressants for the remainder of their
life to prevent episodes of graft rejection and consecutive
graft loss and to assure the success of the SOT.
Immunosuppressive maintenance therapy tends to be
centre-specific. Maintenance therapies normally consist of
a combination of multiple agents, including corticosteroids,
calcineurin inhibitors, anti-metabolites and mTor-Inhibitors
[3]. The combination therapy approach to the use of
immunosuppressive agents is beneficial, because their
mechanisms of actions overlap and are potentially syner-
gistic and because combination therapy allows for a
reduction in the dose of each individual agent, thereby
reducing dose-related drug side effects. The overall thera-
peutic goal, which is quite challenging, is to maintain a fine
balance between over- and under-immunosuppression in
these patients. Over-immunosuppression can lead to mul-
tiple problems, such as organ toxicity (e.g., calcineurin
inhibitor-induced nephrotoxicity) and an increased inci-
dence of adverse drug events (ADEs), as well as an
increased risk of life-threatening infections and post-
transplantation malignancies. The main risk of under-
immunosuppression is that it increases the risk of rejection
and graft loss. This goal is generally achieved by careful
monitoring of immunosuppressant drug levels and corre-
sponding dose individualisation. It may also be achieved by
switching to a different immunosuppressant agent or by
adapting the dose according to the time elapsed since
transplantation.
In addition to the complexity of immunosuppressive
pharmacotherapy itself, there remain multiple other phar-
macotherapeutic issues to consider in the transplant recipient.
Transplant patients are prone to viral (e.g., cytomegalovirus,
herpes simplex virus), bacterial and fungal (e.g., candida,
pneumocystiis) infections and therefore, preventionmeasures
are warranted, but antimicrobial treatment is often necessary.
Furthermore, immunosuppression-related complications
and multiple drug side effects, such as nephrotoxicity,
0
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10.000
15.000
20.000
25.000
30.000
ET OPTN ET OPTN ET OPTN ET OPTN
1995 2000 2005 2007
Kidney Heart Lung Liver Pancreas Total*
Fig. 1 The total number of
single organ transplantations
from both deceased and living
donors over time. * Adapted
from the annual data reports of
Eurotransplant (ET) [37] and
the Organ Procurement and
Transplantation Network
(OPTN) [38]
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hyperkalemia and other electrolyte disturbances, new-onset
diabetes mellitus, hyperlipidemia, hypertension and gastro-
intestinal problems, among others, must be managed.
Polypharmacy is therefore frequent in the transplant
patient population. Patients need to be closely monitored in
order to allow medical providers to recognise and conse-
quently manage ADEs. Because the calcineurin inhibitors
cyclosporine and tacrolimus and the m-Tor-inhibitors
sirolimus and everolimus are metabolised by cytochrome
P450 enzymes, drug-drug interactions (DDIs) are likely to
occur when these medications are given in combination
with inhibitors and inducers of cytochrome P450 enzymes.
The recognition and management of DDIs therefore also
warrants great attention. Counselling patients on the
properties and role of prescribed immunosuppressants in
order to raise their awareness of potential drug side effects
as well as ensuring patients’ compliance with their medical
regimen are additional important aspects of post-transplant
patient care. Close monitoring is especially critical during
the early post-transplantation period, which lasts up to
1 year, and must be continuously pursued, although to a
lesser extent, after that [4].
Transplant patients are generally cared for by a multi-
disciplinary health care team, which includes general
practitioners, medical specialists, nurses, psychologists and
other health care professionals. Clinical pharmacists who
specialise in SOTs are also members of these multidisci-
plinary teams, and they address drug-related therapeutic
issues in this population. Clinical pharmacy services have
proven to be beneficial in the management of many dis-
eases and special patient populations and have contributed
to patient safety, reductions in drug-associated mortality
and hospitalisations, and they have had an overall positive
impact on patient care [5–8].
Aim of the review
The aim of this review is to provide an overview of the
available literature regarding clinical pharmacists’ role in
the care of SOT patients. The review summarises and
discusses the different concentrations of clinical pharmacy
services, the methodological barriers of the studies and
further implications for the wider implementation of SOT
clinical pharmacy services.
Methods
Search strategy
A literature research was conducted using the MEDLINE
(1970—Week 10, 2009), EMBASE (1980—Week 10,
2009) and INTERNATIONAL PHARMACEUTICAL
ABSTRACTS (IPA) (1970—Week 10, 2009) databases to
identify relevant articles.
In MEDLINE, the following combinations of Mesh
(Medline Medical Subject Headings) terms were used as
our search strategy: (‘‘pharmacy service, hospital’’ OR
‘‘pharmacists’’ OR ‘‘pharmaceutical services’’) AND
‘‘transplantation’’.
In EMBASE and IPA, the search strategy combined the
terms (‘‘clinical pharmacy’’ OR ‘‘pharmaceutical care’’
OR ‘‘pharmacist’’ OR ‘‘hospital pharmacy’’) AND
‘‘transplantation’’. We decided to use the umbrella term
‘‘transplantation’’, instead of ‘‘organ transplantation’’ for
our initial search in order to increase the sensitivity of our
search.
Inclusion and exclusion criteria
All studies addressing the impact of clinical pharmacy
services (either at the patient or physician level) on the care
of SOT patients were included. All study types, including
randomised controlled trials (RCT), descriptive studies
(DS) and before-after studies (BAS) were included if they
provided interventional data. Results published in abstract
form (e.g., congress abstracts) only were included if they
provided numerically assessable data, e.g., the number of
interventions, the acceptance rates and the number of
resolved drug-therapy problems (DTP). Publications that
solely addressed the economic impact and cost reduction
associated with pharmacists’ interventions, descriptive
reviews, surveys of pharmacists’ work in the field of
transplantation, and single case studies were excluded. All
types of study settings, e.g., inpatient care, ambulatory
care, etc., were included.
Data collection
The predefined data parameters, namely the study design,
the number of included patients, the study duration, the
types of interventions, the relevant outcomes and the
results were extracted from the literature, summarised and
reviewed.
Results
The initial search in MEDLINE, EMBASE and IPA yiel-
ded 91, 175 and 174 citations, respectively. The detailed
search results are described in Fig. 2. A total of 440 cita-
tions were initially screened for inclusion criteria by
reviewing the title. A total of 98 abstracts were further
screened, and after removing duplicates, a total of 19
Pharm World Sci (2010) 32:7–18 9
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citations remained for full review. The predominant rea-
sons for exclusion were publication type (e.g., reviews,
letters or commentaries), a lack of interventional data or
non-assessable data, and the inclusion of non-SOT patients.
Detailed descriptions of the included studies are shown in
Table 1.
Three study types were identified, including 11 DSs
(58%), 5 RCTs (26%) and 3 BASs (16%). A total of nine of
the published studies (47.4%) were only available as
abstracts. The earliest included study was published in
1991. The study sites were predominantly located in the US
or Canada (13, 68%), three were located in Asia, and three
were located in Europe, reflecting the wider implementa-
tion and development of clinical pharmacy services in
North America. We avoided detailed descriptions of study
settings because most of the studies were conducted in the
ambulatory care setting.
Interventions
Interventions that were performed in the included studies
could be roughly grouped into the following categories: (1)
general clinical pharmacy services (13, 68.5%) [9–21], (2)
general clinical pharmacy services with a focus on thera-
peutic drug monitoring (TDM) (2, 10.5%) [22, 23], (3)
clinical pharmacy services that predominantly addressed
compliance issues (2, 10.5%) [24, 25] and (4) clinical
pharmacy services that focused on patient education (2,
10.5%) [26, 27]. The clinical pharmacists’ activities that
were reported in the 19 included studies are listed in
Table 2.
These categories overlap in many cases and this cate-
gorisation system was largely chosen in an effort to
structure the results. Of the 19 included studies, 15 (78.9%)
described the clinical pharmacists’ interactions between
patients and physicians, and 2 (10.5%) studies described
the pharmacists’ interactions with physicians or patients,
respectively.
Outcomes
The total number of interventions performed or recom-
mendations given, as well as the physicians’ acceptance
rate, were considered relevant outcome parameters in 13 of
the studies (68.4%). Statistically significant findings were
only reported in four RCTs. The sample sizes were gen-
erally small (mean intervention group size: 17; mean
control group size: 15). All RCTs revealed that clinical
pharmacy interventions had a positive impact on patients in
the intervention group.
Interventions were classified using Strand’s classifica-
tion system in six studies (46.2%) [28]. One study [25]
used the PI-Doc System [29]. In six of the studies (46.2%),
the type of classification system that was used could not be
identified. The clinical significance of the interventions and
their impact on patient care were commonly rated using the
criteria published by Hatoum et al. [30]. The significance
of the interventions was only reported in six of the studies
and the assessment was co-reviewed to avoid bias.
The acceptance rates were reported in only seven of the
studies and were generally above 95%. Only in the study by
Wang and colleagues [21] was there information available
regarding rejected pharmacist’s recommendations.
Seven of the studies reported on the drug classes that are
most affected by clinical pharmacists’ interventions (not
shown in Table 1). Immunosuppressants, cardiovascular
drugs and antimicrobials were involved in the interventions
in the majority of studies.
The influence of clinical pharmacists on the optimisation
of specific diagnostic parameters, e.g., blood pressure and
fasting blood glucose levels, was investigated in two
studies[11, 15], both of which showed that clinical phar-
macists had a positive impact on these parameters. The
impact clinical pharmacists had on drug education was
assessed in three of the studies [25–27]. Information
regarding the satisfaction of health care professionals and
patients with the clinical pharmacist participating as a
member of the therapeutic team, as well their appreciation
for clinical pharmacy services, were available in six of the
studies. In a few of the studies, satisfaction rates were
systematically assessed, e.g., by a questionnaire. In most
cases, only comments containing positive perceptions of
clinical pharmacy services could be found. The study by
Lee and colleagues [22] assessed the impact that clinical
Fig. 2 Flow chart of the search strategy and results. * The predom-
inant reasons for exclusion were the study type, a lack of interven-
tions, non-assessable data and the inclusion of non-SOT patients
10 Pharm World Sci (2010) 32:7–18
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pharmacy services had on patient satisfaction and quality
of life using a quality of life questionnaire and found that
clinical pharmacists had a positive impact. Due to the use
of different satisfaction assessment methodologies, a
summary of the overall patient satisfaction with the ser-
vices provided by clinical pharmacists was not possible.
Nevertheless, the rate of satisfaction with the implemented
services was high and the study authors generally inter-
preted these findings as further evidence supporting the
implementation of clinical pharmacy services.
Discussion
Compared to other systematic reviews [6, 8] examining the
impact of clinical pharmacists on different diseases and
different patient populations, very few studies could be
identified that addressed the impact of clinical pharmacy
services on SOT patients. However, clinical pharmacy
services do exist for this specialised patient population,
predominantly in the field of kidney and liver transplan-
tation. According to a survey of transplant centres in the
U.S. [31], 78 (28 out of 36) had clinical pharmacists’
support. We could not identify any published studies
regarding the impact of clinical pharmacists that met both
our inclusion and exclusion criteria and that addressed the
care of heart, lung or pancreas transplant patients. How-
ever, descriptive articles regarding pharmacists’ impact on
patient care and the possible areas in which clinical phar-
macists could contribute to patient care have been pub-
lished [32–36].
Clinical pharmacists’ in-depth education in pharmaco-
therapy empowers them to address the complexity of the
issues associated with the care of transplant patients, such
as the management of an immunosuppressant regimen,
ADEs, DDIs, medication compliance issues and the man-
agement of infectious diseases. Other transplant-related
roles in which clinical pharmacists participate include
education, the development of practice guidelines and
quality outcomes monitoring.
By definition, clinical pharmacy services provide a
multi-faceted intervention and their role can include mul-
tiple different techniques and activities, which are sum-
marised in Table 2. All of the included publications
showed that clinical pharmacy services had a positive
impact on patient care and, when evaluated, high satis-
faction rates regarding the clinical pharmacists’ perfor-
mance were noted. In addition to the relatively small
number of RCTs, there exist a larger number of descriptive
studies that contribute to the overall evidence regarding the
role of clinical pharmacists as part of a multi-disciplinary
care team. Descriptive studies can also raise awareness of
the impact of clinical pharmacy services and identify areas
with further need of clinical pharmacy services. However,
studies addressing definitive outcomes, such as hospitali-
sation time, reduced occurrence of ADEs, disease-related
events or mortality, are lacking. Because studies docu-
menting the impact clinical pharmacists have on hard
clinical end-points do exist in other patient populations [5,
6], we therefore hypothesise that clinical pharmacy ser-
vices do positively influence hard clinical end-points in the
SOT patient population.
Most of the interventions addressed dose-related issues,
e.g., sub- or supra-therapeutic serum drug concentrations,
which highlighted the importance of dosing during the drug
prescribing process. It is not surprising that immunosup-
pressants are one of the classes of drugs that are the most
positively affected by the participation of clinical phar-
macists. Narrow therapeutic indices, complex dosing reg-
imens and high probabilities of DDIs and ADEs are all
properties of immunosuppressants that contribute to the
high likelihood of DRPs occurring during therapy. Car-
diovascular drugs also represent a drug class that should be
closely monitored, largely because of their widespread use
due to post-transplant hypertension or post-transplant
hyperlipidemia.
Our review is subject to publication bias. We could not
identify any studies that showed that clinical pharmacy
services had a negative impact on patient care. It is notable
that seven of the studies (37%) were performed by Chis-
holm and colleagues at one centre, which is a highly active
research centre regarding this topic. One abstract published
by Chisholm and colleagues [13] seems to be a summary
of data previously presented at annual congress meetings
[10, 12]. Furthermore, we decided to include abstracts in
our review because we are convinced that these small
Table 2 The roles of clinical pharmacists in the care of solid organ
transplant patients
Acquisition of complete drug histories
Checking dosage, indications and administration modalities
Identification, resolution and prevention of drug-related problems
Providing of therapeutic recommendations to health care professionals
and patients
Providing drug information to health-care professionals and patients
Educational activities for health-care professionals (physicians,
nurses) and patients
Reporting and management of (suspected) adverse drug events
Management of potential or evident drug-drug and drug-food-
interactions
Dosage adjustments of critical drugs based on pharmacokinetic
calculations
Counselling patients regarding medication administration and therapy
Follow-up (personal contact, phone calls, etc.)
Compliance-enhancing activities
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studies regarding the impact of clinical pharmacy on
patient care contribute to the overall evidence on the topic.
However, due to the small overall number of published
studies with a high quality methodological design that have
addressed SOT patient care, it is too early to draw a
definitive conclusion regarding the impact of clinical
pharmacy services on the care of SOT patients.
We hypothesise that clinical pharmacists are involved in
the care of SOT patients in many transplant clinics and
contribute to their care in many different ways, but there
are only a few clinical pharmacists who engage in the
publication of their work and scientific research in this area
to document and scientifically confirm their everyday
clinical work.
However, further studies investigating clinical pharmacy
services that involve multiple study sites and larger sample
sizes are needed. Additionally, it should be noted that the
level of professionalism, personal performance and indi-
vidual social skills of the involved clinical pharmacists
may influence the reproducibility of the study results and
remain a confounding factor. This bias could potentially be
addressed by investigating the impact of clinical pharma-
cists at multiple study sites. The standardisation of inter-
vention criteria, the DTPs classification systems and an
assessment of significance of the impacts of their inter-
ventions would lead to more easily comparable outcomes.
Studies addressing the influence of clinical pharmacists on
hard clinical-end points are warranted to gain more high
quality evidence on this topic.
Conclusion
The participation of clinical pharmacists inmultidisciplinary
health care teams engaged in the care of SOT patients has
previously been shown to be beneficial to patient care. High
quality evidence based on randomised clinical trials
regarding this topic is scarce, however. Nevertheless, clini-
cal pharmacists address unmet and common drug-therapy
problems, focus on disease- and treatment related outcomes,
ensure immunosuppressive medication compliance and
counsel patients on drug-related issues. Transplant centres
with actively involved pharmacists appreciate the presence
of their clinical pharmacists.
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Abstract
Background: The objectives of this pilot study were to evaluate treatment quality for the risk
factors of hypertension, diabetes and hyperlipidemia as well as the overall treatment quality for
patients on an internal nephrology ward. This evaluation included the collection of data concerning
the quality of therapeutic drug monitoring, drug use and potential drug-drug interactions.
Establishing such baseline information highlights areas that have a need for further therapeutic
intervention and creates a foundation for improving patient care, a subject that could be addressed
in future clinical pharmacy research projects.
Methods: Medical charts of patients treated on a single internal nephrology ward were
retrospectively evaluated using a predefined data collection form. Assessment of further need for
therapeutic intervention was performed.
Results: For 76.5% (n = 78) of the total study population (n = 102), there was either a possibility
(39.2%, n = 40) or a need (37.3%, n = 38) for further intervention based on the overall assessment.
For the risk factors of hypertension, diabetes and hyperlipidemia, the proportions of patients that
require further intervention were 78.8% (n = 71), 90.6% (n = 58) and 87.9% (n = 58), respectively.
Patients with diabetes or hyperlipidemia were less likely to have optimal risk factor control. The
number of drugs prescribed and the number of potential drug-drug interactions were significantly
higher after in-hospital treatment.
Conclusion: Risk factor treatment needs optimisation. Risk factor management, systematic
medication reviews, and screening for and management of potential drug-drug interactions deserve
great attention. Clinical pharmacy services could help in the achievement of treatment goals.
Background
Health-care professionals, such as physicians, nurses, and
(clinical) pharmacists, in both inpatient and outpatient
settings are increasingly confronted with a growing
number of patients with chronic kidney disease (CKD)
and end-stage renal disease (ESRD)[1]. Medical care for
CKD patients is complex due to widespread co-morbidi-
ties and major risk factors (RF) for CKD or cardiovascular
disease (CVD) [2,3]. The progression of CKD and the
deterioration of kidney function from stage 1 CKD [3] to
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more severe stages can be slowed by optimal treatment of
underlying co-morbidities and RFs, which can be accom-
plished with lifestyle modifications and/or different phar-
macological interventions that address the treatment of
hypertension, diabetes mellitus and hyperlipidemia,
among others. The slowing down of disease progression is
pivotal for prolonging the period before stage 5 CKD or
ESRD, which involves the necessary initiation of either
dialysis or evaluation of suitability for kidney transplanta-
tion. Several initiation and progression factors have been
shown to influence disease onset and progression [3,4].
Large-scale efforts that target these RFs have been initiated
to improve outcomes in the CKD population [5].
The involvement of clinical pharmacists as members of
the interdisciplinary patient care team responsible for the
management of many different diseases has proven to be
beneficial and has been associated with positive patient
outcomes [6-8]. Clinical pharmacists have also been influ-
ential in the field of nephrology and have provided valu-
able support for the achievement of defined goals in the
treatment of different RFs and management of drug-
related problems in the ESRD population [9-12].
This pilot study was performed to establish baseline data
that address (1) the quality of RF management, (2) overall
treatment quality, (3) quality of therapeutic drug moni-
toring (TDM), (4) quantitative drug use at admission and
discharge and (5) the frequency of potential drug-drug
interactions (pDDIs) in the studied patient population as
well as in the predefined subgroup of kidney transplant
patients (TX subgroup). The retrospective evaluation of
these parameters should identify areas with the need for
further intervention and possibilities for the improve-
ment of patient care that could be addressed in future clin-
ical pharmacy research.
Methods
Study design, group and setting
A retrospective review was conducted of 102 randomly
selected medical histories of patients receiving treatment
between August 2006 and April 2008 on an internal neph-
rology ward of General Hospital in Vienna. Data were col-
lected between January and May 2008. There were no
direct interventions performed on patients. This descrip-
tive study was approved by the local ethics committee of
the Medical University of Vienna and the Vienna General
Hospital.
Data sources and collection
Medical charts, physicians' admission and discharge let-
ters and cumulative laboratory findings were the only data
sources used. Data were collected according to a prede-
fined data collection form, which was divided into six cat-
egories: (1) sociodemographic criteria; (2) cause of
hospitalisation, further medical conditions (co-morbidi-
ties) and underlying renal disease; (3) treatment of the
predefined RFs of hypertension, diabetes mellitus and
hyperlipidemia in the total population and quality of
TDM in the TX subgroup; (4) drug regimen at the time of
admission and discharge; (5) number and severity of
pDDIs and (6) overall quality of RF treatment. Further-
more, glomerular filtration rates (GFRs) at discharge and
at admission were estimated using the Modification of
Diet in Renal Disease (MDRD) study equation. Stages of
CKD (based on GFR at discharge) were assigned according
to the National Kidney Foundation/Kidney Disease Out-
comes Quality Initiative (NKF/KDOQI) classification [3].
Assessment of RF treatment quality and overall assessment
Treatment quality during hospitalisation was assessed
according to established guidelines for each RF, for quality
of TDM in the TX subgroup and for overall treatment
quality (see Table 1). The quality of RF and TDM manage-
ment as well as overall treatment quality was assessed
numerically on a scale from one to four (see Table 2).
Patient treatment histories that were assessed as being a
two or three on this quality scale were compiled and cate-
gorised as patients for whom further therapeutic interven-
tion would have been either beneficial (2) or necessary
(3) and therefore would represent potential domains for
intervention by a clinical pharmacist.
Screening for pDDIs
Admission drug histories and discharge drug histories
were electronically screened for pDDIs using Medis®.
Table 1: Risk factor reference values
Risk factor Reference Values
Hypertension 23,34 Non-diabetic patients <140/90 mm/Hg
Diabetic patients <130/80 mm/Hg
Patients with diabetic nephropathy <125/75 mm/Hg
Diabetes mellitus 34 Fasting plasma blood glucose <110 mg/dl
Glycosylated haemoglobin HbA1c 4-6%
Hyperlipidemia 25 Low density cholesterol <130 mg/dl
Total cholesterol <200 mg/dl
Triglycerides <200 mg/dl
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pDDIs were classified into four categories of relevance
given by the database, namely severe, moderate, minor and
unknown relevance (see Appendix for detailed explana-
tions). Only pDDIs classified as severe and moderate were
included in the statistical analysis. Individual drug dos-
ages were not taken into account when assessing pDDIs.
Statistical analysis
Absolute and relative frequencies as well as 95% confi-
dence intervals (lower CI and upper CI) are reported for
the four categories of overall assessment for each RF and
for overall RF management. Statistical analyses were con-
ducted on the total study population and for the TX sub-
group. To analyse the influence of the RFs (hypertension,
diabetes mellitus and hyperlipidemia) on assessment cat-
egory, an ordinal logistic regression analysis of assessment
categories one, two or three (see Table 2) was calculated
(category 4 is omitted). The probability of the patient
being in a higher category was also modelled. P-values,
odds ratios and the corresponding 95% confidence inter-
Table 2: Categories for assessment of individual risk factors, therapeutic drug monitoring and overall assessment
Individual RFa and TDMb Assessment of overall treatment quality
Assessment Explanation Assessment Explanation
1 No need for intervention Valuesd according to references in more 
than 2/3 of available values; Values 
better at discharge than at admission; 
Disease/RFa is treated; no severe 
pDDIsc
Very good RFa management No improvements necessary
2 Improvement possible Valuesd outside of reference range in 
more than 1/3 of available values; Values 
worse at discharge; severe pDDIsc; RF is 
treated
Good RFa management Up to two individual RFsa being assessed 
as "improvement possible" (category 2); 
no untreated RFsa (category 3)
3 Disease untreated No drug therapy for RFa treatment; no 
TDM performed, although appropriate
Improvement in RFa 
management needed
More than two individual RFsa or 
TDMsb being assessed as "improvement 
possible" (category 2) or untreated RFa 
(category 3)
4 No conclusion possible Missing data; inconclusive data No conclusion possible Missing data; inconclusive data
a RF = risk factor
b TDM = therapeutic drug monitoring
c pDDI = potential drug-drug interaction
d e.g., blood pressure, fasting blood glucose, lipid levels, plasma levels of immunosuppressants
Table 3: Sociodemographic characteristics, stages of CKD and length of stay
Total population n = 102 TXa subgroup n = 49
n % n %
Men/Women 67/35 65.7/34.3 37/12 75.5/24.5
Age, years
Mean ± SDb 55.5 ± 13.4 55.4 ± 11.4
Range 24-86 29-73
BMIc, kg/m2
Mean ± SDb 26.3 ± 5.1 26 ± 4.8
Range 15-40.2 16-40.2
Stages of CKD n = 80 n = 44
2 3 3.8 2 2.3
3 39 48.8 32 72.7
4 15 18.8 7 15.9
5 23 28.8 3 6.8
Length of stay, days
Mean ± SDb 14.8 ± 10.5 17.06 ± 9.9
Range 2-47 2-41
a TX = transplantation
b SD = standard deviation
c BMI = body mass index
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vals are given. For the analysis, the RFs of diabetes and
hyperlipidemia were both classified into "no diabetes
mellitus" or "no hyperlipidemia" versus "diabetes melli-
tus" or "hyperlipidemia". The analysis was performed
using SAS 9. Means will be presented as mean (range,
standard deviation).
Results
Sociodemographic and patient characteristics
Sociodemographic characteristics and stages of CKD for
the total study population and TX subgroup are shown in
Table 3. Major causes of hospitalisation in the study pop-
ulation and the underlying renal diseases are shown in
Figures 1 and 2, respectively.
RF: hypertension
A diagnosis of hypertension was seen in 88.2% (90) of
patients. The absolute and relative frequencies as well as
the corresponding confidence intervals for hypertension
are given in Table 4 for the four different categories of
overall assessment of the total study population. In 78.8%
(71) of patient cases, there was a possibility or need for
further therapeutic interventions. Hypertensive patients
were treated on the ward for a mean time of 15.2 days (d)
(range 2-47, standard deviation 10.84), with an average of
7.7 d (0-45, 9.87) of blood pressure values out of the indi-
vidual reference range. Estimation of renal function at
admission and discharge showed a mean GFR of 23.1 and
30.1 mL/min/1.73 m2, respectively. Stages 2 to 5 CKD
were present in 4.1, 50.7, 17.8 and 27.4% of hypertensive
patients, respectively.
RF: diabetes mellitus and elevated fasting blood glucose
A total of 62.8% (64) of patients in this RF group had
either a definitive diagnosis of diabetes (diabetes mellitus
type I (3.9%, n = 4) or diabetes mellitus type II (30.39%,
n = 31)) or continuously elevated fasting blood glucose
(FBG) out of reference range (28.4%, n = 29). Absolute
and relative frequencies as well as corresponding confi-
dence intervals for the four different categories of overall
assessment for the total study population are given in
Table 4. The majority (90.6%, 58) of patients had a need
for further therapeutic intervention. Patients with diabetes
mellitus type I were treated on the ward for an average of
11.3 d (4-22, 8.14), with FBG levels out of reference range
on 5.5 d (1-10, 4.65). Patients with diabetes mellitus type
II were treated for an average of 30.0 d (2-45, 11.9), with
FBG levels out of reference on 6.9 d (1-24, 6.36). Patients
with continuously elevated FBG levels were treated for
16.4 d (2-39, 9.89), with elevated FBG for 6.7 d (2-19,
4.6) on average. Glycosylated haemoglobin (HbA1c) lev-
els were evaluated and analysed as a marker of long-term
treatment quality. In 43.8% (n = 28) of patients in the dia-
betes RF group, there was no information available about
HbA1c values. In 25% (n = 16) of patients, reported
HbA1c levels were in accordance with the reference range
(see Table 1), and in 25% (n = 16) of patients HbA1c levels
were outside of the reference range. Of patients with
HbA1cvalues outside of the reference range, 68.8% (n =
11) had diabetes type II. Estimation of renal function at
admission and discharge showed a mean GFR of 23.2 and
30.2 mL/min/1.73 m2, respectively. Stages 2 to 5 CKD
were present in 3.9, 49.0, 21.6 and 25.5% of patients with
the RF of diabetes, respectively.
Major causes of hospitalization, classifiedFigu e 1
Major causes of hospitalization, classified. TX trans-
plantation. ADE adverse drug event.
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Underlying nephrologic disease (where available)Figure 2
Underlying nephrologic disease (where available). 
GN glomerulonephritis. DM diabetes mellitus. SD systemic 
diseases. DT drug toxicity. PK polycystic kidney. IN intersti-
tial nephritis.
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Others;  9
Unknown;  
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RF: Hyperlipidemia
Of the patients reviewed, 64.7% (n = 66) were diagnosed
with hyperlipidemia, while 41.2% (n = 42) showed con-
tinuously elevated cholesterol-levels and 5.9% (n = 6)
showed elevated triglyceride-levels. HMG-Co-enzyme-A-
inhibitors (statins) were used in 17.7% (18) of patients
for cardiovascular event prophylaxis. Absolute and rela-
tive frequencies as well as corresponding confidence inter-
vals of the hyperlipidemia RFs for the four different
categories of overall assessment for the total study popu-
lation are given in Table 4. A possible need for further
therapeutic intervention was found in 87.9% (58) of the
patients in the study. Estimation of renal function at
admission and discharge showed a mean GFR of 21.7 and
28.4 mL/min/1.73 m2, respectively. Stages 2 to 5 CKD
were present in 1.9, 49.1, 20.8 and 28.3% of patients with
the RF of hyperlipidemia, respectively.
Characteristics and quality of TDM
The plasma drug levels of immunosuppressant medica-
tions were determined and the dosages were adjusted in
89.8% (44) of the TX subgroup patients. Immunosup-
pressive medications primarily consisted of a three-way
combination of calcineurin inhibitors (tacrolimus
(79.6%, 35) or ciclosporin (20.5%, 8)), anti-metabolites
(mycophenolate mofetil (70.5%, 35), mycophenolic acid
(18.2%, 8) or azathioprine (4.5%, 2)) and corticosteroids.
In 25% (11) of the TX subgroup patients, a switch in
immunosuppressant medication was necessary due to
adverse drug events (ADEs). For example, tacrolimus
induced tremors and mycophenolate mofetil induced
diarrhoea. The quality of TDM was only assessable if a
defined therapeutic range was available in the medical
chart (61.4%, 27). The number of days with sub-thera-
peutic and supra-therapeutic concentrations was evalu-
ated based on these defined ranges. Absolute and relative
frequencies of TDM for the four different categories of
overall assessment in the TX subgroup are given in Table
4.
Overall assessment of treatment quality
Absolute and relative frequencies and corresponding con-
fidence intervals for overall assessment of treatment qual-
ity in the total study population and TX subgroup are
shown in Table 5. A need for further optimisation of RF
treatment was observed in 76.5% (78) of the total study
population and 81.6% (40) of the TX subgroup.
Influence of individual RFs on overall treatment quality
Regression analysis showed that the diabetes mellitus and
hyperlipidemia RFs had a significant impact on assess-
ment outcome. Patients with diabetes (p = 0.001, OR
4.309, 95%CI: 1.81-10.25) or hyperlipidemia (p =
0.0085, OR 3.146, 95%CI: 1.34-7.39) had a higher overall
Table 4: Assessment of individual risk factors and quality of therapeutic drug monitoring
No need for intervention Improvement possible Disease untreated/
No TDMa
No conclusion possible
% (n) 95% CIb % (n) 95% CIb % (n) 95% CIb % (n) 95% CIb
Hypertension
n = 90
17.8 (16) 0.10-0.26 37.8 (34) 0.28-0.48 41.1 (37) 0.31-0.51 3.3 (3) 0.00-0.07
Diabetes mellitus
n = 64
7.8 (5) 0.01-0.14 42.2 (27) 0.30-0.54 48.4 (31) 0.36-0.61 1.6 (1) 0.00-0.05
Hyperlipidemia
n = 66
9.1 (6) 0.02-0.16 42.4 (28) 0.31-0.54 45.5 (30) 0.33-0.57 3.0 (2) 0.00-0.07
TDMa
n = 44
29.6 (13) 0.17-0.45 34.1 (15) 0.20-0.50 0.0 (0) - 36.4 (16) 0.22-0.52
For explanations of assessment categories see table 2.
a TDM = therapeutic drug monitoring
b CI = confidence interval
Table 5: Overall assessment of treatment quality
Very good RFa management Good RFa management Improvement needed No conclusion possible
% (n) 95% CIb % (n) 95% CIb % (n) 95% CIb % (n) 95% CIb
Total n = 102 19.6 (20) 0.12-0.27 39.2 (40) 0.30-0.49 37.3 (38) 0.28-0.47 3.9 (4) 0.00-0.08
TXc subgroup
n = 49
16.3 (8) 0.06-0.27 32.7 (16) 0.20-0.46 49.0 (24) 0.35-0.63 2.0 (1) 0.00-0.06
For explanations of assessment categories see table 2.
a RF = risk factor
b CI = confidence interval
c TX = transplantation
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risk of being assessed in category 2 (good risk factor man-
agement, but improvement possible) or category 3 (improve-
ment needed). This correlation was not shown for the
hypertension RF (p = 0.2704, OR 2.056, 95%CI: 0.57-
7.40).
Quantitative drug use and pDDIs in the total study 
population
The total sum of prescribed drugs in the total study popu-
lation was 1110 at admission and 1220 at discharge. Table
6 shows the number of drugs prescribed, number of
pDDIs and number of pDDIs per drug prescribed.
All three parameters showed significantly higher values at
discharge compared to admission. Treatment on the ward
was significantly associated with an elevated number of
drugs prescribed and an elevated number of pDDIs.
In the total study population, 45.1% (46) of patients had
an increase in the number of pDDIs during treatment on
the ward, 41.2% (42) had no change in the number of
pDDIs and 13.7% (14) had a decrease in the number of
pDDIs. In 43.2% (44) of all evaluated patients, at least
one pDDI was associated with an increased probability
for nephrotoxicity, thus increasing the risk of acute renal
failure and aggravation of renal function.
Quantitative drug use and pDDIs in the TX subgroup
The sum of drugs prescribed to the TX subgroup patients
was 619 at admission, compared with 650 at time of dis-
charge. The number of drugs prescribed, number of
pDDIs and number of pDDIs per drug prescribed are
shown in Table 6.
In-hospital treatment was associated with a significantly
elevated number of pDDIs per patient and pDDIs per
drug prescribed. When the number of drugs prescribed
per patient was compared, there was no statistically signif-
icant difference. In 44.9% (22) of the TX subgroup
patients, the number of pDDIs increased during treatment
on the ward, 38.8% (19) of patients had no change in the
number of pDDIs and 16.3% (8) of patients had a
decreased incidence of pDDIs during treatment on the
ward. In 83.7% (41) of evaluated patients, at least one
pDDI was associated with an increased probability of
nephrotoxicity, which increased those patients' risk of
developing acute renal failure and having an aggravation
of renal function.
Discussion
The study results show that the management of the indi-
vidual RFs of hypertension, diabetes and hyperlipidemia
requires improvement. In the overall assessment of treat-
ment quality, more than three-quarters of the patients
showed a possibility or evident need for further interven-
tion to reach the treatment goals. Very good RF manage-
ment was evident in less than 20% of patients for each of
the investigated RFs. For diabetes and hyperlipidemia, this
proportion was even under the 10% threshold. Based on
regression analysis, patients with diabetes or hyperlipi-
demia were four and three times less likely, respectively,
to have optimal RF control. Our results are consistent with
published studies and reviews that address treatment
quality and adherence to treatment guidelines for hyper-
tension [13-19], diabetes mellitus [15,20,21] and hyperl-
ipidemia [15,19] in CKD patients.
The apparent need for improvement in RF control in our
study population must be discussed in light of the special
features of the nephrological patient population.
Hypertension, either as a cause or a complication of CKD,
is prevalent in up to 75% of patients with CKD stage 3-5,
in up to 80% of kidney transplant patients and in up to
Table 6: Quantitative drug use and potential drug-drug interactions at hospital admission and discharge
Admission Discharge
Total study population n = 102 Mean ± SDa Range Mean ± SDa Range P-valueb
Number of drugs per patient 10.9 ± 4.2 0-20 12.1 ± 4.3 2-21 <0.0001*
Number of pDDIsc per patient 1.9 ± 1.9 0-8 2.7 ± 2.5 0-11 <0.0001*
Number of pDDIsc per drug prescribed 0.2 ± 0.2 0-0.83 0.2 ± 0.2 0-0.64 0.0016*
TXd subgroup n = 49
Number of drugs per patient 12.6 ± 3.1 4-20 13.3 ± 3.2 5-20 0.055
Number of pDDIsc per patient 1.8 ± 2.4 0-8 2.7 ± 2.8 0-11 0.014*
Number of pDDIsc per drug prescribed 0.1 ± 0.1 0-0.53 0.2 ± 0.2 0-0,64 0.014*
Only pDDIs classified as moderate or severe were included in the analysis.
a SD = standard deviation
b p = statistical significance according to the t-test
c pDDIs = potential drug-drug interactions
d TX = transplantation
* Statistically significant
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90% of maintenance haemodialysis patients [22,23]. Vir-
tually all patients in the study population had kidney
function of CKD stage 3 or worse, nearly 50% had one or
more kidney transplantations performed, and 27% were
dependent on renal replacement therapy (e.g., haemo- or
peritoneal dialysis). The very high prevalence and the
multifactorial pathogenesis of hypertension in renal dis-
ease (e.g., sodium retention and fluid overload and struc-
tural kidney changes) and the steady decline in renal
function make it difficult per se to reach tight treatment
goals. Antihypertensive polypharmacotherapy was there-
fore almost necessary in our study population to even
approximate treatment goals. Our study findings stress
the importance of drawing attention to tight blood pres-
sure control, as in about the half of the treatment period,
blood pressure control was suboptimal. Second, control
of diabetes and hyperlipidemia management was also
suboptimal. The relevance of these findings is emphasised
by the fact that diabetes is not only the leading cause of
CKD in developed countries [24], but diabetes and hyper-
lipidemia are also two of the most important RFs for car-
diovascular disease. Of note, CKD patients represent a
priori the highest risk group for CVD [3]. Therefore, guide-
lines [24,25] recommend strict glycemic and lipidemic
control. Besides patients with a confirmed diagnosis of
diabetes mellitus, we also included patients with continu-
ously elevated FBG in the diabetes RF group. Continu-
ously elevated FBG represents, in itself, a RF for the
development of diabetes mellitus II, and therefore, clarifi-
cation and management deserves attention. One fourth of
patients in the diabetes RF group had glycosylated haemo-
globin values outside of the reference range, confirming
the need for improvement of long-term glycemic control,
especially for diabetes mellitus II where around 68% of
patients had HbA1c levels outside of the reference range.
In nearly 50% of patients in the diabetic subgroup, glyco-
sylated haemoglobin values were totally lacking, and
therefore, no information was available concerning the
long-term control of their diabetes. Furthermore, the pro-
portion of untreated hyperlipidemia of around 45% also
stresses the need for intervention and improvement.
Nearly half of our study population was kidney transplant
patients. Thus, concomitant immunosuppressive therapy
may have also negatively biased RF control, as hyperten-
sion, diabetes and hyperlipidemia are all well-described
side effects of calcineurin inhibitors. However, our study
was not designed to assess a potential correlation. Finally,
the main focus during hospitalisation often lies in curing
acute disease and in necessary treatment, and conse-
quently, optimisation of RF treatment often takes a back
seat. Simple negligence and unintended oversight may
also be considered as reasons for suboptimal RF control.
In summary, there seems to be vast room for improve-
ment in the control of the investigated RFs in our study
population. Clinical pharmacists' activities have proved
beneficial for the achievement of treatment goals [10-12].
Our study also examined the quality of TDM in patients
receiving immunosuppressants. For the quality analysis,
the number of TDM drug levels outside of the reference
range was used as a surrogate parameter. For approxi-
mately 40% of patients, written information regarding the
desired drug concentration range, depending on time
since transplantation, was missing in the medical charts
and therefore could not be assessed. It was found that
only approximately one third of patients with kidney
transplants were without need of further intervention.
This assessment emphasises the fact that immunosuppres-
sant dose adjustments are common and optimal dosing
regimens are difficult to determine, especially in the early
postoperative phase [26,27]. Furthermore, frequent med-
ication changes, namely drug additions and discontinua-
tions, complicate dosing regimen optimisation. Widely-
used immunosuppressives have great inter- and intra-
individual pharmacokinetic variability and many con-
founding factors (e.g., race, time since transplantation, sex
and metabolic profile) that have to be taken into account
when adapting dosages on the basis of plasma drug con-
centration [28]. Constant plasma drug levels correspond-
ing to time since transplantation should be the goal. ADEs
are also common in the kidney transplant patient popula-
tion. Common ADEs seen with immunosuppressives are
as follows: new-onset diabetes mellitus, tremors (tac-
rolimus), hyperlipidemia, hypertension, hypertrichosis
(ciclosporin), and gastrointestinal side effects, such as
diarrhoea (mycophenolate mofetil) [27]. Typical manage-
ment of ADEs considers dose reduction of the offending
drug or switching to another immunosuppressant medi-
cation. All these properties impair dose adjustments and
tight drug-level control of immunosuppressant medica-
tions. There is evidence that clinical pharmacists can con-
tribute to the vigilant supervision and management of
kidney transplant patients [9,29,30].
Evaluation of drug use on the nephrology ward shows that
in-hospital treatment is associated with a significant
increase in the number of prescribed drugs and pDDIs.
Poly-morbidity is frequent, and multiple medications are
almost always necessary to meet treatment goals. Our
study illustrates that poly-medication, which is almost
inevitable in nephrology patients, leads to an increasing
number of pDDIs. Other authors report similar findings
in other patient populations [31,32]. It must be noted that
the number of drugs administered to the patient during
the active in-hospital treatment period is even higher
compared to the number at admission or discharge due to
temporary therapeutic treatments, such as anti-infectives
or anticoagulation drugs. Reviewing drug-drug interac-
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tions at admission and discharge provides only a frac-
tional view of all pDDIs that by definition can never be
complete. According to a published study by Glintborg
and colleagues, the clinical relevance of computerised
screening of pDDIs, as done in our study, tends to be low
[33]. However, in daily practice, this tool proves to be use-
ful for gaining a quick overview and raising awareness of
potential medication-related events. Considering the sen-
sitivity of patients with renal impairment and drug-related
needs, especially for pDDIs leading to increased nephro-
toxicity or aggravation of kidney function, these interac-
tions must be intensely and carefully monitored.
Recognition, avoidance and management of drug-drug
interactions and medication reviews should be done vigi-
lantly [3] as these procedures also represent markers of
treatment quality.
This pilot study was retrospective and was primarily
designed to identify different areas with intervention
needs (e.g., RFs, TDM) and possibilities for improvement
of drug therapy-related aspects (e.g., management of
pDDIs, medication reviews). Evidence from the literature
shows that these tasks are already performed by clinical
pharmacists as a part of their clinical routine. However,
the extent of clinical pharmacists' involvement varies con-
siderably. We are aware that this pilot study itself does not
contribute to the overall evidence on clinical pharmacy
services. However, we hypothesise that clinical pharma-
cists could play an important part in improving treatment
quality, as there is evidence supporting the benefit of clin-
ical pharmacy services in this area [7-11]. Since the proc-
ess of delivering drug therapy to in-hospital patients is a
complex, time-consuming, multi-step and therefore error-
prone process, clinical pharmacy services could enforce
drug-therapy safety and address therapeutic needs that are
being insufficiently met by other health care professionals
in the care delivery process.
As with all studies, our current investigations had limita-
tions. The assessment was done by a single pharmacist
and included only patients from one internal nephrology
ward. Data from other wards were not available. There-
fore, the possibility of data extrapolation is limited.
Conclusion
Our pilot study identifies possibilities and needs for
improvements in the management of hypertension, dia-
betes and hyperlipidemia, which are three major RFs for
renal and/or CV disease. In the subgroup of TX patients,
tight control of immunosuppressant blood levels accord-
ing to the reference range could be optimised. Medication
regimens are complex, and the frequency of pDDIs
increased during in-hospital treatment. Detected pDDIs
were frequently associated with a potential aggravation of
already impaired kidney function. Clinical pharmacy serv-
ices could positively influence RF management, TDM and
the management of pDDIs. However, this hypothesis
must be confirmed in future research. Based on our study
findings, the impact of clinical pharmacy services on drug-
therapy related problems and RF management should be
addressed using a prospective study design in a nephrol-
ogy patient population and a kidney transplant popula-
tion, respectively.
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Appendix
Medis® is an Austrian general drug information tool with
a pDDIs screening function. The data used originates from
Mikropharm - Arzneimittelinteraktionen provided by a
collaboration of the Bundesvereinigung Deutscher Apoth-
ekerverbände (ABDA), Österreichische Apothekerkam-
mer (ÖAK) and Schweizer Apothekerverein (SAV).
The four categories of relevance were:
Severe interaction: combination may be life threatening;
possibility of intoxication; permanent damage may be
induced.
Moderate interaction: combination may lead to therapeu-
tic difficulties and may even be harmful; close patient
monitoring is needed.
Minor interaction: interaction is to be taken into account
but normally causes no harm to the patient.
Unknown relevance: no proven clinical relevance of
described interaction.
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 ABSTRACT 
Background and Objective 
Routine clinical pharmacy services have newly been implemented on an intern  
nephrology ward in an effort to further expand these services. The clinical pharmacist 
participates in ward rounds at least three times per week. The objective is to evaluate 
the contribution of clinical pharmacy services by documentation of the consultations 
made during the ward rounds, classified by type, frequency and complexity.  
Design  
Descriptive, prospective study  
Setting 
Intern nephrology ward of the Vienna General Hospital – University Clinics 
Main Outcome Measures 
Type and frequency of drug- or pharmacotherapy-related questions raised by health 
care professionals during the ward rounds and subsequently answered by the clinical 
pharmacist  
Complexity of questions defined by the total time needed to answer each question 
Problems and barriers identified during the initial period of the clinical pharmacy project 
Results 
From January 2008 to May 2009 (17 months) the clinical pharmacist was asked a total 
of 174 drug- or pharmacotherapy-related questions during participation in the ward 
rounds. Questions mainly derived from physicians (n=154; 88.5%), nurses (14; 8%) or 
medical students (6; 3.5%).  
Based on the total time needed to answer, each question was either categorised into 
group A (up to 15 minutes: 133; 76.4%), group B (up to one hour: 24; 13.8%) or group 
C (more than one hour, extensive and complex literature research: 17; 9.8%).  
The absolute and relative frequency of each type of consultation were: drug therapy 
selection (40; 23%), general drug information (35; 20.1%), dosage and  
pharmacokinetics (31; 17.8%), availability of drugs (19; 10.9%), drug interactions  
(17; 9.8%), adverse drug events (13; 7.5%), application of drugs (8; 4.6%),  
organisation and logistics (7; 4.0%), pregnancy and breastfeeding (2; 1.1%) and  
pharmaeconomics (2; 1.1%).  
The main problems and barriers identified were: (1) continuity of collaboration due to 
changes in medical ward staff each semester, (2) bridging psychological borders  
between physicians and pharmacists, and (3) different levels of professionalism of 
clinical pharmacists due to a lack of systematic clinical pharmacy education  
programmes. 
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 Conclusion 
Interim results of newly implemented clinical pharmacy services are encouraging and 
participation in ward rounds will continue. A prospective study to evaluate  
pharmaceutical care issues in the renal transplant population is ongoing.  
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 ABSTRACT 
Background and Objective 
Knowledge of relevant pharmacokinetic parameters, e.g. protein binding, non-renal 
excretion rate (Q0-value), eliminiation half-life and the presence of active metabolites, 
of commonly prescribed drugs is essential for drug therapy individualisation in patients 
with renal impairment. The objective is to analyse qualitative prescribing patterns on an 
intern nephrology ward and subsequently develop a synopsis of important pharmaco-
therapy relevant parameters.  
Design  
Retrospective analysis of drug prescriptions of 100 randomly selected patients  
Synthesis of a synopsis of drug properties relevant for drug therapy individualisation by 
searching drug information databases and handbooks of clinical drug data 
Setting 
Intern nephrology ward of the Vienna General Hospital – University Clinics 
Main Outcome Measures 
Frequency of the most prescribed drugs  
Frequency of drugs identified with pharmacokinetic properties requiring attention 
Results 
A total of 195 different drugs were identified, adressing typical nephrological pharmaco-
therapy questions, e.g. hypertension, diabetes, electrolyte disturbances, secondary 
hypoparathyreoidism and cardiovascular disease. The ten most prescribed drugs were 
prednisolone (53%), pantoprazole and esomeprazole (88.2%), aspirin (39.2%),  
carvedilol (35.3%), tacrolimus (34.3%), candesartan (30.4%), mycophenolate mofetil 
(29.4%), amlodipine (28.4%) and furosemide (27.45%). Around 50% of the patients 
had kidney transplantation.  
124 drugs were included in the synopsis. Frequency of drugs with pharmacokinetic 
properties to consider (among others) when prescribing in renal impairment were:  
highly (>80%) protein bound drugs (52.1%), Q0-values <0.5 (32.4%), prolonged  
elimination half-life in renal impairment (47.6%) and the presence of active metabolites 
(45.2%). Further parameters investigated were frequency of drugs with the need for 
dose adjustments (49.2%) and the need for therapeutic drug monitoring (10.5%). 
44.4% of the drugs are substrates, inhibitors (18.5%) or inducers (4.0%) of CYP450 
liver enzymes. The synopsis also comprises dosing guidelines for normal and impaired 
renal function and further pharmacokinetic drug parameters. 
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 Conclusion 
Knowledge of altered pharmacokinetic parameters affecting action, efficacy and toxicity 
of drugs, is essential when prescribing drugs to patients with renal impairment. The 
synopsis highlights common drugs requiring special attention. It can be used as a 
teaching tool for health care professionals beginning in nephrology or as a quick  
eference guide at the point of care.  
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THE “RENAL” FOCUS – SYNOPSIS OF DRUG PROPERTIES 
 
POPULAR DRUGS IN NEPHROLOGY - DOSING AND PHARMACOKINETICS  
 
Disclaimer - About the tables 
The drugs included are based on a retrospective review of medication regimens of  
patients treated on an intern nephrology ward. Drugs are classified by the  
Anatomical-Therapeutical-Chemical (ATC) classification system, which is  
recommended by the WHO for drug utilisation research. The international  
non-proprietary names (INN) for the active agents are reported. The brand name refers 
to drugs licensed in Austria.  
 
Information about average drug dosages for adults is reported for normal renal function 
(NRF) and renal impairment (RI), on the basis of the summary of product  
characteristics (SPC). These dosages are meant only as a guide. The dosage of drug 
depends on indication, different patient factors, and disease state. In the dosing section 
for RI, glomerular filtration rate (GFR) is reported in mL/min/1.73m2.  
 
The pharmacokinetic data section contains information on relevant pharmacokinetic 
drug properties that are necessary for drug therapy individualisation and prescribing in 
RI. Only major cytochrome enzymes (CYP) and drug-drug interactions (DDI) are  
reported. For detailed information, refer to other drug information compendia and to the 
SPC.  
 
Literature  
SPCs, in the latest version 
Anderon PO, Knoben JE, Troutman WG. Handbook of Clinical Drug Data. 9th ed. Stamford: Appelton & 
Lange; 1998. 
Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure – Dosing Guidelines for Adults 
and Children. 5th ed. Philadelphia: American College of Physicians; 2007. 
Murphy JE. Clinical Pharmacokinetics. 4th ed. Bethesda, Maryland: American Society of Health-System 
Pharmacists; 2007. 
DRUGDEX® System (electronic version). Thomson Reuters (Healthcare) Inc., Greenwood Village, Colo-
rado, USA. Available at: http://www.thomsonhc.com (cited: 09/30/2009). 
AHFS Drug Information 2009. Bethesda, Maryland: American Society of Health-System Pharmacists; 
2009. 
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 Abbreviations used in the tables and legend 
 
Drug  Name Consider dose reduction in RI! Sensitive parameter in RI 
↑ Increase, increased 
↓  Decrease, decreased  
Q0 Non-renal excretion rate 
Ø  No need for dose reduction in renal impairment 
#  Drug has active metabolite(s) 
%Exun Fraction of drug excreted as unchanged drug in the urine in normal 
renal function 
AC Taken before meals (ante cibum) 
ADE  Adverse drug event 
BB Beta blockers 
BID Taken twice a day 
BUN Blood urea nitrogen 
CHF Chronic heart failure 
CI Contraindication 
CL   Clearance 
CyA Cyclosporine A 
CYP   Drug is a substrate of CYP P450 enzymes 
CYP   Drug is an inhibitor of CYP P450 enzymes 
CYP  Drug is an inducer of CYP P450 enzymes 
d Days 
DR Dose reduction 
ESRD End-stage renal disease 
GI Gastrointestinal 
HL  Drug elimination half life 
im Intramuscular administration 
iv Intravenous administration 
M Metabolite(s) 
MAO Monoaminoxidase 
N None 
ND  No data available 
PB  Protein binding (%) 
PL  Drug elimination half life prolonged 
po Peroral 
PPI Proton pump inhibitor 
PR Prolonged release form 
Q…h Taken every …hour 
QHS Taken every night at bedtime 
QD Taken once a day 
QOD Taken every other day 
QID Taken four times a day 
sc Subcutaneous administration 
SCr Serum creatinine 
T1/2  Drug elimination half life in NRF (mean) 
T1/2ESRD Drug elimination half life in ESRD (mean) 
TDM  Therapeutic drug monitoring recommended or needed 
TE Thromboembolism 
TID Taken three times a day 
TTS Transdermal therapeutic system 
UC Drug elimination half life unchanged 
Vd  Volume of distribution (L/kg), based on an average body weight of  
70 kg 
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The clinical pharmacist’s contributions within the 
multidisciplinary patient care team of an intern 
nephrology ward 
Abstract  
Objective: To describe and evaluate newly implemented clinical pharmacy services and ward 
round participation on a specialized nephrology ward in a large tertiary care hospital. 
Method: All issues addressed by the clinical pharmacist were systematically collected, and 
the contributions were classified by type. Where applicable, physicians’ acceptance rates 
were recorded. The drugs most commonly affected by the clinical pharmacist’s contributions 
are described. 
Results: A total of 158 clinical pharmacist’s contributions were recorded. Approximately 90% 
(n=104) of applicable suggestions (117 out of 158; 74%) were accepted by the treating 
physicians. Most issues were discussed with physicians (85%); the remaining issues were 
discussed with nurses and medical students. Antimicrobials, drugs affecting the alimentary 
system and metabolism, and cardiovascular drugs were among the most commonly affected 
drugs. Issues concerning dosage and drug-therapy selection were common. The clinical 
pharmacist was also involved in developing dosing guidelines and performing literature 
searches.  
Conclusion: The observed effects of a newly implemented clinical pharmacy service on an 
internal nephrology ward are encouraging; acceptance rates of suggestions and the 
multidisciplinary appreciation of clinical pharmacy services are high.  
 
Keywords: clinical pharmacy services, nephrology, kidney, Austria  
 
Impact of findings on practice: 
The clinical pharmacist addresses drug therapy selection and dosing as the most common 
issues during ward round participation on an internal nephrology ward. 
 
The clinical pharmacist’s contributions and suggestions are being appreciated, and even if 
rejected, increase awareness of pharmacotherapy-related problems among other health care 
professionals.  
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 Introduction 
Clinical pharmacists are experts in pharmacotherapy who routinely provide patient care and 
interact with patients and other health care professionals with the goal of optimizing 
pharmacotherapy1. The primary responsibilities of clinical pharmacy services include the 
identification, resolution and prevention of drug-related problems (DRPs) during the 
continuous patient care process. A DRP is defined as an “event or circumstance involving a 
patient’s drug treatment that actually, or potentially, interferes with the achievement of an 
optimal therapeutic outcome”2, and comprises medication errors (MEs) and adverse drug 
events (ADEs). MEs subsume any errors in the process of prescribing, dispensing or 
administering a drug, independent of occuring harm or not. An ADE is defined as any injury 
related to the use of a drug3.  
A review of DRPs in hospitals reported average ME rates of 6% in hospitalized patients and 
1.07 MEs per 100 patient-days. Important risk factors contributing to the occurrence of MEs 
include a lack of information about drugs, errors in patient charts and/or documentation and 
inadequate or decentralized pharmacy services, among others3. Due to the avoidable nature 
of MEs, their management warrants great attention. Furthermore, DRPs contribute 
substantially to drug-associated morbidity and mortality, leading to prolonged hospitalization 
and increased overall health care costs2.  
Clinical pharmacy services have evolved over time, and the involvement of clinical 
pharmacists in multidisciplinary patient care is proven to be influential and has been 
associated with positive patient outcomes4. Several studies have shown that the presence of 
clinical pharmacists on inpatient wards leads to a reduction in the occurrence of MEs3 and 
ADEs5. Clinical pharmacy services have also been shown to be beneficial in the care of 
patients with acute or chronic kidney failure, patients undergoing different renal replacement 
therapies and patients after kidney transplantation6,7. In these settings, specialized clinical 
pharmacists contribute to the management of important issues, such as the increased 
susceptibility to drug toxicity due to impaired renal function, common polypharmacy, altered 
drug pharmacokinetics, and complex underlying comorbidities (e.g., hypertension, diabetes, 
anemia), in this patient population. The prevalence of DRPs is particularly high in patients 
with impaired renal function, whose management is complex6,8. The overall awareness of 
DRPs has increased and ME rates, as one subgroup of DRPs, have decreased secondary to 
the integration of clinical pharmacists in multidisciplinary therapeutic teams3.  
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 Aim  
The aim of the study was to describe, for the first time, the clinical pharmacist’s contributions 
and areas of intervention in the nephrology setting in a large Austrian tertiary care hospital. 
 
Methods 
This descriptive single clinical pharmacist study was designed to prospectively analyze and 
evaluate newly implemented clinical pharmacy services on an intern nephrology ward. The 
highly specialized ward comprises 28 beds, occupied primarily by chronic or acute kidney 
failure patients, those on renal replacement therapies, kidney transplant recipients 
immediately after discharge from the surgical department and those recipients receiving 
continuous post-transplant care. Clinical pharmacy services have been added to routine 
patient care, i.e. the clinical pharmacist joined the ward round team, which then included a 
senior physician, several assistant physicians, nursing staff, and the clinical pharmacist. The 
clinical pharmacist did not receive any formal training. 
The clinical pharmacist participated in the ward round thrice weekly between June 2009 and 
March 2010 (10 months). During the ward rounds, the current medication regimen of 
admitted patients were discussed and the clinical pharmacist made contributions.  
Contributions comprised interventions to DRPs initiated by the clinical pharmacist (proactive) 
and the provision of, by members of the ward round team requested, information and support 
(reactive). All contributions made by the specially assigned clinical pharmacist were 
systematically collected, recorded, and classified according to categories, derived from the 
Guideline for Quality Control of Drug Information in the Hospital Pharmacy, provided by the 
German Society of Hospital Pharmacists9. Issues were subdivided into eight topical 
categories (five and three categories for pro- and reactive contributions, respectively; see 
Table 1 for description of categories) and immediately documented in writing after the ward 
round using an Microsoft® Excel spreadsheet. For proactively performed interventions to 
DRPs, the physicians’ acceptance rate of the clinical pharmacist’s interventions was 
recorded, immediately afterwards or later, but not later than during the next ward round. 
Drugs that were subject to the clinical pharmacist’s contributions were recorded based on the 
WHO-ATC-Code10.  
 
Results 
A total of 158 clinical pharmacist’s contributions were recorded. Frequencies of different 
categories and illustrative examples are given in Table 1. Among all contributions, 74% 
(n=117) were applicable for documentation of acceptance rates; 88.9% (n=104) of 
114
 contributions were accepted by physicians. Predominant reasons for the rejection of 
pharmacist suggestions included missing laboratory data and lack of other relevant 
information for immediate decision-making. The vast majority of contributions (95%) were 
discussed during ward rounds at the point of care. Remaining issues required additional time 
to be addressed, resulting in extensive literature searches, including searches for dosing 
guidelines (e.g., for analgesics in impaired renal function) and teaching aids (e.g., 
comparison chart of total parenteral nutrition solutions). The clinical pharmacist discussed 
most issues with physicians (85,4%), nurses (7%) and students (7.6%). The primary drug 
classes subject to the clinical pharmacist’s contributions were systemic antimicrobials (ATC 
code group J - 26,7%), drugs affecting the alimentary system and metabolism (ATC code 
group A - 17,4%), those affecting the cardiovascular system (ATC code group C - 17,4%), 
those affecting the nervous system (ATC code N - 11,2%), and antineoplastics and 
immunomodulatory agents (ATC Code L - 8,7%) (Table 1).  
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 Discussion 
We report encouraging results regarding the clinical pharmacist’s contributions on an internal 
nephrology ward, including high acceptance rates of recommendations and appreciation of 
implemented services by multidisciplinary team members. Clinical pharmacy services in 
Austrian hospitals are just beginning to grow, and the systematic and widespread 
implementation of such services, as seen in the U.S. and U.K., in Austrian hospitals is still 
lacking. However, small and limited clinical pharmacy efforts are emerging in an increasing 
number of Austrian hospitals.  
Our data analysis demonstrated that the clinical pharmacist’s primary areas of contribution 
include selection and discussion of drug therapy and handling of dosing issues. Regarding 
the type of the clinical pharmacist’s contributions, our results are comparable to those 
described in literature6. Selection of presumptive antimicrobial therapy, adaptation to 
microbial sensitivity results and discontinuation of antimicrobial treatment were among the 
most common issues addressed by the clinical pharmacist. Overdosing of antivirals, such as 
valganciclovir for cytomegalovirus infection prophylaxis in kidney transplant recipients, was 
common. In particular, patients in the early post-transplant period, when renal function is 
prone to fluctuations, required frequent dose adaptations. Over- and under-dosing 
predominantly occurred with antiviral, antibacterial and antihypertensive drugs. 
Immunosuppressants and other routinely prescribed drugs in renal transplant recipients were 
among the top five drug groups affected by the clinical pharmacist’s contributions. 
Immunosuppressant pharmacotherapy is a critically important aspect of post-transplant 
patient care. Due to the complexity of managing transplant recipients (e.g., infection 
prophylaxis, metabolic complications), clinical pharmacists are becoming increasingly 
involved in their care7. The overall rate of contributions regarding drug interactions was low 
with only 3.8%. In other clinical pharmacists’ intervention studies in end-stage renal disease 
patients the proportion of drug interactions was higher with around 10-15%6. One 
hypothetical reason, that we can not, however, support by evidence, may be an already high 
awareness of drug interaction among commonly prescribed drugs by nephrologists.  
The high acceptance rate of nearly 90% of contributions during the ward rounds reported 
here is also encouraging. Our acceptance rates are consistent with acceptance rates that 
have been previously published in the literature4. Reasons for the rejection of initial 
suggestions were primarily missing laboratory data or other clinical data relevant to decision 
making. However, the clinical pharmacist’s recommendations were considered by the 
treating physicians. We, therefore, hypothesize that every issue raised and discussed, 
although rejected, increases the awareness of potential problems and highlights crucial steps 
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 and points to consider. In addition to assisting with pharmacotherapy-related issues, the 
clinical pharmacist also supported the ward team with organizational and logistic concerns 
(e.g. assistance in the drug ordering process of preparations for specific patients, advice on 
stock keeping), which somewhat eased the nurses’ workload.  
Nevertheless, obstacles to the further expansion of clinical pharmacy services in our hospital 
and in Austria in general do exist. The absence of electronic medical records and other 
technology support tools for prescribing, data collection or analysis in our hospital represent 
a major barrier to the growth of clinical pharmacy services and clinical pharmacy research in 
our hospital. The lack of systematic clinical pharmacy education on a national Austrian level 
and the low staffing of hospital pharmacists (0.36 pharmacists per 100 beds)10 further 
complicate the development of systematic clinical pharmacy services for our ongoing 
projects.  
We report the results of a single clinical pharmacist study in a developing area and 
acknowledge the lack of a control group and significance assessment of the clinical 
pharmacist’s contributions as limitations of our study. Study results may be significantly 
influenced by characteristics at the level of the pharmacist, e.g., motivation, workload, 
experience, among others. Further limitations comprise the lack of information on clinical or 
humanistic outcomes. The absence of sociodemographic patient data limits the 
generalizability of our results. Our findings show that a clinical pharmacist can contribute to 
patient care by addressing unmet drug therapy needs. Although limitations exists, our results 
highlight the need for further impulses to expand clinical pharmacy services.   
 
Conclusion 
Based on our encouraging results and appreciation of the contributions of the clinical 
pharmacist to patient care during ward rounds, clinical pharmacy services will continue. The 
presence of clinical pharmacists raised the awareness of potential problems or issues and 
informed the multidisciplinary patient care team. The clinical pharmacist was welcomed 
during ward rounds as a valuable source of pharmacologic knowledge by the interdisciplinary 
care team of physicians, nurses and medical students.  
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Abstract  
Background and objective: Data on clinical pharmacy activities and their characteristics 
in Austrian hospitals and the possible impact on patient care are relatively scarce. The 
objectives were to analyse drug-related problems and the impact of clinical 
pharmacists’ interventions. 
Method: Prospective 22-week observational descriptive clinical pharmacists’ 
intervention study on six different wards of a tertiary care university hospital. In-depth 
analysis of drug-related problems and interventions. Inter- and intra-rater variability 
analysis of interventions’ significance assessment.  
Main outcome measures: Type and frequency of DRPs and clinical pharmacists’ 
interventions and the physicians’ acceptance rate. Further outcome parameters were 
the clinical significance of the interventions and the proportion of those with a cost-
reducing potential. 
Results: A total of 478 drug-related problems were detected during 138 ward rounds. 
The most common drug-related problems related to specific information (30.1%), 
organisational advice (14.2%), medical chart errors (7.7%), untreated indications 
(7.5%) and drug use without indication (6.9%). Clinical pharmacists provided 
information (42.9%), suggested the addition of new drugs (13.4%) and the adaptation 
of drug dosages (12.6%). Antibacterials for systemic use, antithrombotics, and drugs 
for acid related disorders were commonly implicated. Mean acceptance rate of 
interventions was 54.7%. Three out of four clinical pharmacists’ interventions were 
rated to be significant. The inter-rater reliability analysis of clinical significance 
immediately and two weeks after study completion showed a fair to moderate 
agreement (Fleiss’s Kappa 0.35, pairwise Spearman correlation coefficients between 
0.5 and 0.74, all p<0.0001). Every twentieth intervention showed a cost reducing 
potential.  
Conclusions: The results highlight a positive impact of clinical pharmacy services in a 
continually developing environment. Although, on average every second intervention 
was immediately accepted, the proportion of significant interventions was high. Clinical 
pharmacy services are one method of addressing evident drug-related problems in 
hospitalised patients in Austria.  
 
123
Article summary 
Article focus:  
 Clinical pharmacy services are known to improve patient care by addressing 
drug-related problems. 
 The study aimed at evaluating the type and frequencies of drug-related 
problems, and the impact of clinical pharmacists’ interventions in a, regarding 
clinical pharmacy services, continually developing setting.  
Key messages: 
 Need for information, organisational advice, medical chart errors, untreated 
indications, and drugs used without indications were common drug-related 
problems addressed by the clinical pharmacists. 
 Clinical pharmacists valuably contributed to patient care by providing 
information, suggesting the addition of new drugs and drug dosage adaptations.  
 Approximately every second suggested intervention was accepted by 
physicians, and three out of four interventions were rated to be significant 
Strengths and limitations of this study: 
 This study provides evidence of a beneficial impact of clinical pharmacy 
services on drug-related problems in a large tertiary care hospital in Austria. 
 Bias related to the assessment of the significance of clinical pharmacists’ 
interventions was addressed by performing inter-rater and intra-rater analysis. 
 The lack of reporting on patient-related and clinical outcomes has to be 
acknowledged as a major weakness of this study. 
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Introduction 
Clinical pharmacy is defined as the part of pharmacy practice ‘that contributes directly 
to patient care and develops and promotes the rational and appropriate use of 
medicinal products and devices’.[1] In many countries these services have emerged 
over time, and the involvement of clinical pharmacists in multidisciplinary patient care is 
beneficial and has been associated with positive patient outcomes [2-4] and economic 
benefits.[5] 
The cornerstones of clinical pharmacy services are the detection, resolution and 
prevention of drug-related problems (DRPs). A DRP is defined as an ‘event or 
circumstance involving a patient’s drug treatment that actually, or potentially, interferes 
with the achievement of an optimal therapeutic outcome’.[6] Several studies have 
shown that the presence of clinical pharmacists in inpatient wards leads to a reduction 
in the occurrence of common DRPs, e.g., medication errors (MEs)[6] and adverse drug 
events (ADEs)[7], and therefore contributes to overall patient safety.  
However, the extent of the development and implementation of clinical pharmacy 
services vary, primarily when comparing services in Europe to those in the US[4,8], but 
also among European countries themselves. In 85% of European hospitals, some form 
of clinical pharmacy services is implemented. Differences regarding centralised (i.e., 
wards visited at least once daily or less frequently) versus decentralised services (i.e., 
at least 50% of time on the ward) and the overall time pharmacists spend on the ward 
exist.[9]  
In Austria, there is still a system of hospital pharmacy practice that focuses on 
traditional tasks, e.g., production and logistics. The Ordinance Regulation on the 
Operation of 2005 clearly defines and describes, for the first time, the clinical and 
patient-oriented tasks of the hospital pharmacist in Austria. However, systematic full-
time and comprehensive clinical pharmacy services are still non-uniformly implemented 
across Austrian hospitals. A survey of the Austrian Association of Hospital Pharmacists 
showed that there are only 8 full-time clinical pharmacists compared to 140 full-time 
hospital pharmacists, when considering the overall time hospital pharmacists spend on 
ward-based services.[10] To our knowledge, data on the benefits and extent of clinical 
pharmacy services in Austria are only available as poster abstracts[11-14] and a 
narrative report.[15] Further evidence supporting the value of clinical pharmacy 
services in Austria is urgently needed to pursue the development, implementation and 
acceptance of clinical pharmacy services, with the ultimate goal of improved patient 
care.  
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The Vienna General Hospital – University clinics is the largest Austrian tertiary care 
hospital, with a capacity of 2130 in-hospital beds, 1450 physicians, and 30 
pharmacists, 6 of them being involved in the provision of clinical pharmacy services 
during ward round participation and other ward-based activities (e.g., interdisciplinary 
rounds). Clinical pharmacy in our hospital mainly evolved from initial small-scale 
projects of shorter duration that have been adopted into the routine. To date, clinical 
pharmacy services are implemented on three standard care units (SCUs) and three 
intensive care units (ICUs). In the ambulatory drug addiction clinic, clinical pharmacy 
services have been established in close conjunction with the provision of methadone 
and other opioids, as part of the outpatient treatment for opioid addiction maintenance 
therapy.  
Aim of the study 
The aim of this study was to perform a comprehensive evaluation of the implemented 
clinical pharmacy services across all clinical pharmacist–attended clinics by describing 
and analysing DRPs and consecutive clinical pharmacists’ interventions.  
Method 
Study design and setting 
The study was designed as a prospective 22-week observational and descriptive 
clinical pharmacists’ intervention study. A detailed overview of wards with regular 
clinical pharmacy services is given in Table 1. In addition to participation in ward 
rounds, clinical pharmacists are available for consultations on call during the day  
 
Table 1 Overview of wards with regular clinical pharmacy services 
Clinic  
Code Description of clinics 
Ward type and 
frequency of  
ward round 
participation 
Years of experience in 
provision of clinical 
pharmacy prior to 
study 
Years of hospital 
pharmacy 
experience 
CS Department of Surgery, Division of Cardio Surgery SCU - twice weekly 2 25 
GE 
Department of Medicine III, 
Division of Gastroenterology and 
Hepatology 
ICU - once weekly 1.5 2.5 
HE 
Department of Medicine I, 
Division of Haematology and 
Haemostaseology 
SCU - twice weekly 0.2 3 
ID 
Department of Medicine I, 
Division of Infectious Disease and 
Tropical Medicine 
ICU - once weekly 3 11 
NE 
Department of Medicine III, 
Division of Nephrology and 
Dialysis 
SCU - thrice weekly 3 4 
NN 
Department of Paediatrics and 
Adolescent Medicine, Division of 
Neonatology, Intensive Care and 
Neuropaediatrics 
ICU - twice weekly 2 11 
PC 
Department of Psychiatry and 
Psychotherapy, Division of 
Biological Psychiatry 
AC - daily 9 9 
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Description of clinical pharmacy services 
A quality management process for clinical pharmacy services has been developed, 
based on initial experiences with small-scale clinical pharmacy efforts, the results of 
extensive literature reviews and a focus group meeting among all involved clinical 
pharmacists. A schematic description of the clinical pharmacy sequence is depicted in 
Figure 1.  
 
 
Figure 1: Clinical pharmacy process 
 
On the SCUs, the clinical pharmacists screened paper-based medical charts, 
discussed incidental DRPs and provided suggestions for their resolution (intervention) 
during ward rounds. The clinical pharmacists assigned to the ICUs prepared for ward 
rounds centrally in the pharmacy in advance, by accessing the electronic medical 
records, including relevant data, e.g., drug therapy, diagnosis, and lab values. 
However, potential DRPs were also discussed during ICU ward rounds. Ward round 
teams routinely consisted of a senior physician, several junior physicians, nursing staff, 
and medical students. All clinical pharmacists educated themselves about the patient 
cases on their own. The overall time of the individual clinical pharmacist’s attachment 
to the ward prior to study and years of hospital pharmacy experience are also given in 
Table 1.  
Comprehensive documentation system 
The type of DRP, the suggested intervention or contribution (a term related to 
informational or organisational issues), the status of acceptance of interventions, and 
the drug classification according to World Health Organisation (WHO) Anatomical 
Therapeutic Chemical (ATC) Code classification system, therapeutic subgroup level, 
were recorded. For documentation and categorisation purposes, a published and 
validated system[16] was used, which was adapted and amended according to the 
clinical pharmacists’ needs, extracted during the focus group meeting. Acceptance 
rates were assessed using a four-point rating scale comprising the categories 
‘accepted’, ‘taken into consideration’, ‘rejected’, and ‘non-assessable’. The acceptance 
rate was not recorded for contributions related to organisation and information. 
Furthermore, all interventions were judged regarding their cost-reducing potential.  
A detailed explanation of the several documentation categories is shown in the 
appendix (web-only). The clinical significance of interventions was assessed using a 6-
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point significance-rating scale (adverse significance–extremely significant).[17] Every 
intervention or any other contribution was rated by the clinical pharmacist immediately 
at the time of the intervention and again two weeks after the study ended. Upon study 
completion, all interventions and contributions were co-assessed in random order by 
each clinical pharmacist who was blinded to the other clinical information. No formal 
training in documentation or significance assessment was performed prior to the study. 
Main outcome measures 
The main outcome measures were the type and frequency of DRPs, the type and 
frequency of clinical pharmacists’ interventions and contributions, and the physicians’ 
acceptance rate. Further outcome parameters were the clinical significance of the 
interventions and the proportion of interventions with a cost-reducing potential. In-depth 
analysis was performed for all DRPs and for the individual clinical setting. The drugs 
that were most commonly involved in DRPs are reported descriptively.  
Statistical methods  
Absolute and relative frequencies of DRPs, interventions, and commonly implicated 
drugs are provided. To assess the inter-rater and intra-rater variabilities of clinical 
significance, Cohen’s and Fleiss’s Kappa and Spearman correlation coefficients are 
reported. Bowker’s symmetry test was calculated to determine whether the first and 
second assessment were consistently different. 
Results 
DRPs and interventions 
During 138 ward rounds (25 in CS, 16 in GE, 14 in HE, 11 in ID, 38 in NE, 11 in NN, 
and 23 in PC), a total of 478 DRPs were addressed. A mean (± standard deviation) of 
0.3 (± 0.4) and 3.5 (±1.5) DRPs were identified per patient and per ward round, 
respectively. The most common DRPs were related to specific therapy discussions and 
the need for information (30.1%), organisational advice (14.2%), medical chart errors 
(7.7%), untreated indications (7.5%), and drugs used without indication (6.9%). The 
most frequent clinical pharmacists’ interventions and contributions were related to 
general information (42.9%), the addition of new drugs (13.4%), and dose adjustments 
(12.6%). The overall frequency of various DRPs and interventions per clinical area are 
given in Tables 2 and 3, respectively.  
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Table 2: Type and frequency of drug-related problems, per clinical area and total 
CS GE HE ID NE NN PC Total 
 
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Non-conformity to 
guidelines or 
contraindication 
   1 (2.4) 13 (6.2)  3 (11.5) 17 (3.6) 
Untreated indication  11 (11.5) 2 (3.6)   17 (8.1) 1 (3.1) 5 (19.2) 36 (7.5) 
Subtherapeutic dosage 3 (3.1) 4 (7.1)  2 (4.9) 11 (5.3)   20 (4.2) 
Supratherapeutic dosage 5 (5.2) 3 (5.4)  2 (4.9) 22 (10.5)   32 (6.7) 
Drug without indication     33 (15.8)   33 (6.9) 
Drug interaction: To be 
taken into account 
2 (2.1) 9 (16.1)  6 (14.6) 4 (1.9)   21 (4.4) 
Drug interaction: Use with 
caution 
1 (1.0)  1 (5.6) 7 (17.1)   7 (26.9) 16 (3.3) 
Drug interaction: 
Combination to be 
avoided 
1 (1.0) 3 (5.4)     2 (7.7) 6 (1.3) 
Drug interaction: 
Combination contra-
indicated 
        
Adverse drug reaction 2 (2.1)   2 (4.9) 5 (2.4)  1 (3.8) 10 (2.1) 
Improper administration 3 (3.1) 5 (8.9)  2 (4.9) 5 (2.4) 1 (3.1)  16 (3.3) 
Failure to receive drug 2 (2.1)    1 (0.5) 1 (3.1)  4 (0.8) 
Drug monitoring 1 (1.0)   1 (2.4) 2 (1.0)  2 (7.7) 6 (1.3) 
Medical chart error 5 (5.2) 9 (16.1)  2 (4.9) 21 (10.0) 1 (3.1)  38 (7.9) 
Specific information and 
therapy discussion 
48 (50.0) 5 (8.9) 8 (44.4) 8 (19.5) 64 (30.6) 10 (31.3) 1 (3.8) 
144 
(30.1) 
Literature search 2 (2.1) 1 (1.8) 2 (11.1)  2 (1.0) 4 (12.5)  11 (2.3) 
Others 10 (10.4) 15 (26.8) 7 (38.9) 8 (19.5) 9 (4.3) 14 (43.8) 5 (19.2) 68 (14.2) 
Total  96 (100) 56 (100) 18 (100)  41 (100) 
209 
(100)  
32 (100)  26 (100)  
478 
(100) 
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Table 3: Type and frequency of interventions and contributions by the clinical pharmacists, per 
clinical area and total 
CS GE HE ID NE NN PC Total 
 
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Addition of a new drug 22 (22.9) 3 (5.4) 6 (33.3) 5 (12.2) 21 (10.0) 3 (9.4) 4 (15.4) 64 (13.4) 
Drug discontinuation 6 (6.3) 1 (1.8)  2 (4.9) 46 (22.0) 1 (3.1)  56 (11.7) 
Drug switch 9 (9.4) 5 (8.9)  3 (7.3) 6 (2.9) 1 (3.1) 5 (19.2) 29 (6.1) 
Change of administration 
route 
4 (4.2) 4 (7.1)  3 (7.3) 2 (1.0) 3 (9.4)  16 (3.3) 
Drug monitoring  6 (10.7)  10 (24.4) 3 (1.4)  5 (19.2) 24 (5.0) 
Administration modalities 
optimisation 
8 (8.3) 6 (10.7)  3 (7.3) 4 (1.9) 2 (6.3) 1 (3.8) 24 (5.0) 
Dose adjustment 10 (10.4) 5 (8.9) 3 (16.7) 2 (4.9) 38 (18.2) 1 (3.1) 1 (3.8) 60 (12.6) 
Others 37 (38.5) 26 (46.4) 9 (50.0) 13 (31.7) 89 (42.6) 21 (65.5) 10 (38.5) 
205 
(42.9) 
Total 96 (100) 56 (100) 18 (100) 41 (100) 209 (100) 32 (100) 26 (100) 478 (100) 
 
The majority of DRPs (n=413, 86.4%) were addressed and interventions were 
immediately performed by the clinical pharmacist. In total, 13.6% of DRPs resulted in 
an increased need for time to address them (n=48, 10% up to one hour; n=17, 3.6% 
more than one hour). 
In 89.1% (n=426) of DRPs, interventions were discussed with physicians and for the 
other DRPs, interventions were discussed with the nursing staff. Of those interventions 
discussed with nursing staff, 78% were informational in nature or were related to 
organisational advice (e.g., advice on ward stock-keeping or the order of patient-
specific preparations). Five percent of interventions by the clinical pharmacists were 
accompanied with a potential cost reduction, with the most commonly applied strategy 
being the discontinuation of unnecessary drugs (see Figure 2).  
 
30%
14%
9%
47%
Discontinuation Dose reduction
Switch to oral Switch to cheaper drug
 
Figure 2: Interventions with a cost-reducing potential 
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For 71.1% (n=340) of the interventions, an acceptance rate was recorded. The mean 
(±SD) acceptance rate of the suggested clinical pharmacists’ interventions was 54.7% 
(±22.87) (see Figure 3).  
 
7%
39%
54%
Accepted Considered Rejected
 
Figure 3: Overall outcome of clinical pharmacists’ interventions 
 
Including those interventions that were not immediately accepted but were considered 
by the physicians, the mean (±SD) overall acceptance rate increased to 93.5% (±5.60). 
Only 22 suggested interventions were rejected. Crude acceptance rates (%) were 65.8, 
25.8, 91.7, 30.6, 60.9, 46.7 and 40.9 for CS, GE, HE, ID, NE, NN, and PC, 
respectively. 
Significance of interventions 
Analysis of the clinical pharmacists’ self-assessment of the significance of interventions 
upon first-time detection showed an overall proportion of 75.3% of interventions ranged 
as significant (subsumed categories ‘somewhat significant’ to ‘very significant’). 
Compared to the clinical pharmacists’ self-assessment of significance of interventions 
two weeks after the end of the study (68.8% of significant interventions), intra-rater 
analysis showed a moderate agreement between the two different time points (intra-
rater reliability Cohen’s Kappa = 0.58, 95% CI 0.48–0.67). 
The percentage of significant interventions as first assessed was 86.5, 87.8, 61.1, 64.3, 
70.8, 74.0, and 84.6 for CS, GE, HE, ID, NE, NN, and PC, respectively. During the 
study period, there were no interventions classified as ‘extremely significant’. One 
intervention was judged to have adverse significance. This intervention was related to 
the provision of false information regarding the stability of a reconstituted drug on the 
basis of out-dated information. The error was detected shortly after providing the false 
information, and no subsequent errors or patient harm occurred. Regarding the 
significance of interventions, there was a trend towards lower significance assessment 
at the end of the study compared to the initial assessment (symmetry test p=0.006). 
131
The inter-rater reliability analysis of clinical significance immediately and two weeks 
after study completion showed a fair to moderate agreement (Fleiss’s Kappa 0.35, 
pairwise Spearman correlation coefficients between 0.5 and 0.74, all p<0.0001). The 
overall frequency of each significance level of interventions is depicted in Figure 4.  
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Figure Legend: -1, adverse significance; 0, no significance; 1, somewhat significant; 2, significant; 3, very 
significant; 4, extremely significant 
Figure 4: Percentage of overall significance categories of interventions 
 
Analysis of involved drugs 
Anti-infectives for systemic use, drugs affecting the nervous system, and those 
affecting the alimentary system and metabolism were involved in the majority of DRPs 
(see Figure 5).  
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Figure Legend: A02, drugs for acid-related disorders; A12, mineral supplements; B01, antithrombotic 
agents; L04, immunosuppressants; J01, antibacterials for systemic use; J02, antimycotics for systemic 
use; N02, analgesics; N03, antiepileptics; N05, psycholeptics; N06, psychoanaleptics  
Figure 5: The 10 most affected drugs (ATC Code therapeutic subgroup level) 
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Half of the DRPs detected in our study were related to a drug from the 10 most 
prevalent ATC code groups. Drug interactions (all four subcategories) represented a 
common DRP among drugs affecting the nervous system (ATC Code N), 
immunosuppressants (ATC Code L04) and anti-infectives for systemic use (ATC Code 
J). The frequency of drug interactions was significantly higher in immunosuppressants 
compared to non-immunosuppressants (Fisher’s exact test, p=0.004). Furthermore, 
drugs used without indication and under- and overdosages were more prevalent 
among systemic anti-infectives compared to other drug classes (chi-square tests 
p=0.02 and p=0.014, respectively) 
Discussion 
Our study suggests a valuable contribution of the clinical pharmacist to multidisciplinary 
patient care during ward rounds, by addressing DRPs, performing interventions, and 
providing information and organisational support. DRPs are highly prevalent in 
hospitalised patients[18], and optimisation of drug therapy by preventing DRPs 
positively influences costs, reduces mortality and improves patients’ quality of 
life.[19,20] Evidence regarding clinical pharmacy services is published for several 
patient groups and clinical settings, e.g., SCUs[21], ICUs[22,23] and the psychiatric 
setting[24], comparable to those where clinical pharmacy services are implemented in 
our hospital.  
In our study, 50% of interventions were accepted, with a change happening 
immediately. This proportion is lower than published average rates, which range 
between 80 and 90%.[25] However, 39% of interventions were taken into consideration 
by physicians but did not lead to immediate changes (either because of missing data or 
because other information was needed for decision making). We believe that these 
suggestions highlight the problem DRPs and should at least prompt a reconsideration 
of addressed DRPs by the physicians. Thus, by adding this proportion to the crude 
acceptance rate, it increases to the aforementioned rates from other studies. 
Furthermore, the acceptance rates are influenced by several crucial factors, e.g., the 
clinical pharmacists’ knowledge, clinical experience and communication skills, the 
physicians’ confidence in the pharmacists’ intervention, and the multidisciplinary 
working climate. Shortcomings concerning the management of these factors and the 
low familiarity with clinical pharmacy services among clinicians should be urgently 
addressed as one method of improving acceptance rates in our setting.  
Approximately one-third suggested interventions in our study was lost during the 
assessment of acceptance rates, as it was related to informational or organisational 
issues only. Our analysis highlights a need for specific therapy discussions and 
information across all clinical areas of all involved health care professionals, especially 
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among nursing staff, as reflected by the high proportion of 78% of 
information/organisation-related interventions. From our point of view, this and the 
overall low rate of rejected interventions (6.5%) also emphasise that clinical 
pharmacists are seen as a valuable source of pharmacotherapy knowledge.  
The proportion of drug interactions that were detected as DRPs is comparatively higher 
on ICUs than on SCUs. The detection of drug interactions in this area is facilitated and 
therefore enhanced by the availability of an electronic medical record that allows for an 
electronic pre-check before attending the ward rounds. Drug interactions were, not 
surprisingly, a prevalent problem among immunosuppressants. Anti-infectives were the 
drugs that were most affected by interventions, and the clinical pharmacists generally 
addressed the cessation of anti-infectives that were no longer indicated or that 
microorganisms were not susceptible to. Anti-infectives were commonly under- or 
overdosed. In this study, antiviral agents were especially common. Correct dosing is 
crucial, and multiple dose adaptations are common, especially if renal function is 
rapidly changing during the clinical course. 
Clinical pharmacy services have also proved to be cost-effective[5,22], although the 
generalisability of economical studies is often limited due to their dependency on local 
settings and the availability of resources. Our study was not designed to determine the 
economical benefit of clinical pharmacy services. By determining the proportion of 
interventions associated with a cost reduction potential, we wanted to highlight the 
potential cost savings that result when DRPs are addressed. With 5% of interventions 
in our study resulting in cost savings, our proportion was rather small compared to 
another clinical pharmacy study, which reported a proportion of 32%.[26] However, our 
finding of a small cost-reduction potential is difficult to interpret because the four 
categories used were not meant to be a comprehensive list, but rather a sample 
choice.  
The analysis of clinical significance shows that 75% of interventions were significant to 
some extent when self-assessed immediately at the time of documentation. We 
decided to use independent, blinded and random co-assessment of all performed 
interventions by all clinical pharmacists at two different time points to reduce 
assessment bias. Correlation coefficients show a fair to moderate agreement among 
different raters. Consistency among the same rater was moderate. We believe that the 
moderate level of agreement was due to new implementation of the concept of 
significance assessment and consequently a low level of familiarity. Furthermore, the 
specialisation of each clinical pharmacist in his or her clinic and the body of experience 
may influence objective assessment abilities. From our point of view, the issue of 
significance assessment warrants great attention and is important for our further 
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projected studies. Assessment of the value of services is a critically important step in 
health-service research, also with regard to potential reimbursement of additional 
services. This is not yet a matter of broad discussion in Austria, as there is a relative 
lack of systematic services. The documentation and rating process was described as 
time-consuming by all clinical pharmacists. The relative simplicity of the system, 
however, led to a notion of usability and acceptance.  
There are several limitations to our clinical pharmacy services based on the way they 
are currently implemented. The frequency and continuity of ward round participation 
overall has to be increased, as once weekly ward attendance, for example, complicates 
the follow-up of addressed DRPs, suggested interventions and patient outcomes and 
the overall multidisciplinary team work. In particular, the continuous offering of clinical 
pharmacy services, even when the assigned clinical pharmacist who is normally 
responsible for the ward is on leave, has to be pursued. Although the clinical pharmacy 
service process is standardised, the individual characteristics depend on each clinical 
pharmacist and his or her performance, which is in turn influenced by knowledge and 
wealth of experience. Furthermore, the monitoring and documentation of patient 
outcomes, in addition to surrogate parameters, should be the focus of further clinical 
pharmacy work as a method of efficiency determination in our hospital.   
Obstacles to the advancement of clinical pharmacy services and promotion of clinical 
pharmacy research may include the low staffing in hospital pharmacies. With 0.36 
hospital pharmacists per 100 beds, Austria ranks third to last in Europe, compared to 
the European average of 0.93 hospital pharmacists per 100 beds.[27] The majority of 
Austrian hospitals (apart from intensive care units) still depend on paper-based medical 
records. The availability of an electronic patient record and the availability of labs, drug 
prescriptions and physician’s notes in real time would definitely facilitate the growth of 
clinical pharmacy services. The lack of any systematic clinical pharmacy education and 
the relative absence of a promising model for professional advancement in clinical 
pharmacy on a national level is probably the largest obstacle to overcome, as clinically 
active pharmacists often gather their knowledge and experience autodidactically within 
their area. Hence, standardisation is difficult to achieve. Furthermore, psychological 
barriers and a lack of confidence persist concerning the extension of pharmacists’ 
traditional roles and the shift from a reactive drug-focused role towards a more pro-
active patient-oriented role with new responsibilities. Overcoming these barriers would 
allow us to better utilise the specific and unique resources and expertise of the 
pharmacists.  
This study shows the beneficial impact of clinical pharmacists’ activities in a continually 
developing setting by describing DRPs and clinical pharmacists’ interventions and by 
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using surrogate measures (e.g., acceptance rate, significance), whereas, our critical 
analysis highlights the weaknesses of implemented services, documentation, and 
performance as well as the measurement of these services.  
Conclusion 
To our knowledge, this is the first published study to highlight the beneficial effect of 
clinical pharmacy services in the Austrian hospital setting. Although only half of 
interventions were immediately accepted, the proportion of significant interventions was 
high. Clinical pharmacy services will be one method of addressing evident DRPs in 
hospitalised patients in Austria. However, the professional advancement of clinical 
pharmacy services has to be pursued to increase the continuity and professionalism of 
services, the quality of clinical pharmacy research, and overall patient care.  
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ABSTRACT
Background: Sex-specific differences appear particularly relevant in the management of type 2 diabetes 
mellitus (T2DM), with women experiencing greater increases in cardiovascular morbidity and mortality 
than do men. 
Objective: The aim of this article was to investigate the influence of biological sex on clinical care and 
microvascular and macrovascular complications in patients with T2DM in a Central European university 
diabetes clinic. 
Methods: In a cross-sectional study, sex-specific disparities in metabolic control, cardiovascular risk factors, 
and diabetic complications, as well as concomitant medication use and adherence to treatment recom-
mendations, were evaluated in 350 consecutive patients who were comparable for age, diabetes duration, 
and body mass index. Study inclusion criteria included age ≤75 years, T2DM, a documented history of 
presence or absence of coronary heart disease (CHD), and informed consent. Patients were followed in the 
diabetes outpatient clinic between November 2007 and March 2008. 
Results: Two hundred and one patients with T2DM met inclusion criteria (93 [46.3%] women, 
108 [53.7%] men). Women with T2DM had higher mean (SE) systolic blood pressure (155.4 [22.5] vs 
141.0 [19.8] mm Hg for men; P < 0.001) and total cholesterol (TC) (5.28 [1.34] vs 4.86 [1.29] mmol/L for 
men; P < 0.05), but a lower TC:HDL-C ratio (4.1 [1.19] vs 4.5 [1.2] for men; P < 0.05). Slightly more men 
(32.4%) than women (26.9%) reached the therapeutic goal of <7.0% for glycosylated hemoglobin. Women 
with shorter diabetes duration (<10 years) received oral antihyperglycemic therapy less frequently (P < 
0.05). Women with longer disease duration had hypertension more frequently than did their male coun-
terparts (100% vs 86.0%, respectively; P < 0.01). Despite a similar rate of CHD, men were twice as likely 
as women to have had coronary interventions (percutaneous transluminal coronary angioplasty/coronary 
artery bypass graft, 25.0% vs 12.9%, respectively; P < 0.05). Women with CHD also had a higher rate of 
cerebral ischemia than did men (27.6% vs 5.4%, respectively; P < 0.05) and received aspirin less frequent-
ly for secondary prevention (P < 0.001). Men had greater overall adherence to diabetes and cardiovascular 
risk guidelines than did women (66.4% vs 58.9%, respectively; P < 0.01).
Conclusions: In this study of diabetes clinic outpatients, women with T2DM had a worse cardiovascular risk 
profile and achieved therapeutic goals less frequently than did men. Treatment strategies should be improved 
in both sexes, but women with diabetes may be in need of more aggressive treatment, especially when cardio-
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of Vienna, Austria, between November 2007 and 
March 2008, who fulfilled the inclusion criteria 
(age ≤75 years, T2DM, a documented history of 
presence or absence of coronary heart disease, and 
having given informed consent) were included in 
the study. The required sample size was calculated 
using standard formulae for sampling for a survey 
to produce percentage frequency rates of nominal 
data within conventionally acceptable error rates 
(margin of error 5%) and 95% CIs. Sampling was 
carried out using standard data collection. 
A previously described questionnaire was used 
to obtain information about age, known duration 
of DM, height, weight, adherence to drug treat-
ment, smoking habits, alcohol consumption, 
parental history of diabetes, BP, glycemic control, 
lipid profile, and parameters of liver and kidney 
function.6 In addition, the presence of diabetic 
microvascular and macrovascular complications 
and a history of previous percutaneous translu-
minal coronary angioplasty (PTCA) or coronary 
artery bypass surgery (CABG) were assessed. The 
information derived from the questionnaire was 
self-reported, but all data concerning medical his-
tory and clinical characteristics were immediately 
checked and completed using the clinical records. 
All patients maintained stable weight, and moder-
ate physical activity and nutrition therapy were 
recommended for all.
Subgroup analyses were performed to compare 
the above-mentioned criteria, to determine wheth-
er primary prevention or secondary prevention 
therapy was indicated. Patients with cardiovascular 
disease (CVD), defined as ischemic heart disease, 
MI, and/or angina pectoris, were considered as 
requiring secondary prevention. The metabolic 
syndrome was defined according to World Health 
Organization criteria by the presence of DM/
insulin resistance plus ≥2 of the following param-
eters: obesity (body mass index [BMI] ≥30 kg/m2), 
hypertension (BP ≥140/90 mm Hg or use of antihy-
pertensive drugs), and dyslipidemia (triglycerides 
[TG] ≥1.71 mmol/L and/or HDL-C <0.9 mmol/L 
for men and <1.03 mmol/L for women).7
To test the adherence of patient populations to 
evidence-based clinical prescribing recommenda-
tions, a medication assessment tool was employed.6,8 
vascular disease is present. (Gend Med. 2010;7:571–
583) © 2010 Elsevier HS Journals, Inc.
Key words: type 2 diabetes mellitus, gender, dia-
betic complications, cardiovascular risk, blood pres- 
sure, lipid profile.
INTRODUCTION
Women with impaired glucose metabolism have a 
much greater increased risk of coronary artery dis-
ease than do men with impaired glucose control. 
Women aged ≥48 years and men aged ≥41 years 
have a 20% attributed increase in the 10-year risk 
of myocardial infarction (MI), cerebral ischemia, 
or death. These events occur ~15 years earlier in 
patients with diabetes than in those without diabe-
tes.1 In contrast to the pattern of reduced cardiovas-
cular mortality in the nondiabetic population and 
in men with diabetes, the rate of cardiovascular 
death has increased in women with diabetes in the 
past decade. The reason for this difference is 
unknown, but it may, in part, be ascribed to poorer 
achievement of common treatment goals.2–5
Two studies in different countries have reported 
that women achieved therapeutic metabolic goals 
less frequently and also had a more adverse cardio-
vascular risk-factor profile. It is unclear whether 
the underlying causes are predominantly biologi-
cal or psychosocial mechanisms. Thus, the ob- 
served sex disparities might be explained by more 
conservative prescribing of aspirin, lipid-lowering 
agents, and angiotensin-converting enzyme (ACE) 
inhibitors2,5 or, alternatively, by differences in pa- 
tient compliance.
To further describe sex-specific differences in 
cardiometabolic risk factors in patients with type 2 
diabetes mellitus (T2DM), we studied sex dispari-
ties in blood pressure (BP), metabolic control (gly-
cosylated hemoglobin [HbA1c], fasting glucose, and 
lipid levels), diabetic complications, prescribed 
medication, and achievement of therapeutic goals 
at an outpatient department in a Central European 
university clinic.
PATIENTS AND METHODS
Consecutive patients with T2DM attending the 
diabetes outpatient clinic at the Medical University 
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Women with T2DM had higher mean (SE) systolic 
BP (SBP) (155.4 [22.5] vs 141.0 [19.8] mm Hg for 
men; P < 0.001 by Student t test) and total choles-
terol (TC) (5.28 [1.34] vs 4.86 [1.29] mmol/L for 
men; P < 0.05 by Student t test), but a lower 
TC:HDL-C ratio (4.1 [1.1] vs 4.5 [1.2] for men; P < 
0.05 by Student t test). Slightly more men (32.4%) 
than women (26.9%) reached the therapeutic goal 
of HbA1c <7.0%. In patients with mean (SE) HbA1c 
?7% (67 women: 8.6% [1.8%] vs 71 men: 8.5% 
[1.4%]), both SBP (159.3 [21.8] vs 140.6 [19.0] mm 
Hg; P < 0.001 by Student t test) and diastolic BP 
(88.4 [12.9] vs 83.7 [12.9] mm Hg; P < 0.05 by 
Student t test) were significantly higher in women 
than in men, respectively. Women with longer dis-
ease duration had hypertension more frequently 
than did their male counterparts (100% vs 86.0%, 
respectively; P < 0.01 by Student t test). In women 
compared with men, significantly higher SBP levels 
were observed in most subgroups, including the 
overweight (152.7 [21.2] vs 135.8 [23.7] mm Hg; 
P < 0.01 by Student t test) and obese (156.9 [23.9] 
vs 143.2 [17.1] mm Hg; P < 0.001 by Welch t test) 
patients. Even in patients without hypertension, 
women had notably higher SBP values than did 
men (135.3 [7.5] vs 127.2 [13.1] mm Hg, respec-
tively; P < 0.05) by Mann-Whitney U test.
TC was also significantly higher in women than 
in men (Table I), including the subgroup (87 wom- 
en, 97 men) of hypertensive patients (204.3 [52.6] 
vs 188.1 [50.1] mg/dL; P < 0.001 by Student t test). 
In the group requiring secondary prevention, 
fewer women (n = 29) reached the LDL-C goal 
and, consistently, they had higher mean LDL-C 
levels than did men (n = 37) (2.94 [1.11] vs 2.37 
[0.93] mmol/L, respectively; P < 0.05 by Student 
t test). In all subgroups, women were characterized 
by higher HDL-C levels, resulting in a lower mean 
TC:HDL-C ratio compared with men. In the sub-
groups of patients with diabetes duration <10 years 
or a BMI ?30 kg/m2, TG levels were significantly 
lower in women than in men (P < 0.05 by Student 
t test).
Diabetic Complications
Some differences in diabetic macrovascular com- 
plications, but no differences in diabetic microvas-
This 23-item instrument is based on the guidelines 
established by the Scottish Intercollegiate Guidelines 
Network (SIGN),9 which is in accordance with the 
guidelines of the American Diabetes Association10 
and the European Society of Cardiology.11 For every 
patient, each criterion of the item was judged as 
“applicable,” “insufficient data” (lack of informa-
tion), “not applicable” (criterion relevant for patient 
but patient’s data did not meet the qualifying state-
ment), or “justified nonadherence” (explanation for 
a patient’s treatment not meeting a quality criteri-
on). Adherence to the guideline recommendations 
was calculated as previously described in detail.6,8 
Levels of adherence were compared using the ?2 
test and P < 0.05 as the threshold for statistical sig-
nificance. A Microsoft Access (Microsoft Corpora- 
tion, Redmond, Washington) database was created, 
from which data from the specific subgroups were 
extracted. These data were statistically evaluated 
using SPSS 16.0 (SPSS Inc., Chicago, Illinois).
For metric and ordinal characteristics, the num-
ber of patients and arithmetic means with stan-
dard errors are given. For evaluation of statistically 
significant sex-dependent differences within the 
whole sample and specific subgroups, the Student 
t test, Welch t test, and Mann-Whitney U test were 
used, depending on the sample size and test crite-
ria. For nominal characteristics, the number of 
patients and percentage are given. Statistically sig-
nificant sex-dependent differences for the whole 
sample and specific subgroups were calculated 
using the ?2 and Fisher exact tests. Statistical sig-
nificance was determined at levels of P < 0.05, P < 
0.01, and P < 0.001.
RESULTS
Metabolic Syndrome and Patient Profile
Of 350 consecutive patients with T2DM attend-
ing the diabetes outpatient clinic, 201 patients 
(93 [46.3%] women, 108 [53.7%] men) met the 
inclusion criteria. Eighty-six women (92.5%) were 
postmenopausal. Only one of these women was 
taking hormone replacement therapy (estradiol 
and norethisterone). The metabolic syndrome 
affected 68.7% of the entire study sample, with a 
significantly higher rate in women than in men 
(79.6% vs 59.3%, respectively; P < 0.05) (Table I). 
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0.05 by ?2 test) (Figure 1A). In the subgroup 
requiring secondary prevention, women featured 
a similar rate of angina pectoris compared with 
men (65.5% vs 56.8%, respectively), but under-
went PTCA/CABG less frequently (41.4% vs 73.0%; 
P < 0.01 by ?2 test). Concerning macrovascular 
cular complications (neuropathy, nephropathy, 
or retinopathy), were observed between women 
and men (Figures 1 and 2). Despite a similar rate 
of coronary heart disease, men were twice as likely 
to have had coronary interventions as were women 
(PTCA/CABG: 25.0% vs 12.9%, respectively; P < 
Table I.  Clinical characteristics and cardiovascular risk of patients attending a diabetes outpa-
tient clinic. Data are shown as mean (SE), unless otherwise indicated.
Characteristic
Women  
(n = 93)
Men  
(n = 108)
Age, y 60.5 (8.6) 58.2 (9.6)
Geriatric (>65 y), % 37.6 35.2
Age at diagnosis, y 50.5 (9.4) 49.9 (9.5)
Duration of diabetes, y 10.1 (7.7) 8.4 (7.0)
Smoker, no. (%) 14 (15.1)* 30 (27.8)
Abstain from alcohol, no. (%) 72 (77.4)† 58 (53.7)
Noncompliant to medication, no. (%) 12 (12.9) 14 (13.0)
Family history of CVD, no. (%) 40 (43.0) 36 (33.3)
Metabolic syndrome, no. (%) 74 (79.6)‡ 64 (59.3)
Fasting blood glucose, mg/dL 140.8 (65.0) 138.4 (47.1)
HbA1c
 <7.0%, no. (%) 25 (26.9) 35 (32.4)
HbA1c, % 8.0 (1.8) 7.8 (1.6)
Hypertension, no. (%) 87 (93.5) 97 (89.9)
SBP, mm Hg 155.4 (22.5)§ 141.0 (19.8)
DBP, mm Hg 86.5 (12.2) 83.3 (12.5)
BMI, kg/m2 31.8 (6.2) 31.6 (5.6)
Overweight, no. (%) 36 (38.7) 31 (28.7)
Obese, no. (%) 50 (53.8) 68 (63.0)
Hyperlipidemia, no. (%) 87 (93.6) 93 (86.1)
TC, mmol/L 5.28 (1.34)‡ 4.86 (1.29)
LDL-C, mmol/L 3.00 (1.11) 2.73 (1.08)
HDL-C, mmol/L 1.36 (0.36)§ 1.13 (0.33)
TC:HDL-C ratio 4.1 (1.1)‡ 4.5 (1.2)
Triglycerides, mmol/L 2.34 (1.72) 2.44 (1.40)
Secondary prevention, no. (%) 29 (31.2) 37 (34.3)
FHS risk score, % 24.2 (0.8) 26.0 (0.7)
FHS risk score for primary prevention and age >60 y, % 26.5 (2.3)‡? 29.9 (0.8)
CVD = cardiovascular disease; HbA1c = glycosylated hemoglobin; SBP = systolic blood pressure; DBP = 
diastolic blood pressure; BMI = body mass index; TC = total cholesterol; FHS = Framingham Heart 
Study.
*P < 0.05, by ?2 test. 
† P < 0.001, by ?2 test.
‡ P < 0.05, by Student t test.
§ P < 0.001, by Student t test.
???P < 0.01, by ?2 test.
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Figure 1.  (A) The percentage of women and men with percutaneous transluminal coronary angioplasty/coronary artery 
bypass graft (PTCA/CABG) is shown for the total sample and in relation to duration of type 2 diabetes mellitus, 
glycosylated hemoglobin (HbA1c), secondary prevention (sec prev), body mass index (BMI), and for hypertensive 
(hyperten) and hyperlipidemic (hyperlip) patients. (B) Percentage of women and men with cerebral ischemia is 
presented for the total sample and all subgroups. Women experienced cerebral ischemia more often than did 
men, and this difference became significant for secondary prevention. (C) Men had myocardial infarction more 
frequently than did women; the difference became significant with BMI <30 kg/m2. This tendency was reversed 
in the subgroup of obese patients. Symbols indicate significant sex differences within a subgroup: *P < 0.05 
and †P < 0.01.
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present study, HbA1c <6.5% was achieved with diet 
in patients with short (<10 years) disease duration 
only (6.4% of women vs 1.5% of men; P < 0.05 by 
?2 test). Women with shorter diabetes duration 
(<10 years) received oral antihyperglycemic therapy 
less frequently (P < 0.05 by ?2 test). Fewer women 
were treated with insulin alone (25.8% vs 27.8%; 
P = NS by ?2 test), but more women than men 
tended to take insulin in addition to an oral antidi-
abetic drug (OAD) (35.5% vs 23.1%; P = NS by 
?2 test). This latter sex difference was more evident 
in the subgroup of hypertensive patients (37.9% of 
women vs 23.7% of men; P < 0.05 by ?2 test). A 
complications, significant sex differences were ob- 
served in the prevalence of cerebral ischemia 
(Figure 1B) and MI (Figure 1C). The rate of cere-
bral ischemia was markedly higher in women 
than in men with CVD (secondary prevention 
group) (27.6% vs 4.7%, respectively; P < 0.05 by 
Fisher exact test).
Pharmacotherapy
For patients with diabetes, most diabetes asso-
ciation guidelines recommend an HbA1c goal of 
<7.0%, with the exception of an optimal goal of 
<6.5% if it can be easily and safely achieved. In the 
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Figure 2.  (A) The percentage of women and men with nephropathy is shown for the total sample and for subgroups. There 
was a tendency toward more women than men having nephropathy, but no significant sex differences were 
observed. (B) Women experienced peripheral neuropathy more often than did men; however, the differences 
were not statistically significant. HbA1c = glycosylated hemoglobin; sec prev = secondary prevention; BMI = 
body mass index; hyperten = hypertensive; hyperlip = hyperlipidemic.
 (continued)
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the therapeutic target (8.5% women vs 26.1% men; 
P < 0.05 by ?2 test). In most cases, a combination of 
antihypertensive drugs was administered, includ-
ing diuretics, ACE inhibitors, ?-adrenoceptor block-
ers, angiotensin II type 1 receptor blockers, calcium 
antagonists, ?1-blockers, and ?2-agonists.
The overall adherence to prescribing guideline 
criteria (SIGN) was significantly lower in women 
than in men (59.8% vs 66.4%, respectively; P < 
0.01 by ?2 test) (Table II), especially in the sub-
group requiring secondary prevention (60.0% 
women vs 74.0% men; P < 0.001 by ?2 test). More 
men than women received aspirin for secondary 
total of 16.7% of female patients and 22.8% of male 
patients were treated with ≥1 OAD; P = NS by ?2 test). 
No significant sex differences were found in the per-
centage of patients taking OADs (60% were taking 
metformin, 37% sulfonylureas, 13% glitazones, 
4% gliptins, and 3% both ?-glucosidase inhibi- 
tors and glinides). Overall, significantly fewer wom- 
en than men achieved BP values ≤130/80 mm Hg 
(13.3% vs 36.3%, respectively; P < 0.001 by ?2 test) 
despite a similar rate of antihypertensive therapy 
compared with men (86.4% vs 84.7%; P = NS). In 
the subgroup of patients requiring primary preven-
tion, even fewer patients, especially women, reached 
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Figure 2  (continued). (C) No significant sex differences were found between women and men with retinopathy. (D) No 
significant sex differences were found between women and men with peripheral artery occlusive disease.
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trast to previous findings in patients requiring sec-
ondary prevention.2 Overall, only about one third 
of the patients reached the therapeutic goal of 
HbA1c <7.0% at our tertiary care center; however, 
we observed that fewer women than men reached 
this goal.
We found female gender to be associated with 
higher SBP levels despite a similar rate of antihyper-
tensive treatment. Interestingly, women achieved 
the BP treatment goal of <130/80 mm Hg less fre-
quently than did men, which is, in part, consistent 
with previous reports.12,13 Of note, women with 
good metabolic control did not differ from their 
male counterparts regarding high BP, suggesting 
that worsening of metabolic control is associated 
with hypertension, particularly in women. Chu et 
al,14 however, reported an association between 
HbA1c and SBP only in males with diabetes, thus 
arguing against a prominent gender effect. Causal- 
ly, various factors might contribute to sex/gender 
disparities in BP regulation, including not only 
prevention (88.6% men vs 51.9% women; P < 
0.001 by ?2 test), whereas no significant sex differ-
ences were observed in those without CVD (pri-
mary prevention group). If aspirin was contraindi-
cated or not tolerated, men tended to receive 
clopidogrel more frequently than did women 
(35.7% vs 16.7%, respectively; P = NS by Fisher 
exact test) and achieved target cholesterol levels 
more often while taking statins (68.3% vs 56.9%; 
P = NS by ?2 test).
DISCUSSION
Risk Profile
In contrast to previous analyses, no significant 
sex differences in age or diabetes duration were 
observed in our study sample, rendering women 
and men comparable for the evaluation of cardio-
vascular risk and complications. There also were 
no significant sex differences in glycemic control, 
which is consistent with another study in patients 
without CVD (primary prevention),12 but in con-
Table II.  Adherence to selected criteria of the Scottish Intercollegiate Guidelines Network in primary prevention and 
secondary prevention, using a medication assessment tool (MAT).*
Adherence
Women Men
MAT Criteria
Yes/ 
Applicable
%  
(95% CI)
Yes/
Applicable
%  
(95% CI) P
Patient receives aspirin (75–150 mg/d) 36/86 42 (32–52) 51/90 57 (46–66) <0.052
Patient with TC ≥5.16 mmol/L receives statin 62/85 72 (63–81) 66/97 68 (58–77) 0.52
Patient receiving statin achieved re-test TC <5.16 mmol/L 33/58 57 (44–69) 43/63 68 (56–79) 0.26
Patient receiving antihypertension therapy 76/88 86 (78–92) 83/98 85 (76–91) 0.84
Patient receiving antihypertension therapy achieved  
BP ≤130/80 mm Hg 10/75 13 (7–23) 29/80 36 (27–47) <0.01
Patient appropriately prescribed ACE inhibitor† 45/71 63 (52–74) 50/79 63 (52–73) 1.00
Overweight patient in need of OAD is  
prescribed metformin 55/58 95 (85–99) 58/63 92 (82–97) 0.72
Overall adherence (1466 criteria) 401/681 59 (55–63) 521/785 66 (63–70) <0.01
TC = total cholesterol; BP = blood pressure; ACE = angiotensin-converting enzyme; OAD = oral antidiabetic drug.
 *  Adherence to the guideline recommendations in the patient group was calculated for each criterion and for the MAT overall by sum-
ming the “yes” responses to the application of the standard, expressed as the percentage adherence to the standard, using the number 
of applicable criteria as the denominator.
  †   Patient with no apparent contraindication/intolerance to an ACE inhibitor who falls into any of the following categories: postmyocar-
dial infarction; left ventricular systolic dysfunction; age >55 years with at least one other known risk factor (smoking, hypertension, 
TC >5.16 mmol/L or HDL-C ≤1.03 mmol/L, microalbuminuria).
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represent a greater hazard for women.28 However, 
the importance of serum TG as an independent 
predictor of CVD remains controversial.29 A recent 
analysis reported that the combination of fenofi-
brate with a statin had some gender-dimorphic 
effects, with benefit in males and potential harm 
in females.30
In the present study, men had a more adverse 
cardiovascular risk-factor profile in relation to 
cigarette smoking and alcohol consumption. 
Nicotine abuse has been associated with a more 
dramatic increase in the risk of MI in women com-
pared with men.31
Diabetic Complications
We did not find significant sex differences 
regarding microvascular disease or peripheral vas-
cular disease. Although female gender is associated 
with relative protection with regard to the devel-
opment and progression of nondiabetic kidney 
disease, at least in premenopausal women, the 
current literature is inconclusive as to the presence 
of diabetes and sex differences in diabetic neph- 
ropathy, retinopathy, or neuropathy.32 
As men were more frequent smokers, other athero-
genic risk factors (eg, lipid disorders or changes in 
oxidative stress) seemed to mainly contribute to 
peripheral arterial disease (PAD) in women with dia-
betes. Indeed, except for smoking, age and diabe-
tes have been found to be the most important 
predictors of PAD, which has also been related to 
increased mortality in both women and men.33 In 
the present study, PAD was associated with CVD in 
both sexes, in agreement with other published find-
ings.34 In those findings, the condition showing the 
strongest association with vascular disease in females 
was diabetes, but in males it was smoking.
In nondiabetic subjects, CVD tends to become 
manifest 10 years earlier in men than in women.1,5 
The presence of diabetes, however, seems to limit 
sex differences and increases the prevalence of CVD 
and MI at all ages—more prominently in women 
than in men.35 In past years, CVD-associated mor-
tality rates have decreased in men both with and 
without diabetes, irrespective of glucose tolerance, 
but have remained unchanged in women who 
have diabetes. Although no significant sex differ-
sex-related differences in renin–angiotensin system 
activity, salt sensitivity, and menopause-associated 
alterations in circulating sex hormone levels, but 
also gender gaps in hypertension awareness and 
risk-factor management.15–19 Furthermore, differ-
ences in atherogenic risk-factor clustering with 
more unfavorable changes in coagulation, endothe-
lial function, and inflammatory processes in women 
have already been described very early in the 
development of T2DM, suggesting that “the clock 
starts ticking earlier” in women.20,21
The United Kingdom Prospective Diabetes Study 
found that a decrease in SBP of 10 mm Hg was 
associated with an 11% risk reduction of MI and a 
13% risk reduction of macrovascular disease.22 
These data underscore the clinical implications of a 
14-mm Hg sex difference in mean SBP in our study, 
because even moderate increases in BP markedly 
increase the risk of CVD in women with diabetes.
Premenopausal women usually have a less 
atherogenic lipid profile, which deteriorates after 
menopause. In accordance with other studies,2,3,23 
we found both TC and HDL-C to be increased in 
women compared with men. Of note, in our 
study, distinct sex differences in lipid profile were 
observed in the subgroup requiring secondary pre-
vention. Women requiring secondary prevention 
more often failed to achieve their sex-specific 
treatment goal in HDL-C (40 mg/dL in this study), 
which was associated with higher LDL-C levels. 
Consistent with previous results,12 this finding 
might be attributable to more conservative use of 
antihyperlipidemic therapy. In primary prevention 
in our study, LDL-C tended to be increased in 
women and has been found to be significantly 
higher in other studies as well.2,24 In fact, the age-
related loss of female sex hormones is associated 
with a more pronounced disruption of lipid homeo-
stasis in women, which may be further aggravated 
by impaired glucose metabolism with concomitant 
subclinical inflammation and increased oxidative 
stress.25,26
Even slight sex differences in LDL-C might be of 
relevance, as an increase of 1 mg/dL increases car-
diovascular mortality risk by 4%.27 Although TG 
levels were not significantly different between the 
sexes in our study, hypertriglyceridemia appears to 
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scribed in terms of the level of prescribing adher-
ence to evidence-based treatment recommenda-
tions. In contrast to other studies reporting on 
lower frequency of statin use in women,38 we 
found no significant sex differences, although 
there was a trend for target cholesterol to be 
achieved more often in men. BP targets were 
achieved in <25% of patients and this was much 
more of a problem in women. Similar findings 
have been reported in other studies.2,12,24 Regard- 
ing secondary prevention, women were less likely 
to receive aspirin (P < 0.05) and perhaps ACE 
inhibitors (nonsignificant trend). Overall, women 
had lower adherence to pharmacotherapy guide-
lines, especially in respect to attention to second-
ary prevention decisions.
Regarding therapeutic antihyperglycemic strat-
egy, we found that, compared with men, women 
with shorter disease duration more often received 
only lifestyle therapy. Furthermore, there was a 
trend for women to be treated more frequently 
with a combination of oral antihyperglycemic 
therapy and insulin than were men; this differ-
ence became significant in the presence of hyper-
tension, which is in line with previous findings.12 
Despite similar glycemic control in both sexes, we 
cannot determine whether women more readily 
accepted insulin injections, were prescribed insu-
lin more often, or more frequently needed insulin 
to control their metabolism. In any case, careful 
consideration of diabetic treatment is required—
epidemiologic studies have found that metformin 
is associated with a lower risk for cancer and that 
exogenous insulin may be associated with an 
increased risk, although these associations are 
complex and may be confounded by biological 
diabetes/obesity-related changes.39,40 In particular, 
insulin therapy has been related to increased risk 
of breast cancer, which could be explained by acti-
vation of insulin-like growth factor signaling 
pathways and increased signaling through the 
estrogen receptor. On the other hand, women 
with diabetes and breast cancer who were taking 
metformin therapy have experienced better che-
motherapy response rates, possibly due to reduc-
tion of growth factor signaling and induction of 
cell cycle arrest.40 
ence in CVD or MI was observed in our study, 
women tended to show a higher frequency of 
CVD in some subgroups (age <60 years, good 
metabolic control, or secondary prevention). 
Despite this fact, women notably were less likely 
to have a history of PTCA or CABG. This finding 
also applied to the subgroups. Similar results with 
regard to risk-factor screening, cardiac interven-
tions, and pharmacotherapy have been found in 
other studies in different populations, but without 
differentiation between individuals with or with-
out diabetes.36 Such inequality in treatment strate-
gies might be ascribed, in part, to atypical symp-
toms and false stress electrocardiogram test results, 
which are more common in women with CVD. 
These findings suggest that it might be worth-
while to increase physicians’ awareness about sex 
differences in cardiovascular risk.
In the present study, the difference in MI rates 
between women and men with diabetes was 18%, 
and therefore much lower than the 45% reported 
for the Austrian population in 2007.37 This dis-
crepancy might be explained by the exclusion of 
nondiabetic subjects in our study and is consistent 
with the data reported by Mulnier et al.35 The 
observed sex difference in MI rates was smaller in 
the subgroups with a diabetes duration >10 years 
and HbA1c ≥7.0%, suggesting that longer duration 
of the disease and worse metabolic control may be 
a greater hazard in women.36
The prevalence of cerebral ischemia is, in gen-
eral, similar between the sexes, although the rela-
tive risk has been reported to be increased in 
women with diabetes, particularly at younger 
ages.23 In our study, there was a nonsignificant 
trend for women to have cerebral ischemia in the 
total cohort as well as in all subgroups, but this 
was statistically significant in women with CVD 
(secondary prevention group).
Pharmacotherapy
Women with diabetes, based on these findings 
and those in other studies, could a priori have a 
more adverse diabetes-associated cardiovascular 
risk profile or be subject to differences in prescrib-
ing and/or pharmacologic responsiveness. In the 
present study, we also evaluated medication pre-
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they point to the need for more aggressive treat-
ment, in particular for women with T2DM, and they 
further outline the importance of sex- and gender-
specific medical assessment and intervention.
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Abstract
Background: New-onset diabetes mellitus after transplantation (NODAT), a frequent and serious complication after
transplantation, is associated with decreased graft and patient survival. Currently, it is diagnosed and treated
primarily according to existing guidelines for type II diabetes. To date, only a few trials have studied antidiabetic
drugs in patients with NODAT. Vildagliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor that improves
pancreatic islet function by enhancing both a- and b-cell responsiveness to increased blood glucose. Experimental
data show potential protective effects of DPP-4 inhibitors on islet function after exogenous stress stimuli including
immunosuppressants. Therefore, the therapy of NODAT with this class of compounds seems attractive. At present,
vildagliptin is used to treat type II diabetes as monotherapy or in combination with other antidiabetic drugs, since
that it efficiently decreases glycated hemoglobin (HbA1c) values. Additionally, vildagliptin has been shown to be
safe in patients with moderately impaired kidney function. This study will evaluate the safety and efficacy of
vildagliptin monotherapy in renal transplant recipients with recently diagnosed NODAT.
Methods/Design: This study is a randomized, placebo-controlled, double-blind, prospective phase II trial. Using the
results of routinely performed oral glucose tolerance tests (OGTT) in stable renal transplant patients at our center,
we will recruit patients without a history of diabetes and a 2 h glucose value surpassing 200 mg/dl (11.1 mmol/l).
They are randomized to receive either 50 mg vildagliptin or placebo once daily. A total of 32 patients with newly
diagnosed NODAT will be included. The primary endpoint is the difference in the 2 h glucose value between
baseline and the repeated OGTT performed 3 months after treatment start, compared between the vildagliptin-
and the placebo-group. Secondary endpoints include changes in HbA1c and fasting plasma glucose (FPG). The
safety of vildagliptin in renal transplant patients will be assessed by the number of symptomatic hypoglycemic
episodes (glucose <72 mg/dl or 4 mmol/l), the number of adverse events, and possible medication-associated
side-effects.
Discussion: NODAT is a severe complication after kidney transplantation. Few trials have assessed the safety and
efficacy of antidiabetic drugs for these patients. The purpose of this study is to assess the safety and efficacy of
vildagliptin in renal transplant patients with NODAT.
Trial Registration: ClinicalTrials.gov NCT00980356.
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Background
New-onset diabetes after transplantation (NODAT), also
called post-transplant diabetes mellitus (PTDM),
remains a severe metabolic complication in patients
after organ transplantation. NODAT leads to an
increased incidence of cardiovascular disease (CVD) and
consequently reduced graft and patient survival [1,2]. In
non-transplanted patients, diabetes mellitus (DM) has
been identified as a major independent risk factor for
CVD [3]. CVD includes atherosclerotic coronary heart
disease, heart failure, myocardial infarction, stroke and
peripheral vascular disease [4]. Patients with CVD and
DM suffer from a worse prognosis for survival than
patients without these conditions. In organ transplant
recipients, mortality due to CVD remains the most com-
mon cause of mortality [1]. In renal transplant recipients
NODAT is associated not only with increased cardiovas-
cular morbidity and mortality, but also with impaired
long-term graft function and increased risk of graft loss
[4,5]. Hence, NODAT needs medical attention and
treatment and therefore clinical trials with antidiabetic
drugs for the therapy of NODAT remain of high
interest.
The reported incidence of NODAT varies between 2
and 53%. This high variability is due the lack of a stan-
dard definition in clinical studies [6]. Some reports
define NODAT by the requirement for exogenous insu-
lin without further examinations, such as an oral glucose
tolerance test (OGTT). Currently, the diagnosis of
NODAT is based on guidelines for type II diabetes
(T2DM) from the American Diabetes Association
(ADA), which include impaired glucose tolerance (IGT)
and impaired fasting glucose (IFG) as diagnostic para-
meters [7]. Development of NODAT has modifiable (e.
g. body weight, immunosuppressive drug therapy) and
non-modifiable (e.g. age, ethnicity, polycystic kidney dis-
ease) risk factors [8]. The role of immunosuppressants
(e.g. corticosteroids or calcineurin inhibitors (CNIs)) in
the clinical course of diabetes is clearly established, and
disease development is probably mediated by an
increased beta-cell apoptosis and impaired insulin sensi-
tivity [4,9]. The incidence of steroid-induced diabetes is
related to the treatment duration and the dose of corti-
costeroids [10]. Some authors propose steroid reduction
or complete withdrawal as a means to reduce the inci-
dence of NODAT, but steroid withdraw has been asso-
ciated with an increased risk for graft rejection [4].
Most centers currently follow so-called “step-up” stra-
tegies established for the treatment of T2DM starting
with non-pharmacological therapies and life-style modi-
fication, subsequently followed by oral antidiabetic ther-
apy and finally insulin [4]. Pharmacodynamic and
pharmacokinetic drug properties may be altered in
patients with renal impairment and new drugs have to
be studied regarding safety and effectiveness in patients
with impaired renal function. In renal transplant
patients, drugs are at additional risk of interacting with
immunosuppressive agents as well as with other co-
medications [11].
Vildagliptin, a dipeptidyl peptidase IV (DPP-4) inhibi-
tor that, belongs to a new class of oral antidiabetic
drugs [12]. DPP-4 inhibitors enhance the activity of
incretin hormones in response to a glucose load by
blocking the hormones responsible for incretin degrada-
tion [13]. Incretins are gut hormones that are secreted
from enteroendocrine cells into the blood within
minutes after food intake. The incretin hormones
glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1) have been reported to
exert numerous metabolic effects contributing to the
regulation of blood glucose levels [14]. Vildagliptin
decreases glycated hemoglobin (HbA1c) in patients with
T2DM when given as monotherapy or combined with
metformin or glitazones [15-19]. Furthermore, vildaglip-
tin has been shown to be safe in patients with mild to
moderately impaired kidney function [20].
This study aims to assess the safety and efficacy of vil-
dagliptin in patients with NODAT.
Methods/Design
Hypothesis
Vildagliptin improves glucose metabolism in patients
suffering from newly diagnosed NODAT.
Objectives
This 16-week trial aims to evaluate the safety and effi-
cacy of vildagliptin in stable renal transplant recipients
with newly diagnosed NODAT.
The primary outcome parameter will be the difference
in 2 h glucose levels obtained during an OGTT between
stable renal transplant patients receiving vildagliptin or
placebo after 3 months treatment.
The secondary study outcomes will include change in
HbA1c and fasting plasma glucose after three months of
treatment, the safety of vildagliptin in renal transplant
recipients regarding kidney function, liver function and
the potential for drug-drug interactions with immuno-
suppressive medications (Intention to treat (ITT) analy-
sis), the safety of vildagliptin for glycemic control in
patients with impaired kidney function, and the long-
lasting effects of vildagliptin on b-cell function one
month after treatment stop.
Study design and setting
This study is a prospective, single-center, double-blind,
randomized, placebo-controlled, phase II trial in patients
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with newly diagnosed NODAT. Patient recruitment and
follow-up are conducted at the Medical University of
Vienna. The study recruitment has started in February
2010.
Study setting
Patients with a stable kidney allograft, more than 6
months after transplantation, without a history of
T1DM or T2DM routinely undergo an OGTT at our
outpatient department. All patients with a pathological
OGTT (serum glucose levels ≥ 200 mg/d (11.1 mmol/
L)) are classified as patients suffering from NODAT. 32
Patients eligible for the study are invited to the outpati-
ent clinic and therapeutic options are discussed. Patients
who are willing to take part in the study and have
signed their informed consent form are randomized in a
1:1 ratio into study arm A (vildagliptin) or study arm B
(placebo). The detailed study flow chart and an overview
of study procedures are depicted in Figure 1 and 2,
respectively.
Study intervention
Patients will receive their study medication (vildagliptin
or placebo) with instructions to take it once daily 30
minutes before breakfast. Patients will receive continu-
ous counseling on lifestyle modification (e.g. diet, physi-
cal exercise) until the end of the study. Participants in
the study have to be on a triple immunosuppressive
therapy consisting of a CNI (tacrolimus or cyclosporine
A), prednisolone, and mycophenolic acid, either as the
prodrug (mycophenolate mofetil) or as delayed-release
mycophenolic sodium. All changes in concomitant med-
ication will be recorded. Patients will have a visit at our
outpatient clinic during weeks 2, 4, 8, 12, and 16 (Fig-
ure 2). At each visit, blood samples are collected to
determine blood parameters including complete blood
count, serum chemistry, C-reactive protein, creatinine,
calculated glomerular filtration rate (cGFR) using the
“Modification of Diet in Renal Disease” (MDRD) for-
mula, potassium, sodium, phosphate, chloride, calcium,
total bilirubin, ALAT, ASAT, total protein, LDL, HDL,
triglycerides. Patients with a cGFR between 30 and 50
mL/min./1.73 m2 will have weekly blood checks com-
prising creatinine and ASAT/ALAT during the first
month for safety reasons. Each patient is expected to
parcipate in the study for 120 days. Unblinding of the
study will be performed after the end of the complete
trial. Patients whose OGTT did not improve 4 months
after study start will be treated by the physicians of our
outpatient clinic according to the guidelines.
Informed consent
The investigator explains the nature of the study, its
purpose, procedures, expected duration, and the poten-
tial risks and benefits associated with study participation
along with any discomfort that may be expected.
Patients will be informed about the strict confidentiality
of their subject data, but also that their medical records
may be reviewed for trial purposes by authorized indivi-
duals other than their treating physician. Each subject
will be informed that study participation is voluntary
and withdrawal is possible at any time during the study
period. Withdrawal will not prejudice the subject’s sub-
sequent care. Subjects are given time to read and under-
stand the statements before signing consent and dating
the document. Subjects receive a copy of the signed
written statement and the original copy of the informed
consent is stored in the investigator study files. No sub-
ject is entered into the study until informed consent has
been obtained.
Safety assessments
Safety assessments will include the monitoring and
recording of all adverse events (AE), including serious
adverse events (SAE). An AE is any undesirable experi-
ence associated with the use of a medical product in a
patient. An SAE is defined as any untoward medical
occurrence that at any dose results in death, is life-
threatening, requires inpatient hospitalization or prolon-
gation of existing hospitalization, or results in persistent
or significant disability/incapacity. The most probable
AEs caused by vildagliptin are consistent with the
known side-effects, which are the cause of the previously
described exclusion criteria (table 1), such as wound
healing disorders or severe renal impairment. The
Figure 1 Flowchart of the Study.
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interruption or premature discontinuation of the study
drugs might be triggered by AE, diagnostic or therapeu-
tic procedures, abnormal laboratory values (e.g. basal
ASAT/ALAT 50% elevated or more, serum creatinine
25% elevated or more) and for administrative reasons, in
particular the withdrawal of the patient’s consent.
Statistical analysis plan
The statistical analysis plan (SAP) provides full details
regarding the analyses, the data display, and the algo-
rithms to be used for data derivations. The SAP includes
the definition of major and minor protocol deviations
which will be identified by medically trained staff before
the study closure. Safety and tolerability are analyzed
descriptively. Safety analysis is performed on the ITT
population.
The study sample will consist of 32 patients with
newly diagnosed NODAT. For the primary endpoint
analysis, we will assess the differences between treat-
ment and control group in the 2 h glucose value
obtained during an OGTT (75 g glucose) after 3 months
of vildagliptin or placebo treatment. Based on a two-
sided testing and a standard deviation of 20% in relative
changes of 2 h OGTT glucose values, a = 0.05 and ß =
0.2, a sample size of 16 patients per group can detect a
minimal difference in serum glucose level of 20 mg/dl at
the 2 hour time point of the OGTT when comparing
baseline levels to levels on day 90. The “Last observation
carried forward” (LOCF) method will be used for miss-
ing data.
Two different analysis sets are defined for safety and
efficacy, respectively. The efficacy of vildagliptin is
assessed in all subjects who received the study drug (at
least one dose) and did not violate the protocol in a way
that might affect the evaluation of the effect of the
study drug(s) on the primary objective, i.e. without
major protocol violations. The per-protocol set is
employed in the analysis of efficacy variables. A sensitiv-
ity analysis will be performed for efficacy with the ITT
population.
The safety analysis set includes subjects who were ran-
domized and received at least one dose of the study
drug (modified intention to treat). The safety set is
employed in the analysis of tolerability and safety vari-
ables. Statistical analysis is performed with SPSS.
Approval of the ethics committee and the regulatory
authority
The trial is performed in accordance with the Declara-
tion of Helsinki as well as the Austrian drug law. It sub-
scribes to the principles outlined in the most recent
version of the International Conference on Harmoniza-
tion on Good Clinical. Approvals were obtained from
the ethics committee of the Medical University of
Vienna and the Vienna General Hospital (Reference
Number 645/2009) and from the Austrian regulatory
authority (Federal Office for Safety in Health Care, Aus-
trian Agency for Health and Food Safety) and was regis-
tered to the European Clinical Trials Database
(EUDRACT number: 2009-14405-14). The study has
also been registered in a public clinical trial database
(Identifier Number NCT00980356, http://clinicaltrial.
gov).
Discussion
Risk-benefit assessment
We expect all patients participating in this study to ben-
efit because of patient counseling and emphasis placed
on life-style modification in both study arms. Counsel-
ing is performed according to the guidelines of the
Figure 2 Study procedures. OGTT, oral glucose tolerance test.
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International Diabetes Federation (IDF) [4]. If the
hypothesis is true, the vildagliptin group (study arm A)
will experience improved glycemic control. Vildagliptin
is well tolerated in patients with mild to moderate renal
impairment [20]. Patients with severe renal impairment
(GFR < 30 mL/min/1.73 m2) will not be included in our
study. Patients with a GFR between 30 and 50 mL/min./
1.73 m2 will have weekly visits at our outpatient clinic
during the first 4 weeks (serum-creatinine and ASAT/
ALAT) for safety. If renal function declines for any rea-
son to a level below 30 mL/min/1.73 m2, administration
of the study medication will be stopped.
NODAT continues to be a common and serious meta-
bolic complication after organ transplantation. Cur-
rently, NODAT is diagnosed and treated like T2DM,
but there is only limited evidence about the efficacy and
safety of the novel antidiabetic drug vildagliptin in
patients with NODAT, although it is already commonly
used in T2DM. Based on the differences in pathophy-
siology between T2DM and NODAT, the complex drug
profiles in transplanted patients, and the possible influ-
ence of renal impairment on the pharmacokinetic prop-
erties of vildagliptin, the antidiabetic efficiency of this
drug in NODAT remains to be established. This trial
will investigate whether vildagliptin is efficient and safe
in patients with NODAT.
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 4 DISCUSSION 
This doctoral thesis deals with the implementation and scientific evaluation of renal 
clinical pharmacy services in the largest Austrian tertiary care hospital, the Vienna 
General Hospital (VGH). Data on such important patient care services in Austria are 
completely lacking. The underlying publications forming this scientific work address the 
possible roles of clinical pharmacists in renal clinical pharmacy services in general, 
describe areas in which clinical pharmacists can contribute in the inpatient care sector, 
and provide data on DRPs. Regarding the professional advancement of the clinical 
pharmacy discipline and the implementation of research and scientific evaluation, the 
Austrian situation can be called a developing system. This work represents the first 
comprehensive scientific thesis of applied clinical pharmacy research in Austria.  
 
The introduction concisely highlights the background and concept of clinical pharmacy 
services in general and that of renal clinical pharmacy services in particular. The few 
available studies on clinical pharmacy services at a national level in Austria are  
summarised and discussed within the basic legal and educational framework that they 
are based on. Furthermore, the introduction illustrates why patients with impaired renal 
function are especially susceptible to DRPs and focuses on several factors to consider 
when treating patients with renal insufficiency. A detailed, in-depth description and 
analysis of the clinical pharmacists’ role in renal clinical pharmacy has been provided. 
This analysis is provided in the two literature reviews on clinical pharmacy services in 
CKD and dialysis patients, and SOT patients.  
 
Renal clinical pharmacy services are well established in routine patient care in several, 
especially English-speaking countries. Special care needs of patients with impaired 
renal function are addressed. No border exists for the provision of renal clinical  
pharmacy services at the transition of patients from the inpatient to the outpatient  
setting. Furthermore, evidence for the clinical pharmacist’s impact on different aspects 
of nephrology patient care in the ambulatory care sector is published in the two  
literature reviews. Even in healthcare systems with advanced renal clinical pharmacy 
services, such as in the UK or the US, the scope, characteristics, and level of services 
may vary. One can only hypothesise to what extent services are established and can 
only extrapolate from the available relevant scientific publications in this field. This may 
not, however, necessarily reflect the true extent of services, as not all hospitals,  
especially smaller, non-university affiliated hospitals, may be engaged in hospital 
pharmacy-based research or research on applied clinical pharmacy services.  
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 Therefore, two goals have been achieved by performing the literature reviews on  
clinical pharmacy activities in CKD and ESRD patients, and in SOT patients, respec-
tively. First, the literature reviews contribute to the overall understanding of the value of 
implementing such services. Strengths, weaknesses, and differences among  
implemented services were identified. Second, various areas in which the hospital or 
clinical pharmacist can engage in the care of patients with renal impairment are  
described.  
 
These reviews could be seen as a vital step in setting up services in a new setting by 
establishing a theoretical knowledge base on renal clinical pharmacy services. In the 
VGH, there were few practical experiences regarding the concurrent establishment and 
scientific evaluation of new clinical pharmacy services. Hence, evidence and  
information of previously published projects were the only sources for orientation, 
benchmarking, and service comparisons. The description of the pharmacists’ work, 
although often only narrative and out of the explicit context of scientific research, was 
truly valuable for defining target areas and processes and for the establishment of 
structural service criteria, e.g., defining the type of co-working during ward round  
participation and the documentation criteria. Examination of the published literature on 
renal clinical pharmacy services was essential to define a modus operandi and yielded 
valuable information. 
 
Knowledge of risk factors and their management is essential for the preservation of 
kidney function, management of established kidney disease, and reduction in disease 
progression. In our work on risk factor management of patients treated on an internal 
nephrology ward, we clearly showed the need for further improvement of risk factor 
treatment in this in-hospital patient population. During a retrospective medical chart 
review and assessment of treatment quality regarding several risk factors,  
e.g., hypertension and diabetes, we identified suboptimal control in a majority of  
patients. Other problems, e.g., potential DDIs, were identified in the study population 
and in the subgroup of kidney transplant patients. We hypothesised that clinical  
pharmacy services could be one way to approach these care gaps, as evidence from 
literature shows that clinical pharmacists positively influence these risk factors  
(KABOLI et al. 2006, VIKTIL and BLIX 2008). The methodology of this retrospective, 
descriptive study undoubtedly has its limitations and does not contribute to the  
evidence of clinical pharmacy services. However, seen as an audit measure, needs for 
improvement in care were highlighted.  
 164
 To definitely describe the impact of the clinical pharmacist in the nephrology setting in 
the VGH, several small- to large-scale studies were conducted. In the analysis of 
prescribing patterns of patients treated on the ward and the synthesis of a synopsis of 
highly prevalent drugs, a knowledge framework for the clinical pharmacist and  
concerned physicians was established. The provision and availability of additional  
information regarding the pharmacologic properties of commonly used drugs and  
essential (dosing) information on drug prescribing in patients with impaired kidney  
function addressed a constant need of the members of the multidisciplinary healthcare 
team. The high level of clinical pharmacist input related to informational contributions, 
which was detected across all descriptive studies, further reflects this need.  
 
Out of three clinical pharmacist intervention studies (STEMER and  
LEMMENS-GRUBER 2010, STEMER and LEMMENS-GRUBER 2011,  
STEMER et al. 2011), evidence was generated on the clinical pharmacist’s  
contributions during ward rounds, the clinical pharmacist’s contributions on DRPs, and 
the clinical pharmacist’s interventions, respectively (see 3.4, 3.6, and 3.7). The type of 
interventions performed and problems addressed (e.g., sub- and supratherapeutic  
dosages, need for additional drugs) are comparable to other studies  
(MANLEY et al. 2005, MANLEY and CAROLL 2002). This similarity is not surprising, as 
the complexity of patient care and related pitfalls (e.g., the occurrence of ADEs,  
inaccuracy in patient charts, prescribing errors, and dosing errors) generally do not 
differ between individual healthcare settings and systems. However, these are the first 
data to describe this concept in the Austrian setting.  
 
Whereas the methodology of the first study (STEMER and LEMMENS-GRUBER 2010, 
see 3.4) was descriptive in terms of the clinical pharmacist’s contributions to questions 
raised by other healthcare professionals of the multidisciplinary patient care team, the 
second study (STEMER and LEMMENS-GRUBER 2011, see 3.6) mainly yielded data 
on proactively performed interventions by clinical pharmacists. In other words, the 
influence and work style of the clinical pharmacist during ward rounds evolved from a 
reactive to a proactive method of addressing evident or potential DRPs. This change 
was definitely due to the steady evolution of knowledge and increase in  
professionalism on the clinical pharmacist’s side, and overall longer duration of  
co-working in which the clinical pharmacist was a member of the team for a longer time 
period and established a good and trustful working climate.  
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 Furthermore, the evolution of the study methodology included the measurement of the 
physicians’ acceptance rates of the clinical pharmacist’s interventions as an outcome 
parameter. Information on the drugs most involved in the clinical pharmacist’s interven-
tions and most implied in DRPs, information on the cost reduction potential of interven-
tions, and an assessment of the clinical significance of the interventions were amended 
in the methodology of further studies. By reviewing data on all DRPs and interventions 
in the VGH-implemented clinical pharmacy services, a comprehensive evaluation of the 
clinical pharmacists’ contributions in individual settings was undertaken.  
Thus, the thinness of single results was further enhanced, and the comparison of  
specific characteristics in the renal setting to other clinical areas was possible. In the  
in-depth analysis of the results presented for the nephrology area, high proportions of 
drugs used without indication and supratherapeutic dosages were detected. These two 
types of DRPs are of great importance, as the overall number of drugs is generally  
already high in this special patient group, and a high number of drugs is associated 
with several, well-known potential problems (e.g., weaning compliance, drug-drug  
interactions, and prescribing cascade). The acceptance rate of the clinical pharmacist’s 
interventions on the nephrology ward was 61%, with 71% of all interventions assessed 
as significant. Approximately 37% of all proposed interventions were associated with 
cost reduction potential (STEMER et al. 2011, see 3.7).  
 
The involvement of the clinical pharmacist in other clinical research projects, apart from 
his or her own clinical pharmacy research agenda, is described as a major task of  
clinically active pharmacists (SCROCARRO et al. 2000). During this project, the clinical 
pharmacist was involved in two clinical studies on various levels and (co)-responsible 
for the planning, data analysis, and the discussion of results in this study. The clinical 
pharmacist valuably contributes by integrating a unique set of competencies and  
capabilities (e.g., pharmacological knowledge, knowledge on drug production, and 
pharmacoepidemiological knowledge) and, therefore, enriches multidisciplinary clinical 
research groups (ASHP 1991).  
 
As previously illustrated and discussed, the study methodology applied evolved and 
broadened over the period of this project. The prospectively conducted clinical  
pharmacy evaluation studies mainly involved a conservative approach of monitoring, 
describing, and assessing the clinical pharmacist’s interventions as an indirect  
measure of their effects on patients. The monitoring of clinical pharmacists’ interven-
tions is a widespread method applied in clinical pharmacy research and is seen here as 
a valuable tool (CALVERT 1998). However, limitations of intervention monitoring result 
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 from assessment of their value in terms of quality or costs. Monitoring and  
documentation is a time-consuming and error-prone process (CALVERT 1998). The 
essential assumption that nothing would have been done without the pharmacists’  
interventions is made. This assumption, however, represents a paradox, as this  
assumption further implies the direct correlation between the number of interventions 
and their impact and value. In an ideal and optimal setting with high quality patient 
care, the number of interventions should actually approach zero, as no interventions 
addressing improvement of patient care would be indicated (CALVERT 1998). These 
considerations must be considered when interpreting data on interventions.  
The measurement of outcome parameters according to the ECHO (Economical –  
Clinical – Humanistic Outcomes) Model remains important in the analysis of  
pharmaceutical treatments and services (KOZMA et al. 1993). Clinical outcomes are 
medical events that occur as a result of a disease or treatment. Economic outcomes 
are direct, indirect, and intangible costs compared with the costs of medical treatment 
alternatives. Humanistic outcomes consist of consequences of disease or treatment on 
patient functional status or quality of life (GUNTER 1999). 
The studies included in this thesis do not generally report on outcomes  
according to this model, apart from information on the cost reduction potential that lies 
within clinical pharmacist interventions (STEMER et al. 2011, see 3.7).  
DRPs, precursors of the most important outcome variables that have influenced eco-
nomic, clinical, and humanistic outcomes, have been investigated. The limitation of not 
being able to establish an association between our observed DRPs and the clinical 
pharmacist’s interventions and the occurrence or avoidance of a definitive final  
outcome must be acknowledged. However, we know from the literature 
(VAN DEN BEMT et al. 2000, GASTELURRUTIA et al. 2011) that DRPs are strongly 
linked to the occurrence of final outcomes. By assessing the clinical significance of 
performed interventions, the weight of every single intervention and the possible im-
plied impact on patient care could be underlined. In the descriptive clinical pharmacist 
intervention studies forming this thesis, socio-demographic data on the study  
population, i.e., patients admitted to an internal nephrology ward of a large tertiary care 
hospital, is limited. However, we report data on the average patient population of our 
study ward (an internal nephrology ward), including comorbidities and underlying dis-
eases, in the publication of risk factor management. It must be clearly stated that the 
lack of socio-demographic data represents a weakness that limits our ability to general-
ise the study results.  
 
 167
 Fundamental difficulties regarding the generation of evidence in clinical pharmacy  
research from an evidence-based medicine/pharmacy standpoint exemplarily demon-
strate the need for large study populations, long follow-up periods, and the involvement 
of multiple centres and multiple pharmacists. In their comprehensive analysis on the 
impact of pharmaceutical services in community and ambulatory care, SINGHAL et al. 
also published recommendations for future research. Although deduced and extrapo-
lated from the ambulatory care setting, these recommendations may similarly apply to 
clinical pharmacy research in the hospital setting as well (SINGHAL et al. 1999). 
SINGHAL et al. report, among others, on several concerns on external validity. A single 
pharmacist and/or a single centre study may be biased in that the observed effects 
may occur only in this setting. The results may not necessarily be transferable to other 
settings. Study results may be significantly influenced by characteristics at the level of 
the pharmacist, e.g., motivation, workload, social interaction skills, and previous  
experiences. The goal should be uniform and standardised skills of each clinical phar-
macist participating in the study. By applying a broad, multi-centre, multi-pharmacist 
study design, these threats to external validity could be approached (SINGHAL et al. 
1999). A comment on the possibility and limitation of extrapolating study results to  
different settings was published by the German Pharmaceutical Society in reaction to a 
Swedish clinical pharmacist intervention study by GILLESPIE et al. (2009). The study 
investigated the effectiveness of interventions by ward-based pharmacists on morbidity 
reduction and use of hospital care among older patients. The authors state that the 
addition of a pharmacist to healthcare teams leads to major reductions in morbidity and 
healthcare costs. The comment clearly states the difficulties in extrapolating data from 
other settings and underlines the necessity for multi-centre clinical pharmacy studies, 
external funding of studies, and further enhancement and pursuit of research on patient 
safety. As research has its main focus in the university setting, the dissolution of old 
and established conventions, exploration in new research areas, new professorships, 
and qualified staff are necessary (BERTSCHE et al. 2009). 
 
The implementation of renal clinical pharmacy services and its scientific analysis in the 
scope of a doctoral thesis approached a completely new area in Austria from both a 
healthcare system and a scientific standpoint. Difficulties arose because of the relative 
lack of experience in conceptualising the idea of setting up clinical pharmacy services 
with a focus on renal clinical pharmacy services and in forming research questions to 
be answered by the underlying scientific thesis. To summarise, several limitations were 
encountered that must be mentioned. These limitations significantly contributed to  
difficulties in further implementing clinical pharmacy services, scientifically evaluating 
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 them, and pursuing the advancement of this profession. These system barriers may 
also have significantly influenced the results and outcome of this thesis. 
 
First, there is, what could be called, an education gap. Clinical pharmacists working in 
specialised clinical areas are often autodidactically trained and must develop skills on 
their own. An education system of clinical pharmacy on a national level is absent. The 
lack of such a system results in variations of individual knowledge when clinical  
pharmacy services are performed and makes comparison difficult, even among clinical 
pharmacists working in the same hospital. Further variations from other publications 
derive from the fact that the provision of services could not be continuously offered, as 
there was only one clinical pharmacist providing services, and no substitute was 
available if he was on leave. The absence of substitutes is one of the major  
weaknesses in the VGH-implemented clinical pharmacy services. The results reflect 
the individual performance of a single clinical pharmacist, with his individual  
capabilities, and, thus, they may not necessarily reflect the true reality. This limitation 
must be considered when comparing the results of this thesis to other publications.  
To address the issue of performance standardisation and variation reduction, a quality 
management process for clinical pharmacy services, including standard operating  
procedures (SOPs), was implemented in the VGH. A similar process is underway in 
other hospitals that provide clinical pharmacy services in Austria as well  
(WUNDER et al. 2011).  
The standardised provision of clinical pharmacy services mainly focuses on compre-
hensive and standardised documentation criteria for DRPs and respective clinical 
pharmacist interventions. By self-assessing the intervention significance first followed 
by co-assessment of all involved clinical pharmacists at two different time points,  
a measure of the value of the interventions was documented (STEMER et al. 2011). 
The co-assessment at two different time points aimed at bias reduction in the 
judgement of significance. Inter- and intra-rater variability of intervention significance  
assessment is reported, and the correlation coefficients indicate moderate agreement. 
We attribute this moderate agreement to the fact that the process of significance  
assessment according to the published categories by HATOUM et al.  
(HATOUM et al. 1988) was newly implemented and familiarity was low. 
 
A vast amount of literature has been published on the necessity, importance, and pre-
requisites of documentation of clinical pharmacist interventions (VAN MIL et al. 2004, 
GRANAS et al. 2010).  
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 In the VGH, a published, validated documentation system (ALLENET et al. 2006) was 
adapted during the implementation of the quality management process. Practicability 
and usability was assessed during the prospective comprehensive clinical pharmacist 
intervention study in all clinical areas where clinical pharmacy services are  
implemented in the VGH. All involved clinical pharmacists reported a good level of 
practicability and usability for the system. 
 
Clinical pharmacy services can only be successful if the process of gaining respect and 
trust as a member of multidisciplinary patient care teams is successful, as a close  
collaboration is essential. During this process, psychological barriers and “prejudices” 
of other involved professionals must be addressed and often defeated. In a traditional 
hierarchy, there may still be prejudices against the role of the clinical pharmacist, the 
capabilities of the individual pharmacists, and (unjustified) fears of losing competencies 
and interfering with duties of other professionals. Shared understanding of roles and 
expertise, transparency in decisions, negotiation, and a non-competitive,  
non-hierarchical approach to patient and care is needed (SMADU 2008). 
A high level of social skills, in addition to professional skills, is needed. Working in a 
trustful climate allows for addressing sources of errors and areas with a need for  
improvement with sensibility and professionalism, which will ultimately succeed in the 
goal of providing the best patient care possible. Mutual trust and respect are essential 
elements of interprofessional relationships (LIAW and PETERSON 2009). 
A model of mentorship, compared with the profession of physicians, or a model of  
training “junior” clinical pharmacists on the job by “senior” clinical pharmacists is  
absent, but would definitely facilitate the process. The joint education of pharmacists 
and physicians with enhanced possibilities to exchange knowledge, experiences, and  
a professional discourse would also be helpful. The adoption of a more  
research-oriented attitude, similar to that of physicians, by clinical pharmacists would 
be a positive development.  
 
As mentioned in the introduction, in addition to a weak educational structure for clinical 
pharmacists, a gap in legislation also exists. Although the term clinical pharmacist  
occurs in Austrian law, a detailed description of duties, responsibilities, and qualifica-
tions is lacking. The visibility of the discipline of clinical pharmacy, its achievements, 
and its implied potential to stakeholders in the health system, however, must be  
pursued and amplified, thus underlining the importance of clinical pharmacy services in 
addressing the needs of patient care. Furthermore, awareness should be raised on 
pharmacotherapy-associated problems and the use of drugs as an error-prone  
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 process. Only a few studies on the various aspects of drug safety, medication errors, 
and DRPs and their consequences (i.e., ADRs) are have been conducted in Austria. A 
study performed by SCHULER et al. shows that 17.8% of patients admitted to selected 
internal wards had experienced an ADR. In the majority of these cases, the ADR was 
the reason for hospital admission (SCHULER et al. 2008). 
The data gap regarding these two areas should be addressed by surveying and  
performing epidemiological research, which will define requirements for additional  
services on a national healthcare system level. The regulatory bodies and politicians 
currently handle trials on quality, efficacy, and safety, but do not necessarily devote 
adequate attention to drug therapy safety (BERTSCHE et al. 2009).  
 
It is important to clearly state the reasons why hospital pharmacy and clinical pharmacy 
research is vital for the profession, the healthcare system, and the individual patient. 
Research is an important educational tool for junior hospital pharmacists and an  
excellent opportunity to build networks with other healthcare professionals, facilitating 
the development of new service and exploration of new tasks. To establish a sound 
and reliable research project, specialised problem solving knowledge should be  
available and the project should involve the development of new activities and collabo-
ration, communication, and education of others (BONABRY, 2011).  
Implementation of research and communication of results and achievements could act 
as stimuli for further projects, especially as the communication of results to stake-
holders and healthcare professionals (other pharmacists, physicians, nurses)  
increases. The discipline of hospital pharmacy and the concepts of clinical pharmacy 
and pharmaceutical care are applied core disciplines in the overall pharmacy specialty.  
In the medical area, research represents a key activity and quality indicator, and as the 
hospital and clinical pharmacist are members of the hospital patient care team, it is 
time to pursue clinical pharmacy research in addition to basic pharmacy research at a 
university level (BONABRY, 2011). However, according to the EAHP survey in 2005, 
only 51% and 27% of hospital pharmacies are engaged in research of inpatients and 
outpatients, respectively. The majority of hospital pharmacies is involved in clinical drug 
trials (which deal more with the logistics or production of the study drugs). Clearly,  
a minority of pharmacists are involved in drug use evaluations (DUEs) or medication 
use evaluations (MUEs), and only 20% are involved in pharmacoepidemiological re-
search tasks (EAHP, 2005). 
 
The present thesis provides evidence that supports the benefit of renal clinical  
pharmacy services in the setting of a large tertiary care hospital. In the included  
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 publications, several issues on the roles of the clinical pharmacist (e.g., addressing 
DRPs, analysing situations and deducting measures or indicators, establishing  
guidance) are described. 
In the discussion of the thesis the overall scientific work has been set in association to 
its constituting individual pieces, has been discussed in the framework of other clinical 
pharmacy services in the same setting, and in the framework of published evidence, 
with the background of clinical pharmacy research. Furthermore, the discussion high-
lighted the value of advancement, difficulties, barriers, and implementation of clinical 
pharmacy services in a developing system. 
 
Compared with previously published evidence, this thesis contributes data for the  
Austrian in-hospital patient care sector for the first time. On a national level, it  
contributes by describing the evolution of clinical pharmacy services and their scientific 
evaluation for the first time within the scope of a doctoral thesis in a new applied  
research area. It aims at serving as a stimulus for further research projects and  
contributes to the further recognition of clinical pharmacy services within the Austrian 
healthcare system, by various Austrian healthcare services, by professional bodies, 
and by schools of pharmacy. The importance of clinical pharmacy services with regard 
to an overall ageing population, polypharmacy, several comorbidities, increasing  
complexity in drugs used, and patient care will be enhanced from both an institutional 
perspective and the perspective of society as a whole.  
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 5 SUMMARY 
 
5.1 ABSTRACT ENGLISH 
Renal clinical pharmacy services focus on special drug- and pharmacotherapy-related 
issues in patients with renal impairment (e.g., CKD patients, ESRD patients, kidney 
transplantation patients). Patients with renal insufficiency are characterised by several 
different comorbidities that affect many organ systems.  
Opportunities for the clinical pharmacist to contribute to the complex care of these 
patients at various stages and in the aforementioned patient groups are described. 
Possible areas in which the clinical pharmacist can contribute are risk factor manage-
ment (e.g., hypertension, cardiovascular disease, and diabetes), management of  
comorbidities (e.g., anaemia, metabolic bone disease), and prevention and  
management of DRPs.  
Patients with renal impairment are especially susceptible to DRPs. Non-adherence to 
dosing guidelines often leads to the occurrence of preventable ADEs. Accurate  
assessment of kidney function and assurance of dosage adaptation is key to avoid 
unwanted drug effects and, ultimately, to ensure optimal patient outcomes. Factors 
including the severity and prevalence of coexistent medical conditions and different 
procedures (e.g., form of dialysis) may influence the pharmacokinetics and pharmaco-
dynamics of the drugs used and, therefore, contribute to the occurrence of DRPs. 
Successful implementation of clinical pharmacy services on an internal nephrology 
ward was evaluated by describing and evaluating the impact of a clinical pharmacist’s 
participation during ward rounds. Data on commonly detected DRPs (e.g., dosing  
issues, use of unindicated drugs, inaccuracies in medical records), performed  
interventions, affected drugs (e.g., antibiotics, proton pump inhibitors, antivirals), the 
physicians’ acceptance rate of the suggested interventions, and the significance  
assessment of the interventions are reported. Limitations to the results and their impact 
are mainly due to issues in study methodology.  
 
This thesis represents the first scientific thesis in the area of applied clinical pharmacy 
research on a national level in Austria and yields data on its implementation in the renal 
setting and the clinical pharmacist’s role in the evolving system of clinical pharmacy 
services.  
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5.2 ABSTRACT DEUTSCH 
Klinisch-pharmazeutische Dienstleistungen im Bereich Nephrologie befassen sich  
unter anderem mit speziellen Arzneimittel- und Arzneimitteltherapie-assoziierten  
Problemen in Patienten mit eingeschränkter Nierenfunktion bei chronischer Nieren-
insuffizienz, terminalem Nierenversagen oder nach Nierentransplantation.  
Charakteristische Begleiterkrankungen in dieser Patientenpopulation sind häufig.  
Für den Klinischen Pharmazeuten bieten sich in diesem komplexen Umfeld viele  
Möglichkeiten einen Beitrag zu leisten und es gibt umfangreiche wissenschaftliche  
Literatur hierfür. Möglichkeiten umfassen u.a. das Management von Risikofaktoren 
(z.B. Hypertonie, kardiovaskuläre Erkrankungen und Diabetes), das Management von 
Begleiterkrankungen (z.B. Anämie, Störungen im Calcium-, Phosphat- und Vitamin-D-
Haushalt), sowie die Prävention und das Management von Arzneimittel-assoziierten 
Problemen. Patienten mit eingeschränkter Nierenfunktion sind besonders empfindlich 
für Arzneimittel-assoziierte Probleme. Die fehlende Berücksichtigung von Dosierungs-
empfehlungen bedingt häufig eigentlich verhinderbare Arzneimittelnebenwirkungen. 
Die Beurteilung der Nierenfunktion und korrekte, an diese angepasste Arzneimitteldo-
sierungen sind unerlässlich, um unerwünschte Arzneimittelwirkungen zu vermeiden 
und letztendlich eine optimale Patientenversorung zu gewährleisten. Die Existenz von 
Begleiterkrankungen, deren Schweregrad und verschiedene Verfahren (z.B. Dialyse) 
beeinflussen die Pharmakokinetik und die Pharmakodynamik von Arzneimitteln und 
können so zum Auftreten von Arzneimittel-assoziierten Problemen beitragen.  
Auf der nephrologischen Normalpflegestation einer großen österreichischen Universi-
tätsklinik wurden erfolgreich klinisch-pharmazeutische Dienstleistungen implementiert 
und durch Beschreibung und Auswertung der klinisch-pharmazeutischen Interventio-
nen und anderen Beiträgen während der Stationsvisiten evaluiert.  
Häufige Arzneimittel-assoziierte Probleme (z.B. Dosierungsfehler, Gebrauch nicht indi-
zierter Arzneimittel, Fehler in der Dokumentation), häufig betroffene Arzneistoffe (z.B. 
Antibiotika, Protonenpumpenhemmer, Virustatika), die Akzeptanzrate der  
vorgeschlagenen Interventionen seitens des ärztlichen Personals und die Beurteilung 
der Signifikanz wurden erhoben. Die Ergebnisse müssen unter Berücksichtigung me-
thodischer und systematischer Grenzen interpretiert werden.  
 
Die vorliegende Arbeit stellt die erste wissenschaftliche Arbeit im Bereich angewandter 
klinisch-pharmazeutischer Forschung auf nationaler österreichischer Ebene dar. Sie 
liefert Ergebnisse zur Implementierung klinisch-pharmazeutischer Dienstleistungen und 
unterstreicht den Beitrag des Klinischen Pharmazeuten in  
einem diesbezüglich noch in den Kinderschuhen steckenden Umfeld.
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 7 ABBREVIATIONS 
 
AAHP Austrian Association of Hospital Pharmacists 
ABDA Bundesvereinigung Deutscher Apothekerverbände – Federal Alliance of German 
Pharmacy Associations 
ABO Apothekenbetriebsordnung – Regulation on the operation of pharmacies 
ACCP American College of Clinical Pharmacy 
ACEI Angiotensin-converting enzyme inhibitor 
ADE Adverse drug event 
ADR Adverse drug reaction 
AHRQ Agency for Healthcare Research and Quality 
ARB Angiotensin receptor blocker 
BNF British National Formulary 
CKD Chronic kidney disease 
CrCL Creatinine clearance 
DDI Drug-drug interaction 
DPhG Deutsche Pharmazeutische Gesellschaft – German Pharmaceutical Society 
DRP Drug-related problem 
DTPA Diethylenetriamine pentaacetate 
DUE Drug use evaluation 
EAHP European Association of Hospital Pharmacists 
EDTA Ethylenediamine tetraacetate 
ERA-EDTA European Renal Association – European Dialysis and Transplantation Association 
ESA Erythropoiesis stimulating agent 
ESCP European Society of Clinical Pharmacy 
ESRD End-stage renal disease 
FIP International Pharmaceutical Federation 
GFR Glomerular filtration rate 
iPTH Intact parathyroid hormone 
KDIQO Kidney Disease: Improving Global Outcomes 
KDOQI Kidney Disease Outcomes Quality Initiative 
LDL Low density lipoprotein 
LVH Left ventricular hypertrophy 
MDRD Modification of Diet in Renal Disease 
ME Medication error 
MSc Master of Science 
MUE Medicines use evaluation 
NHANES National Health and Nutrition Examination Survey 
NKF National Kidney Foundation 
NSAID Non-steroidal antiinflammatory drug 
PGY Pre-registration year 
ÖAK Österreichische Apothekerkammer – Austrian Chamber of Pharmacists 
SCr Serum creatinine 
SOP Standard operating procedure 
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 SPC Summary of product characteristics 
SOT Solid organ transplantation 
VGH Vienna General Hospital 
UK United Kingdom 
UKCPA United Kingdom Clinical Pharmacy Association 
UKRPG United Kingdom Renal Pharmacy Group 
US United States 
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 8 APPENDIX 
 
8.1. INTERIM RESULTS OF NEWLY IMPLEMENTED CLINICAL PHARMACY 
SERVICES ON AN INTERN NEPHROLOGY WARD 
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RESULTS: The clinical pharmacist was asked a total of 174 drug- or pharmacotherapy-related questions
during participation in the ward rounds. Questions mainly derived from physicians (n=154; 88.5%), nurses
(14; 8%) or medical students (6; 3.5%). 
CONCLUSION: Interim results of newly implemented clinical pharmacy services are encouraging and 
participation in ward rounds will continue. 
BACKGROUND: Routine clinical pharmacy 
services have newly been implemented on an 
intern nephrology ward in an effort to further 
expand these services. The clinical pharmacist 
participates in ward rounds at least three times 
per week. 
Interim results of newly implemented clinical pharmacy 
services on an intern nephrology ward
Gunar Stemer1, Rosa Lemmens-Gruber2
1Pharmacy Department, Vienna General Hospital, Austria
2Departement of Pharmacology and Toxicology, University of Vienna, Austria
DESIGN AND SETTING: Descriptive, prospective study on an intern nephrology ward of the Vienna General 
Hospital – University Clinics; January 2008 – May 2009 (17 months)
MAIN OUTCOME MEASURES:
 Type and frequency of drug- or pharmacotherapy-related questions raised by health care professionals 
during the ward rounds and subsequently answered by the clinical pharmacist 
 Complexity of questions defined by the total time needed to answer each question
 Problems and barriers identified during the initial period of the clinical pharmacy project
Contact: gunar.stemer@akhwien.at
OBJECTIVES: To evaluate the contribution of clinical 
pharmacy services by documentation of the consultations 
made during the ward rounds, classified by 
type and frequency, and 
complexity. 
Problems and barriers identified were:
 continuity of collaboration due to changes in medical ward staff each semester,
 bridging psychological borders between physicians and pharmacists, and
 different levels of professionalism of clinical pharmacists due to a lack of systematic clinical pharmacy 
education programmes.
Based on the total time needed to answer, each question was either 
categorised into group A (up to 15 minutes: 133; 76.4%), group B (up 
to one hour: 24; 13.8%) or group C (more than one hour, extensive 
and complex literature research: 17; 9.8%). 
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The absolute and relative frequency of each type of 
consultation were: drug therapy selection (40; 23%), general 
drug information (35; 20.1%), dosage and pharmacokinetics
(31; 17.8%), availability of drugs (19; 10.9%), drug interactions
(17; 9.8%), adverse drug events (13; 7.5%), application of 
drugs (8; 4.6%), organisation and logistics (7; 4.0%), 
pregnancy and breastfeeding (2; 1.1%) and 
pharmaeconomics (2; 1.1%). 
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 8.2 PRESCRIBING PATTERNS ANALYSIS ON AN INTERN NEPHROLOGY 
WARD: THE “RENAL” FOCUS! 
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RESULTS: A total of 195 different drugs were identified, adressing typical nephrological pharmacotherapy 
questions, e.g. hypertension, diabetes, electrolyte disturbances, secondary hypoparathyreoidism and 
cardiovascular disease. Around 50% of the patients had kidney transplantation. 
124 drugs were included in the synopsis. 
CONCLUSION: Knowledge of altered pharmacokinetic parameters affecting action, efficacy and toxicity 
of drugs, is essential when prescribing drugs to patients with renal impairment. 
The synopsis highlights common drugs requiring special attention. It can be used as a teaching tool for 
health care professionals beginning in nephrology or as a quick reference guide at the point of care. 
BACKGROUND: Knowledge of relevant pharmacokinetic parameters, e.g. protein binding, non-renal 
excretion rate (Q0-value), eliminiation half-life (HL) and the presence of active metabolites, of commonly 
prescribed drugs is essential for drug therapy individualisation in patients with renal impairment (RI). 
DESIGN: Retrospective analysis of drug prescriptions of 100 randomly selected patients; 
Synthesis of a synopsis of drug properties relevant for drug therapy individualisation by searching drug 
information databases and handbooks of clinical drug data
MAIN OUTCOME MEASURES:
 Frequency of the most prescribed drugs 
 Frequency of drugs identified with pharmacokinetic properties requiring attention in RI
Contact: gunar.stemer@akhwien.at
OBJECTIVES: To analyse qualitative prescribing patterns on an intern nephrology ward and subsequently 
develop a synopsis of important pharmacotherapy relevant parameters. 
The synopsis also comprises dosing guidelines for normal and impaired renal function and further 
pharmacokinetic drug parameters.
Pharmacokinetic properties to consider (among 
others) when prescribing in RI were: 
 High protein binding rate
 Non-renal excretion rate (Q0-values <0.5) 
 Prolonged elimination HL in RI 
 Presence of active metabolites 
The 10 most prescribed drugs were 
 prednisolone (53%), 
 the PPIs pantoprazole and esomeprazole (88.2%), 
 aspirin (39.2%), 
 carvedilol (35.3%), 
 tacrolimus (34.3%), 
 candesartan (30.4%), 
 mycophenolate mofetil (29.4%), 
 amlodipine (28.4%) and 
 furosemide (27.45%). 
Prescribing patterns on an intern nephrology ward: 
The „renal“ focus!
Gunar Stemer1, Rosa Lemmens-Gruber2
1Pharmacy Department, Vienna General Hospital, Austria
2Departement of Pharmacology and Toxicology, University of Vienna, Austria
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Further parameters investigated were frequency (FQ) of drugs with the need for dose adjustments and 
the need for therapeutic drug monitoring (TDM). 
44.4% of the drugs are substrates, inhibitors (18.5%) or inducers (4.0%) of CYP450 liver enzymes.
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8.3 CLINICAL PHARMACY SERVICES IN THE LARGEST AUSTRIAN  
TERTIARY CARE HOSPITAL 
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